Natural immunity to pneumococcal Pilus-1 RrgA and RrgB antigens, and its relationship with pneumococcal carriage by Ahmed, Muhammad Shamsher
i 
 
 
 
 
Institute of Infection and Global Health 
Department of Clinical Infection, Microbiology and Immunology 
 
 
 
 
Natural Immunity to Pneumococcal Pilus-1 
RrgA and RrgB Antigens, and Its Relationship 
with Pneumococcal Carriage  
 
 
 
 
Thesis submitted in accordance with  
the requirements of the University of Liverpool  
for the degree of Doctor in Philosophy  
 
by 
 
Muhammad Shamsher Ahmed 
October 2013 
 
ii 
 
Abstract 
Streptococcus pneumoniae (pneumococcus) is a leading cause of childhood morbidity and 
mortality around the world. The available polysaccharide-based vaccines are limited by 
either low efficacy in young children or narrow serotype coverage. Recent research has 
focused on developing protein vaccines. Pneumococcal pilus-1 proteins play an important 
role in pneumococcal adherence to host respiratory epithelium and subsequent bacterial 
colonization or invasion; and may therefore be an effective vaccine candidate. This PhD 
project investigated natural immunity in humans to pneumococcal pilus-1 proteins and its 
association with nasopharyngeal carriage of pneumococcus. 
Nasopharyngeal carriage of pneumococcus was analysed by bacteriological culture of nasal 
swabs on blood agar. Pneumococci were identified based on their colony morphology and 
optochin sensitivity; and further confirmed by PCR detection of pneumolysin gene in the 
isolates. Pneumococcal carriage was found to be common in young children, which 
gradually decreased with advancing age. PCR detection of pilus islet 1 (PI-1) gene revealed 
that percentage of pilus-1 positivity was low among these carriage isolates. This low 
prevalence may be associated with the recent introduction of pneumococcal conjugate 
vaccination, which covers the common piliated serotypes.  
ELISA based measurement of serum and salivary antibodies to pilus-1 proteins detected 
significant antibody levels to both RrgA and RrgB, presumably developed as a part of 
natural immune response in children and adults. An age-dependent increase in serum 
antibody levels to both RrgA and RrgB was also observed, and anti-RrgA appeared to 
develop earlier in childhood than anti-RrgB. Moreover, higher levels of antibody, especially 
anti-RrgA were found in children who were culture-negative than in those who were culture-
positive for pneumococcus. It suggests that these naturally developed antibodies may 
contribute to the protection against pneumococcal carriage in humans.   
Using an in vitro model of human NALT, the study revealed that adenotonsillar tissues are 
important induction sites for immune response to these antigens, by priming B cell memory. 
The induction of antibody secreting cells in NALT was enumerated by ELISpot assay; and 
the antibody production was measured by antigen-specific ELISA. In vitro stimulation with 
a wild type (TIGR4) pneumococcal culture supernatant (containing both RrgA and RrgB 
proteins) induced a significant memory B cell and antibody response in adenotonsillar cells. 
Current carriage in vivo enhanced the memory B cell response and antibody production.  
Flowcytometric analysis of CFSE labelled adenotonsillar MNC suggested that 
pneumococcal pilus-1 proteins RrgA and RrgB were capable of stimulating CD4
+
 T cell 
proliferative response in human NALT. Stimulation with pneumococcal CCS induced Th17 
related cytokines production in both human adenotonsillar MNC and PBMC culture 
supernatant. Importantly, this in vitro production of Th17 cytokines after stimulation with 
TIGR4wt CCS was significantly higher than that of CCS derived from its isogenic RrgA
-/-
 
and RrgB
-/-
 mutants, indicating a contribution from both of these proteins. The ability of 
these pilus-1 proteins to stimulate CD4
+
 T cell proliferation and Th17 response may 
contribute to the natural immunity to pneumococcus in humans. 
This study has revealed that both of these pilus-1 proteins, RrgA and RrgB are immunogenic 
and are capable of priming for memory B and T cell response in human NALT. These 
findings aid to our understanding on the naturally developed immune response to pilus-1 
proteins, and may inform future vaccination strategy with intranasal immunisation 
containing protein antigens against pneumococcal infection.  
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1.1 Natural Immunity to Streptococcus pneumoniae  
Streptococcus pneumoniae (pneumococcus), a Gram positive bacterium, is 
responsible for a wide spectrum of diseases in humans, ranging from asymptomatic 
colonisation of upper respiratory tract to life threatening infections. It is one of the 
leading causes of childhood morbidity and mortality around the globe. Infection rate 
is particularly high in developing countries (O'Brien et al. 2009). Pneumococcus is 
responsible for some common mucosal infections in childhood, such as otitis media. 
It also causes a number of invasive infections, such as bacteraemic pneumonia, 
septicaemia and meningitis (CDC 2000). It is responsible for over 50% of severe 
pneumonia cases, and probably a higher proportion of fatal cases (Hodge 2006). It is 
the leading cause of community acquired bacterial meningitis and septicaemia in 
childhood (Peltola 2001).  
Pneumococci are transmitted by direct contact with respiratory secretions from 
patients or healthy carriers. They may remain as a part of normal microbial flora in 
the upper respiratory tract in 5-40% humans (Brooks and Carroll 2007). The primary 
site of colonisation is nasopharynx. This carriage is generally asymptomatic in 
immunocompetent individuals. However, prolonged nasopharyngeal carriage favours 
the escape of pneumococcus into the middle ear cavity and normally sterile parts of 
the respiratory tract, resulting in otitis media and pneumonia. The other severe forms 
of infection (septicaemia or meningitis) occur as a sequel of these mucosal 
infections. The persistence of carriage also serves as a potential source for spreading 
the infection to close contacts (Bogaert et al. 2004a).  
The onset of colonisation varies in different part of the world. But it is believed that, 
almost every child is colonised by at least one of the pneumococcal serotypes before 
their second birthday (Käyhty et al. 2006). Pneumococcal carriage is potentially 
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immunogenic, and triggers both local mucosal and systemic immune response, 
conferring protection against re-colonisation or invasive pneumococcal disease 
(Ferreira et al. 2013). Pneumococcal carriage in the early childhood primes for 
immunological memory to pneumococcal antigens (Vukmanovic-Stejic et al. 2006) 
and that may lead to the development of protective immunity in later life (Zhang et 
al. 2006b).  
Considering the huge burden of diseases caused by pneumococcus, development of 
vaccines against pneumococcus has been one of the priorities. Reports of the strong 
immunogenicity of pneumococcal capsular polysaccharides identified them as 
vaccine candidates (Heidelberger and Avery 1924). Based on the success of a 
preliminary trial (MacLeod et al. 1945), the first commercial production of a 
quadrivalent pneumococcal polysaccharide vaccine was started after the end of the 
Second World War. However, pneumococcal capsular polysaccharides are highly 
variable, which serve as the basis of its classification into more than 92 serotypes 
(Calix and Nahm 2010). Later efforts were concentrated more on increasing the 
serotype coverage and eventually a 23-valent polysaccharide vaccine (PPSV23) was 
introduced in 1977. However, the polysaccharide vaccines do not induce T cell 
dependent antibody and memory response. Hence it is not effective in young 
children (<2 years), who are the most vulnerable to pneumococcal colonisation and 
invasion (Bogaert et al. 2004b).  
Conjugation of a protein carrier to capsular polysaccharide has overcome these 
limitations, but the coverage they offer is limited. In addition, invasive infections by 
serotypes not covered in these vaccines are posing increasing threats (Spratt and 
Greenwood 2000). Moreover, they are too expensive to be included in the universal 
immunisation schedule in the developing countries. For these reasons, efforts have 
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been made to develop protein vaccines, which will be effective against most 
serotypes. Also commercial production of protein vaccines is relatively easy and 
may be more cost effective (Bogaert et al. 2004b). Identification of suitable protein 
vaccines has therefore become a key target in the pneumococcal vaccine research. A 
number of surface proteins are being evaluated for this purpose.  
1.2 Pneumococcus and Disease Burden 
S. pneumoniae is the commonest aetiologic agent of community-acquired pneumonia 
(Welte et al. 2010). According to a WHO report in 2005, pneumonia was ranked as 
the top-most killer disease of under-five (<5 years) children, which was responsible 
for nearly one-fifth of the 10.6 million deaths around the world (Bryce et al. 2005). 
Nearly 156 million under-five children suffered from pneumonia in the year 2000; 
more than 95% of them were in developing countries. One out of 12 cases of 
pneumonia was severe enough to be hospitalised, with the death toll approaching 2 
million per year. Most of those death occurred in Africa and South-East Asian 
countries (Rudan et al. 2008). The pneumococcal burden is high in the developed 
countries also, with remarkably increased vulnerability in elderly. Pneumococcus is 
responsible for nearly half of the cases of community-acquired pneumonia in adult 
population in the UK (Lim et al. 2001) and in Finland (Jokinen et al. 2001). In 
developed countries the incidence rate is higher among the underprivileged and 
indigenous population compared to the average national burden (Davidson et al. 
1994; Torzillo 1997).  
People of any age may be infected by pneumococcus, but those in extremes of age 
(<2 years and >65 years) are at particular risk. Chronic heart or lung disease, 
smoking and splenectomy increase the hazard (Örtqvist et al. 2005). Any preceding 
viral infection of the lungs (i.e. influenza) enhances the susceptibility and fatality of 
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pneumococcal infection (Brundage 2006). Another important risk factor is HIV 
infection (Hart et al. 2000). The risk of pneumococcal colonisation and infection is 
higher in densely populated communities (Dagan et al. 2000).  
1.3 Microbiology of Streptococcus pneumoniae 
Streptococcus pneumoniae are Gram-positive, encapsulated cocci. In Gram stained 
smears they often appear as elongated cocci, with outer curvatures somewhat 
pointed; giving them the shape resembling lancets. They usually occur in pairs 
(diplococci), may also appear in solitary or in short chains (Brooks and Carroll 
2007). The average diameter of the bacterium varies from 0.5µm to 1.25µm. They 
are usually non-motile, non-sporeforming, facultative anaerobes. Like other 
Streptococci, they are catalase negative, but can be differentiated from the β-
haemolytic group A Streptococci by their characteristic α-haemolytic (green) 
colonies in blood agar. On blood agar, they produce glistening raised colonies, 
measuring roughly 1mm in diameter. With progression of time, the colonies start to 
flatten and small depressions appear in the centre, owing to the activities of an 
autolytic enzyme. This typical plateau-shaped colony morphology, popularly termed 
as ‘draughtsmen’ colonies; together with some special biochemical tests are used to 
differentiate them from other α-haemolytic upper respiratory tract commensals. The 
properties of inulin hydrolysis, bile solubility and optochin (ethylhydrocupreine) 
sensitivity are used to distinguish Streptococcus pneumoniae from the other α-
haemolytic (viridans) Streptococci (Ryan 2003). 
Almost all pathogenic strains of Streptococcus pneumoniae have a polysaccharide 
capsule surrounding their cell wall (Mitchell and Mitchell 2010). These capsular 
polysaccharides react with the specific antisera, showing the ‘Quellung’ (swelling) 
reaction. Based on this property of capsular polysaccharides, pneumococci were 
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classified into 90 different serotypes (Henrichsen 1995). Later, two new serotypes 
6C (Park et al. 2007) and 11E (Calix and Nahm 2010) were identified.  
Like other gram positive bacteria, pneumococcal cell wall is composed of thick 
peptidoglycan layer, teichoic and lipotiechoic acid residues. Teichoic acid residues 
are bound to the N-acetylmuramic acid of peptidoglycan. They contain two forms of 
phosphorylcholine (PCho), free or protein bound. PCho are capable of triggering 
innate response by C-reactive proteins and lung surfactants. Also, the proteins 
anchored on them are important mediators of pneumococcal inflammation and tissue 
damage in the host (McCullers and Tuomanen 2001). The lipoteichoic acids are 
attached to the cell membrane by their lipid moiety. Recently, hair-like projection, 
also known as pili were found in the surface of many pneumococcal strains 
(Barocchi et al. 2006).   
The complete genomic sequence of ‘The Institute for Genomic Research’ serotype 4 
(TIGR4) strain of Streptococcus pneumoniae, revealed 2,160,837 base pairs in a 
single circular chromosome. The genome contains 2,236 predicted protein coding 
regions, 1440 of those was biologically functional (Tettelin et al. 2001).  Some of 
these proteins are integrated in the cell wall. The others are membrane-associated 
lipoproteins of various structure and functions. Many of these proteins contribute to 
the virulence of pneumococcus; and some of them elicit protective responses, 
showing the prospect of being potential vaccine candidates. 
1.4 Pathogenesis of Pneumococcal Diseases  
From their ecological niche in the nasopharynx, pneumococci might spread 
endogenously to the carrier or exogenously to other individuals through respiratory 
droplets. The endogenous spread of pneumococci down to the respiratory tract, 
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paranasal sinuses, the middle ear cavity, CNS or blood stream causes inflammatory 
reaction in these organs leading to mucosal infection or invasive diseases. The 
pathogenic routes for pneumococcal infection are shown in the Figure (Bogaert et al. 
2004a). 
 
Figure-1.4: Pathogenic routes for S. pneumoniae infection. Organs in sky-blue colour get 
infected by airborne droplets; organs in red are invaded through haematogenous route 
(Bogaert et al. 2004a).   
Otitis media: It is the commonest bacterial infection of children and most frequently 
caused by pneumococcus (Gray et al. 1980). The middle ear cavity is connected to 
the nasopharynx by the eustachian tube, through which the organism spreads from its 
colonisation site.  
Acute bacterial pneumonia: S. pneumoniae may be transmitted down to the lower 
respiratory tract leading to suppurative infection in the lungs. Pneumococcal 
infection triggers release of fibrinous exudates and polymorphonuclear infiltration 
into the alveoli, resulting in lung consolidation (Johnston 1991). Bacteria are 
abundant in these exudates and may spread to the bloodstream via the lymphatic 
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drainage. The onset of pneumococcal pneumonia is usually sudden, with high fever, 
chills, sharp pleural pain and productive cough.  
Bacteraemia and Septicaemia: Bacteraemia in the absence of a focus of infection is 
commonly caused by pneumococcus, especially in splenectomised individuals. 
Pneumococcal bacteraemia can lead to severe complications like meningitis, 
endocarditis, and septic arthritis.  
Meningitis: S. pneumoniae is a common cause of bacterial meningitis. This disease 
has a high mortality rate, even when treated appropriately. Infection usually extends 
from the mastoid, also can follow pneumococcal sepsis.  
1.5 Pneumococcal Virulence Factors 
1.5.1 Polysaccharide Capsule 
Pneumococcal polysaccharide capsule is anti-phagocytic, protecting the bacteria 
from polymorphonuclear leukocyte attack (Kadioglu et al. 2008). It acts as a 
defensive barrier around the bacteria, impeding attachment of complement 
components and immunoglobulins with bacterial cell wall. As a result, bacteria 
multiply freely before the appearance of anti-capsular antibodies. Capsules also 
prevent mechanical clearance of the bacteria by airway mucous (Mitchell and 
Mitchell 2010).  
1.5.2. Pneumolysin  
This pore-forming toxin is well conserved among pneumococcal isolates (Kadioglu 
et al. 2008). Pneumolysin (Ply) is located within the bacterial cytoplasm and released 
after autolytic degradation of bacteria (López et al. 1997). Pneumolysin mediates 
host cell damage by two mechanisms; pore formation and complement activation 
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(Gilbert et al. 1999). It is also involved with production of proinflammatory 
cytokines and chemokines (van der Poll and Opal 2009).  
1.5.3. Pneumococcal Surface Proteins 
Pneumococci express several proteins on their surface. They could be classified into 
five broad categories: choline binding proteins (CBP), lipoproteins, LPXTG 
proteins, histidine triad proteins and non-classical surface proteins (NCSP) (Pérez-
Dorado et al. 2012; Adamou et al. 2001). Many of these proteins play specific roles 
in different stages of pneumococcal infection and disease process. The individual 
contribution of many proteins to the virulence are well-documented by this time. 
However, their effects are not mutually exclusive. Knocking-out of an individual 
protein compromises related virulence properties (adherence, colonisation, invasion, 
spreading), but does not necessarily make the bacteria totally avirulent. 
Understandably, the virulence of pneumococcus is multi-factorial; the essence of 
which is achieved by their coordinated interplay. Their cumulative effect favours for 
bacterial survival and thriving (Gámez and Hammerschmidt 2012). The roles of 
different groups of proteins are briefly discussed here.  
1.5.3.1 Choline Binding Proteins (CBP) 
Choline binding proteins (CBP), share a common structural organisation (Gosink et 
al. 2000). They are composed of a biologically active site projecting from the 
bacterial surface; and a choline binding site, anchoring the protein by a non-covalent 
attachment with phosphorylcholine residues of cell wall teichoic acids. The 
characteristic of this family is the choline binding motif, usually contains 
homologous repeats of 20 amino acid residues. So far 16 members of this family 
have been identified. Several of them, including PspA, CbpA and LytA are 
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implicated for significant contribution to pneumococcal virulence (Pérez-Dorado et 
al. 2012). Most of the CBPs are adhesins and exert their pathogenic role through host 
pathogen interactions. However some of them are associated with enzymatic 
functions (Frolet et al. 2010).   
1.5.3.2 Pneumococcal Lipoproteins   
Lipoproteins (LP) appear to be very crucial component for bacterial survival, as 
evident by their universal expression on bacterial surface. Genomic sequencing and 
informatics analyses identified 46 lipoproteins on the Streptococcus pneumoniae 
(TIGR4) genome (Tettelin et al. 2001); most of them contributing to its wellbeing 
and survival. Pneumococcal lipoproteins contributing to its virulence include; 
divalent metal ion binding ABC transporters (PsaA, PiaA, PiuA), sortases (SrtC, 
SrtD), and peptide isomerises (PpmA, SlrA) (Bergmann and Hammerschmidt 2006). 
1.5.3.3 Pneumococcal LPXTG Proteins 
This group of proteins share a common mechanism of covalently anchoring 
themselves to the cell-wall peptidoglycan. Genomic sequence analyse identified at 
least 18 LPXTG proteins in pneumococcal TIGR4 strain (Tettelin et al. 2001). Most 
of these proteins are associated with enzymatic or adhesin functions. Interaction of 
pneumococcal LPXTG adhesins (PavB, MucB, PclA, PsrP, PfbA and Spr1806) with 
host sugar or protein molecules allows them to colonise in nasopharyngeal mucosa 
(Löfling et al. 2011). The enzymatic proteins possess specific domains required for 
their homing to the target tissues, where they catalyse various substrate molecules. 
Pneumococcus has six polysaccharide lyasing glycosyl hydrolases; these are SrtH, 
NanA, BgaA, EndoD, SpuA and Eng. There are also four proteases; ZmpA, ZmpB, 
ZmpC and PtrA. These proteases hydrolyse host glycoproteins, glycosaminoglycans 
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and intracellular glycans; thus playing an important role in pneumococcal 
pathogenesis. The mechanism of pneumococcal adhesion and colonisation is shown 
in figure-1.5.3.1. 
 
Figure-1.5.3.1: Pneumococcal adherence and colonisation. Pneumococcal adhesins 
interact directly with human ECM components, soluble plasma proteins and/or cellular 
receptors at the host epithelium. PavA, PavB, PfbA, RrgA, and PspC interact with ECM 
proteins such as fibronectin, laminin and collagen. PspA, PspC, PavB, PfbA, RrgA, enolase 
and GAPDH interact with the circulating plasma proteins like plasminogen, human serum 
albumin, complement regulator Factor H, C3b, IgA, and lactoferrin. Interactions of PspC 
with laminin receptor and pIgR, PsrP with Keratin 10, and PsaA with E-cadherin are also 
shown (Gámez and Hammerschmidt 2012). 
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1.5.3.4 Pneumococcal Histidine Triad Proteins 
This group of proteins share one common thing, four to six repeating histidine triad 
motifs (HXXHXH) within their sequence (Adamou et al. 2001). These motifs bind 
to divalent cations, especially with the Zn
2+ 
ions. Their interaction with this co-factor 
was found to have important regulatory effect on the catalytic activity of human 
phosphodiesterase enzyme, hydrolysing cAMP to AMP (Omburo et al. 1998).  
1.5.3.5 Pneumococcal Non-classical Surface Proteins  
Streptococcus pneumoniae express a number of proteins that do not show the 
classical features of other surface proteins. These proteins lacking conventional 
anchoring or secretory signals are known as non-classical surface proteins. They are 
cytoplasmic proteins with intracellular metabolic functions, not directly taking part 
in host–pathogen interactions. However, they could be translocated to the cell 
surface by mechanisms not yet specified. Some of them act as adhesins to different 
host molecules; and promotes pneumococcal invasion and the spread of the 
infection. This group includes six proteins, PavA, Eno, GAPDH, 6PGD, HtrA and 
PGK.  
1.5.3.6 Pilus in Pneumococcus  
1.5.3.6.1 Bacterial Pilus  
A number of surface structures have been identified to facilitate bacterial adhesion 
on the host epithelial cells. One of these structures is known as pilus, which is a hair-
like projection on bacterial surface; helps them to adhere with the host epithelium. 
Pilus was first described in Gram-negative bacteria by Charles Brinton Jr. in 1965 
and in Gram-positive bacteria by Yanagawa and colleagues in 1968 (Telford et al. 
2006).  
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Figure 1.5.3.6.1: Pilus-mediated adherence of streptococcus to cell surfaces. (a)  
Bacteria initiate attachment to host cells by extending their pili towards the apical surface of 
host cells in a process involving a tip protein (red). (b) An intimate attachment follows, in 
which ancillary pilus proteins (green) mediate a zipper-like adhesion of pili to host 
cells. (c) This leads to colonisation of the apical surface of the host cell, in a process 
mediated by the expression of high-affinity surface adhesins (Telford et al. 2006). 
Gram-positive pili differ from Gram-negative pili structures and assembly 
mechanisms. Gram-negative pili are composed of non-covalently linked protein 
subunits, whereas Gram-positive pili are formed by covalent linkage of protein 
subunits. Pilus in Gram-positive bacteria comprises three protein subunits; each 
containing an LPXTG motif. They are assembled by covalent linkage of their 
subunit proteins catalysed by the sortase enzymes. These sortases also attach them to 
the cell wall peptidoglycan layer by a transpeptidase reaction (Telford et al. 2006). 
These Gram-positive pili proteins act like microbial surface components recognizing 
adhesive matrix molecules (MSCRAMM). They bind to the extracellular matrix 
components (fibronectin) of the host mucosa (Schwarz-Linek et al. 2004). Apart 
from mediating their adhesion to host mucosa to initiate colonisation, pili also assist 
in bacterial aggregation to build a microbial community in the infected tissue. 
Bacterial colonisation particularly with this higher bacterial density leads to a 
heightened inflammatory reaction and robust immune response (Telford et al. 2006). 
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1.5.3.6.2 Pneumococcal Pilus Proteins   
Barocchi et al. reported the presence of pilus (later designated as pilus type-1) in 
some of encapsulated strains (TIGR4 and ST162) of pneumococcus (Barocchi et al. 
2006). Later on, a different type of pilus (pilus type-2) was demonstrated in some 
other strains belonging to serotype 1, 2, 7F and 19A (Bagnoli et al. 2008). Pilus-1 
has been reported to be present in 30% of pneumococcal strains (Moschioni et al. 
2010a); and 27% of the pneumococcal isolates responsible for invasive diseases 
(Aguiar et al. 2008). On the other hand, 7% of pneumococcal strains possess pilus-2 
gene (Moschioni et al. 2010a); and among the invasive isolates its prevalence has 
been reported as high as 16% (Bagnoli et al. 2008). A recent study in Malawi has 
revealed relatively lower prevalence of pilus-1 (9%) and pilus-2 (6%) among the 
invasive pneumococcal isolates (Kulohoma et al. 2013). Prevalence of pilus genes 
has been reported to be higher in antibiotic resistant strains of pneumococcus 
(Moschioni et al. 2010a).  
Cryo-electron microscopic analysis of purified type-1 pilus of TIGR4 has shown 
them as elongated structures with a maximum length of 1µm (Hilleringmann et al. 
2008). TIGR4 pilus is composed of three subunits. The major structural component 
is the RrgB, from where subunit RrgA extends to the periphery and subunit RrgC 
remains attached to the bacterial cell wall (Hilleringmann et al. 2009). RrgA binds to 
the extracellular matrix (ECM) components; such as, collagen I, laminin, fibronectin, 
fibrinogen and lactoferrin, but not to vitronectin (Hilleringmann et al. 2008). Binding 
of RrgB and RrgC to these ECM components is negligible (Hilleringmann et al. 
2008). In addition to that, RrgA binds to host respiratory epithelial cells (Nelson et 
al. 2007). 
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Figure-1.5.3.6.2: Schematic diagram of S. pneumoniae pilus 
structure. The TIGR4 pilus consists of a shaft composed of RrgB, 
with RrgA at its distal and RrgC at its proximal end. Sortase SrtC-1 
mediates the polymerisation of RrgB via the LPXTG motif (§, 
IPQTG) and pilin motif (#) into a single string of monomers, 
covalently linked head-to-tail. Sortases also mediates the addition of 
the ancillary proteins RrgA and RrgC to the pilus shaft, and 
anchorage of RrgC to the peptidoglycan cell wall, using respective 
LPXTG motifs for RrgA (*, YPRTG) and RrgC (¶, VPDTG) 
(Hilleringmann et al. 2009). 
Like other Gram-positive pili, these proteins possess C-terminal sorting signals, 
functioning as MSCRAMMs. The C-terminal sorting signals of TIGR4 pilus protein 
shows conserved LPXTG motifs and charged tails (Figure-1.5.3.2), except the 
leucine of LPXTG is substituted by tyrosine, isoleucine and valine in RrgA, RrgB 
and RrgC respectively (Hava and Camilli 2002). 
 
Figure-1.5.3.6.3: The C-terminal sorting signals of TIGR4 pilus proteins. Underlined 
portions denote hydrophobic regions (Hava and Camilli 2002).  
Two functionally similar variants of RrgA has been reported, clade I (893 amino 
acids) and clade II (890 amino acids). Both variants have similar structural 
organizations with an N-terminal leader sequence and an LPXTG-like (YPRTG) C-
terminal region (Moschioni et al. 2010b).  Overall, they share 84% to 98% sequence 
identity; and the variability is mostly located in the distal D3 (head) domain, leaving 
a well conserved D1, D2, and D4 (stalk) domains (Moschioni et al. 2008; Moschioni 
et al. 2010b). RrgB, the major component of pilus-1 is also organised into four 
immunoglobulin-like domains; D1 (residues 1-184), D2 (residues 184–326), D3 
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(residues 326–446) and D4 (residues 446–627) (Gentile et al. 2011; Spraggon et al. 
2010). Each of the D2, D3, and D4 domains is stabilized by one covalent 
intramolecular isopeptide bond, giving them a rigid molecular structure and protect 
them from proteolytic cleavage (Gentile et al. 2011). Among the three pilus-1 
components, RrgB is the least conserved subunit protein, which exists in three 
different variants with 49% to 67% sequence homology (Moschioni et al. 2008). The 
most conserved subunit protein of pilus-1 is RrgC showing 98% to 99% sequence 
homology (Moschioni et al. 2008). 
1.5.3.6.3 Pneumococcal Pilus Genes 
The genes encoding the two types of pneumococcal pili reported so far are 
designated as pilus islet (PI) -1 and 2. The PI-1 genes are located in the rlrA 
pathogenicity islet of pneumococcal TIGR4 strain (Barocchi et al. 2006). This islet 
contains seven genes; namely rlrA, rrgA, rrgB, rrgC, srtB, srtC, and srtD. The rlrA 
is a regulatory gene; rrgA, rrgB, and rrgC encode pilus-1 proteins; others (srtB, srtC, 
and srtD) encode sortases, which are catalytic enzymes (Hava et al. 2003). 
The PI-2 locus consists of five genes pitA, sipA, pitB, srtG1and srtG2. Two of them 
(srtG1 and srtG2) are sortases; another two code for LPXTG-type pilus protein 
subunits (pitB and pitA); and the other one codes a signal peptidase-related product 
(sipA). PitB is the major structural subunit, which forms the backbone of type-2 
pilus. SrtG1- and SipA- dependent polymerisation of PitB is the essential step for PI-
2 pilus assembly on the bacterial surface. The other two genes srtG2 and pitA are not 
essential for pilus assembly; and there is not much evidence on their ability to 
encode functional proteins.  
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Figure-1.5.3.6.4: The genomic organization of pilus-encoding islets PI-2 (A) and PI-1 
(B) in S. pneumoniae. Schematic representation of genomic regions in TIGR4 (positive for 
PI-1 and negative for PI-2); and INV104 strains (positive for PI-2 and negative for PI-1) are 
shown (Bagnoli et al. 2008).  
1.6 Host Immunity to Pneumococcus 
1.6.1 Innate Immune Response 
The Human innate immune response to pneumococcus includes mucociliary 
clearance of bacteria in the upper respiratory tract; complement mediated lysis and 
opsonisation followed by phagocytosis. On recognition of the bacteria by various 
pathogen recognition receptors (PRR), host respiratory epithelium signals to recruit 
phagocytes, such as neutrophils and macrophages. Apart from phagocytising 
bacteria, these cells also release many inflammatory mediators, which contribute to 
the clearance of bacteria.  
Apart from providing a protective barrier and mucociliary cushion, respiratory 
epithelium secretes many other protective molecules against pneumococcal 
infection. These include various cytokines, chemokines, anti-microbial peptides, 
lysozyme, lactoferrin, β-defensins, phospholipase A2, and surfactants (Bals and 
Hiemstra 2004). Breach of these innate defence results in an acute inflammatory 
response, marked by neutrophil influx at the site of invasion. Failure of this 
inflammatory response to clear the bacteria, results in their dissemination to the 
lungs (Kadioglu et al. 2008).   
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In the lungs, three types of cellular responses occur. The cell type which engages 
first is the resident alveolar macrophages (AM), which can contain the infection by 
phagocytosis if the bacterial load is low (Dockrell et al. 2003). If the bacterial load is 
high, the polymorphonuclear cells are recruited for phagocytosis, while alveolar 
macrophages play a scavenging role to remove apoptic inflammatory cells (Knapp et 
al. 2003). Finally the monocyte-derived macrophages (MDM) get involved in the 
phagocytosis process (Smith et al. 2011). Eventually all phagocytic cells undergo 
apoptic process to prevent spreading of bacteria in circulation (Dockrell et al. 2003).  
Phagocytosis of pneumococcus is facilitated by complement mediated opsonisation. 
Activation of complement may be triggered by the bacteria itself, but a more robust 
activation occurs in the presence of a pre-existing serotype-specific antibody. The 
importance of complement in innate host defence against the pneumococcus is well 
documented. Complement deficient patients are vulnerable to more severe form of 
pneumococcal infections; usually in recurrent episodes throughout their life. The 
classical pathway seems to be the most important, as its defect is associated with 
pneumococcal septicaemia and other fatal consequences (Brown et al. 2002). 
1.6.1.1 Pattern Recognition Receptors (PRR) 
A number of PRR have been suggested to be involved in the recognition of 
pneumococcus. These include C-reactive protein (CRP), LPS binding proteins 
(LBP), toll-like receptors (TLR), specific ICAM-3 grabbing nonintegrin-related 1 
(SIGN-R1), macrophage receptor with collagenous structure (MARCO) and 
intracellular nod-like receptors (NLR) (Paterson and Mitchell 2006). A schematic 
diagram of pneumococcal interaction with different PRR is shown in figure (Gámez 
and Hammerschmidt 2012). 
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Figure-1.6.1: The PRR sensing pneumococci. The interaction of pneumolysin with TLR4, 
the recognition of LTAs, TAs and PCho by TLR2, TLR1, TLR6 and CD14; and the sensing 
of the pneumococcal capsule by MARCO, CD14 and SIGN-R1 are depicted. The 
interactions between pneumococci and integrin receptors (αMβ2 and αVβ3) together with their 
molecular bridges (factor H and vitronectin); complement protein C3b with PspA; and 
Factor H with PspC are also shown (Gámez and Hammerschmidt 2012). 
1.6.2 Adaptive Immune Response 
The adaptive immune response to pneumococcus develops following exposure to 
pneumococcal antigens during symptomatic infection or asymptomatic bacterial 
colonisation. 
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1.6.2.1 Antibody Response to Pneumococcus 
As in other extracellular pathogens, the elimination of Streptococcus pneumoniae 
mostly depends on killing by various phagocytes including alveolar or tissue 
macrophages, and neutrophils. However, antibodies developed against capsular 
polysaccharides crucially contribute to this elimination process by opsonising the 
bacteria, and making them available for phagocytic killing or complement mediated 
lysis (Weinberger et al. 2008). Antibodies developed against non-capsular protein 
antigens also play an important role (Vukmanovic-Stejic et al. 2006). Patients 
suffering from various B cell defects with impaired antibody production were found 
to be more susceptible to recurrent and severe forms of pneumococcal infections 
(Picard et al. 2003). This suggests that antibodies are important component of host 
protective immunity against pneumococcus.  
1.6.2.1.1 Antibodies to Capsular Polysaccharides  
Production of antibodies against capsular polysaccharide is serotype-specific and 
associated with asymptomatic nasopharyngeal colonisation or symptomatic 
pneumococcal infection (Soininen et al. 2001). These antibodies confer serotype-
specific and some cross protective immunity (Lipsitch et al. 2005). The protective 
efficacy of anti-polysaccharide antibodies have been well documented by the success 
of pneumococcal polysaccharide vaccines (Cornu et al. 2001), and polysaccharide 
conjugate vaccines (Gertz et al. 2003). The evidence of their protective function can 
be traced as early as 1938, in a paper (Lord and Heffron. Pneumonia and serum 
therapy), showing bacterial clearance with serum containing type-specific anti-
capsular antibodies (Weinberger et al. 2008). 
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1.6.2.1.2 Antibodies to Non-capsular Antigens  
Apart from inducing anti-capsular antibodies, nasopharyngeal carriage of 
pneumococcus also leads to generation of antibodies against other pneumococcal 
components, particularly surface-exposed proteins. An experimental carriage model 
in healthy adult human found that, pre-existing antibodies to pneumococcal surface 
protein A (PspA) was protective against pneumococcal colonisation (McCool et al. 
2002). A study using a mouse model (Briles et al. 2000) showed that, a number of 
other proteins; pneumolysin (Ply), pneumococcal surface adhesion A (PsaA), 
pneumococcal surface protein C (PspC) were also able induce protective antibody 
responses. Subsequent studies have also validated the protective effect of responses 
to pneumococcal surface proteins, showing age dependent increase of antibody titre 
with a decreasing nasopharyngeal carriage; and a higher antibody levels to culture-
negative children (Zhang et al. 2006b; Vukmanovic-Stejic et al. 2006). These 
antibodies appear early in the childhood, achieving a good titre before the second 
birthday; as evidenced in a Finnish (Rapola et al. 2000) and a Kenyan study (Ellis 
and Beaman 2004). Considering the fact that, the anti-capsular antibodies start to 
develop during the second and third year of life; antibodies to protein antigens could 
play a crucial protective role in young children (Lipsitch et al. 2005). 
Serum analysis of convalescent children recovering from invasive infections showed 
high titre of antibodies to commonly expressed pneumococcal proteins. Sera from 
their parents, understandably exposed to the organism, were also analysed. High 
titres of antibody were observed in their parents also, which were possibly generated 
from their exposure to the bacteria. These antibodies seemingly had protective 
capacity, as none of them were colonised with pneumococcus (Giefing et al. 2008). 
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1.6.2.1.3 Antibody subclasses induced by pneumococcal antigens 
Analyses of pre-vaccination antibodies against several pneumococcal serotypes (3, 
24 and 18C) in adults revealed a predominance of IgM and IgG2 isotypes, although 
IgGl, IgG3, IgG4, and IgA were also detectable. However, after vaccination with 
pneumococcal polysaccharide vaccine (PPSV23), isotypes IgG1, IgG2, and IgA 
showed the strongest responses (Sarvas et al. 1989). Other studies also reported a 
predominant IgG1 and IgG2 responses following vaccination with polysaccharide 
antigens (Chudwin et al. 1987). In healthy children both IgG1 and IgG2 subclasses 
were found to be higher than in otitis prone children; although IgG1 seemed to be the 
predominant subclass (Freijd et al. 1984). In general, antibody response to 
pneumococcal polysaccharides in adults is mostly contributed by IgG2; and in 
children the predominant subclass is IgG1 (Bruyn et al. 1992).  
On the other hand, microbial protein antigens induce an antibody response 
dominated with IgG1 and IgG3 subclasses (Hjelholt et al. 2013). This trend has been 
shown for pneumococcal proteins also (Zhang et al. 2006b). The ability of different 
IgG subclasses to activate complement varies. Generally, IgG3 is the most potent 
complement activator, followed by IgG1 than IgG2; and IgG4 has no complement 
activation property (Ram et al. 2010). Considering this, the pneumococcal protein 
antigens might be more efficient than the capsular polysaccharides in generating 
functional antibody responses. 
1.6.2.2 Cellular Immunity to Pneumococcus 
Antibody mediated protective responses were believed to be the key against 
pneumococcal infection, before evidence regarding involvement of adaptive cellular 
immunity became available. Mice, genetically rendered unresponsive to 
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polysaccharide antigens (CBA/N) or deficient of mature B cells (µMT), were able to 
clear experimental pneumococcal colonisation (McCool and Weiser 2004). The 
crucial role played by CD4
+
 T cells in anti-pneumococcal immunity was 
immediately evidenced, with a study showing their migration towards the site of 
infection (Kadioglu et al. 2000); and higher susceptibility of MHCII-knockout mice 
to pneumococcal colonisation and invasion (Kadioglu et al. 2004).  
The superiority of T cells over antibody mediated immunity was also documented, as 
nasopharyngeal colonisation of pneumococci was inhibited in experimental mice 
lacking antibody responses, not those lacking T lymphocytes. Evidently, this 
protective response was mediated by CD4
+
 cells, rather than the CD8
+
 subset 
(Malley et al. 2005). Experimental colonisation by live pneumococcus or killed 
whole-cell vaccine (WCV) confers protection in antibody deficient, but not in CD4
+
 
T cells deficient mice (Lipsitch et al. 2005). A number of pneumococcal proteins, 
including pneumolysin, PspA, CbpA, PsaA can also induce CD4
+
 T cell mediated 
protective response (Kadioglu et al. 2004; Basset et al. 2007a; Zhang et al. 2007; 
Mureithi et al. 2009). This antigen-specific induction may occur as both primary and 
memory CD4
+
 T cell response (Zhang et al. 2007; Trzciński et al. 2008).  
1.6.2.2.1 Phenotypes of CD4
+
 T cells Involved in Pneumococcal Immunity 
By assessing the cytokine response triggered by stimulation from different 
pneumococcal antigens, involvement of all major phenotypes (Th1/Th2/Th17) of 
CD4
+
 T cells has been reported. A number of Th1 cytokines take part in the host 
defence against pneumococcus, including IFN-γ, TNF-α, IL-2 and their inducers 
such as IL-12 and IL-18 (Khan et al. 2002). CD4
+
 T cells migrating towards the site 
of pneumococcal challenge shows higher IFN-γ expression than the non-migrating 
population (Kadioglu et al. 2004). Appearance of TNF-α in the host serum is the 
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quickest cytokine response to pneumococcal lung infection. Together with another 
early response cytokine IL-1, it enhances neutrophil recruitment to induce a local 
pro-inflammatory response; and assist in bacterial elimination through NF-κB 
mediated pathway (Jones et al. 2005). IL-12, an IFN-γ inducer, also plays a 
protective role in pneumococcal lung infection. A murine study demonstrated that, 
intranasal administration of IL-12 was associated with decreased severity of 
pneumococcal pneumonia with a lower bacterial burden and a higher survival rate; 
seemed to be mediated by IFN-γ induced polymorphonuclear recruitment (Sun et al. 
2007).  
An up-regulated expression of IL-4, the signature cytokine of Th2 type response was 
also reported in CD4
+
 T cells migrating towards the site of pneumococcal challenge 
(Kadioglu et al. 2004), suggesting the importance of Th2 support required for an 
effective antibody-mediated immune response against pneumococcus. Another Th2 
related cytokine IL-10 contributes to pneumococcal immunity by suppressing Th1 
type response and shifting the balance towards a potent antibody response (Zhang et 
al. 2006a).  
Subsequently, a subset of CD4
+
 T cells secreting IL-17A (Th17 cells) has been 
identified as an important effector for both innate and acquired immune response 
against pneumococcus. IL-17A production by cultured mice splenocytes has been 
shown to be up-regulated when stimulated with pneumococcal cell wall 
polysaccharides (Malley et al. 2006). Moreover, prior treatment of experimentally 
colonised mice with anti-IL-17A antibody was associated with marked reduction in 
the nasopharyngeal clearance of pneumococci (Malley et al. 2006). IL-17A recruits 
phagocytic cells in both primary and secondary pneumococcal colonisation (Zhang 
et al. 2009). Pneumococcal WCA stimulation has also been shown to induce a strong 
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IL-17A response in human adenotonsillar MNC culture. Also an enhanced 
phagocytosis of pneumococci by human polymorphonuclear cells has been reported 
after pre-incubation with IL-17A (Lu et al. 2008). Another Th17 related cytokine, 
IL-22 is has been shown to be induced by pneumococcal WCA and pneumolysoid 
(PdT) (Lundgren et al. 2012).  
1.6.3 The Mucosal Immune System 
Based on the location and function, the mucosal immune system can be subdivided 
into two components; the site of immune induction and the effector site (McGhee 
and Fujihashi 2012). The immune induction takes place in the organised lymphoid 
tissues in various organs, collectively known as mucosa-associated lympho-reticular 
tissues (MALT). These are the sites for activating antigen-specific B and T cells 
along with assignment of their homing signals. These activated lymphocytes then 
move to the mucosal effector sites in the lamina propria region for polymeric IgA 
synthesis and T cell response (Kiyono and Fukuyama 2004). MALTs are distributed 
widely along the various mucosal surfaces and are known as different names, such 
as; gut-associated lymphoid tissues (GALT), nasopharynx-associated lymphoid 
tissues (NALT), and some less defined lymphoid tissues in other mucosal sites 
(McGhee and Fujihashi 2012).  
1.6.3.1 Nasopharynx Associated Lymphoid Tissue (NALT) 
Human nasopharynx-associated lymphoid tissue (NALT) includes tonsils, adenoids, 
inducible bronchus-associated lymphoid tissues (iBALT), cervical lymph nodes and 
hilar lymph nodes (McGhee and Fujihashi 2012). The major contributor of the 
human NALT is the ‘Waldeyer’s ring’, an interrupted circle of lymphoid tissues at 
the junction of the nasopharynx and oropharynx, which is strategically positioned to 
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guard against both airborne and ingested pathogens. Besides, playing a crucial role in 
immune induction, they also contribute as an effector site for local systemic and 
secretory mucosal immunity (Brandtzaeg 2011).  
 
 
 
 
 
 
 
Figure-1.6.3.1: The Waldeyer’s ring, formed by the adenoid, tubal tonsils, palatine tonsils 
and lingual tonsil 
Structurally, adenoids and tonsils resemble lymph nodes, except they do not have the 
afferent lymphatics to carry the antigens into them. Rather they encounter antigens 
which are trapped into the numerous crypts containing microfold or ‘M’ cells. This 
trapping expose the luminal antigens to local antigen presenting cells (APC) 
(Brandtzaeg 2003). Apart from the abundance of B cells, adenotonsillar tissues are 
also rich in macrophages and dendritic cells for presenting antigens, which help them 
to develop both Th1 and Th2 types of responses to these antigens (Boyaka et al. 
2000). Adenotonsillar MNC, contains various types of lymphocyte populations, 
including naive (CD45RA
+
), memory (CD45RO
+
) and recently activated (CD25
+
) 
cells, and are capable of inducing both primary and secondary immune responses 
(Brandtzaeg 2011).  
Pharyngeal tonsil (Adenoid)   
Upper midline in the nasopharynx 
Tubal tonsil  
Around opening of 
auditory tube  
Palatine tonsil          
Either side of the 
oropharynx 
Lingual tonsil 
Under mucosa of the posterior third of the tongue 
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Anatomically human adenoid and tonsils are divided into four specialized lymphoid 
compartments; the reticular crypt epithelium, the extra-follicular area, the mantle 
zones of lymphoid follicles, and the follicular germinal centres (GC) (Brandtzaeg 
2003). Adenotonsillar GCs are formed by activated B cells upon interaction with 
exogenous antigens. This process initiates shortly after birth as a part of T cell-
dependent B-cell responses (Brandtzaeg 2003). The extra-follicular region contains 
both T and B lymphocytes.  The latter is also found in the germinal centers of the 
lymphoid follicles, the mantle zone and the reticular sites of the tonsillar crypts 
(Boyaka et al. 2000). Unlike the peripheral blood compartment, where T cells are the 
predominant lymphocyte population, adenotonsillar tissues are rich in B cells. CD4
+
 
T cells were found to be the predominant T cell subtypes in adenotonsillar tissues, 
with a low percentage of CD8
+
 cytotoxic T cells (Passàli et al. 2003). IgG is the 
predominant antibody isotype of B cells in adenotonsillar tissues and the frequency 
of IgM and IgA isotypes are low (Passàli et al. 2003). 
1.6.3.2 Effect of Adenotonsillectomy 
In this study adenotonsillar tissues were collected from patients underwent routine 
tonsillectomy and/or adenoidectomy. Common indications for surgical removal of 
these tissues include hypertrophy associated with obstructive respiratory symptoms 
(like mouth breathing, sleep disturbance) and recurrent infections (Mattila et al. 
2010; van Staaij et al. 2005).  
The effect of adenotonsillectomy on the immune system, especially on the upper 
respiratory mucosal immune response remains questionable. One of the common 
indications for their surgical removal is to get rid of chronic infections. Yet there 
were reports of an increased risk of nasopharyngeal colonisation by respiratory 
pathogens after adenotonsillectomy (Mattila et al. 2010). A meta-analysis on the 
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effect of adenotonsillectomy on upper respiratory tract infections showed only a 
small reduction in episodes of sore throat and associated school absence, and upper 
respiratory infections (van Staaij et al. 2005).  
Following adenotonsillectomy, immunoglobulin levels seem to fall transiently. IgA 
titre is the most affected isotype, although IgG1 and IgG2 levels also decrease 
(Østergaard 1977). However, the antibodies often rise to the original level within one 
year or so, particularly when repeated infections are encountered (van den Akker et 
al. 2006). This suggests that a compensatory mechanism exists, where the remaining 
mucosal lymphoid tissues compensate for the initial loss of antibody responses after 
surgical removal of adenotonsillar tissues.  
NALT are important induction and effectors site for immunity against respiratory 
pathogens. Adenotonsillectomy seems to increase the likelihood of pneumococcal 
carriage especially when performed in very early age, and decrease the 
pneumococcal polysaccharide-specific antibody response (Mattila et al. 2010). This 
suggests that adenotonsillar tissues are crucially involved in the immune response to 
pneumococcus in children.  
1.7 Pneumococcal Vaccines  
1.7.1 Historical Perspective of Pneumococcal Vaccine Research  
The first successful vaccination attempt was reported a century earlier in 1911, when 
Wright and his colleagues developed a pneumococcal crude whole cell vaccine and 
immunised gold mine workers in South Africa (Butler et al. 1999). Subsequently, 
Heidelberger and Avery reported the polysaccharides nature of pneumococcal 
capsule (Heidelberger and Avery 1923) and suggested of their immunogenic 
potential (Heidelberger and Avery 1924). In 1930, researchers (Tillett and Francis 
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1930) observed capsular polysaccharide induced specific antibody response in 
humans. Inspired by these findings, efforts to develop vaccines from pneumococcal 
capsular polysaccharides went on with development of a quadrivalent vaccine from 
capsular polysaccharides of serotype 1, 2, 5 and 7 (MacLeod et al. 1945). 
Commercial production of this pneumococcal polysaccharide vaccine started after 
the end of the World War II. In the meantime, with the discovery of penicillin and 
other antibiotics; the attention was diverted from preventive vaccines to curative 
approach. The researches on vaccine development lost momentum and by the middle 
of the last century pneumococcal vaccines disappeared from the market (Butler et al. 
1999). 
 1.7.2 Pneumococcal Polysaccharides Vaccines (PPSV) 
With the emergence of antibiotic resistance, the need for pneumococcal vaccine was 
raised again (Austrian and Gold 1964). Austrian and co-workers pioneered the 
revival of pneumococcal vaccine research and reported the safety and high efficacy 
(78.5%-82.3%) of polyvalent vaccines, prepared from purified capsular 
polysaccharides in three different trials (Austrian et al. 1976). Subsequently, a 14-
valent PPSV was approved for general use in 1977, which consisted of 50µg purified 
capsular polysaccharides from each of the following serotypes; 1, 2, 3, 4, 6, 8, 9, 12, 
14, 19, 23, 25, 51 and 56 (Hilleman et al. 1978). Soon after that, the serotype 
coverage was increased in a 23-valent polysaccharide vaccine (PPSV23), which was 
licensed in 1983 (Lee et al. 1991). PPSV23 consists of 25µg capsular 
polysaccharides from serotypes; 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 
15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F (CDC 1997). PPSV23 covers 
against most of the invasive pneumococcal serotypes, with a very good efficacy in 
immunocompetent adults and older children (Shapiro et al. 1991). 
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Selection of these serotypes was based on the worldwide prevalence, which varied 
among different regions. The prevalence of invasive pneumococcal diseases by these 
vaccine serotypes ranged from 72% to 95% in different part of the world (Huss et al. 
2009). In the developed countries of Europe and America PPSV23 covers serotypes 
responsible for nearly 90% of invasive pneumococcal infections (Butler et al. 1993). 
In Britain the 80-90% of the severe pneumococcal infections occurred by the vaccine 
serotypes (Noah 1988). A study in Scotland revealed that, nearly 99% non-invasive 
isolates in <5 children and 96% isolates in >65 adults were covered with PPSV23 
(Kyaw et al. 2002). However, some of the developing countries reported lower 
coverage. A Malaysian study showed that, 62.7% of total pneumococcal infections 
and 71% of invasive diseases occurred with these 23 serotypes (Rohani et al. 1999). 
A study in Bangladesh found that, these vaccine serotypes are responsible for about 
70% of the pneumococcal infections (Saha et al. 1997). 
1.7.3 Pneumococcal Conjugate Vaccines (PCV) 
Soon after the introduction of PPSV23 for routine vaccination it was apparent that it 
is poorly immunogenic in younger children, particularly in those aged less than 2 
years (Borgoño et al. 1978), who are the most vulnerable group for pneumococcal 
infection. Therefore, development of a vaccine effective in young children and infant 
was much needed. In the meantime, the utility of conjugation of carrier protein with 
polysaccharide antigens was evident on the meningococcal and Haemophilus 
conjugate vaccines. Several carrier proteins were tested for conjugation with 
pneumococcal capsular polysaccharides.  
At first, a tetra-valent conjugate vaccine was prepared with outer membrane protein 
complex of Neisseria meningitides; which showed good immunogenicity in 31 
toddlers as well as 62 infants in Finland (Käyhty et al. 1995). Another tetravalent 
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vaccine conjugated with diphtheria toxoid also found to induce a good memory 
response upon boosting (Åhman et al. 1998). Subsequently, a penta-valent 
(6B,14,18,19F,23F) (Ahman et al. 1996) and a hepta-valent (4,6B,9V,14,18C,19F 
and 23F) polysaccharide vaccine (Shinefield et al. 1999) conjugated to a nontoxic 
form of diphtheria toxin CRM197 were found to induce a good antibody response in 
infant and toddlers.  
A large scale safety and efficacy trial of the hepta-valent vaccine (PCV7) conjugated 
to CRM197 was carried out in Northern California, USA; which included 37,868 
children in a randomly selected double blinded trial (Black et al. 2000). The safety 
and efficacy of that vaccine was reported to be excellent. It revealed that, 3 doses of 
the vaccine in two months interval, starting from the 2 months age; followed by a 
booster dose on the second years, had successfully protected the children from 
pneumococcal diseases (Black et al. 2000). With the success of this trial, PCV7 was 
approved for the routine immunisation schedule of children in USA in the year 2000. 
Since then, it has been routinely used in children younger than 2 years of age, 
administered in a 3 doses schedule, followed by a booster at 12-15 months (CDC 
2000). A contemporary Finnish trial also reported a good safety and efficacy profile 
of the PCV7 (Eskola et al. 2001). As a result, the polysaccharide vaccine was 
replaced with PCV7 in the European countries; and by the year 2007, PCV7 had 
been licensed in more than 70 developed countries in the world (WHO 2007).  
After its inclusion in the routine childhood immunisation programme, PCV7 
successfully reduced the rates of invasive pneumococcal disease among in USA; 
from 97 to 24 cases per 100,000 of population. Invasion by vaccine-type strains fell 
from 80 to 4.6 cases per 100,000 populations (Mahon et al. 2006). Possibly through 
generation of herd immunity, PCV7 significantly decreased the incidence of 
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pneumococcal disease among unvaccinated individuals in USA (Whitney et al. 
2003). Another study suggested that, introduction of PCV in USA reduced the 
incidence of invasive diseases and hospitalizations in elderly by 22.6%, 30.2% and 
40.6% in the year 2002-01, 2001-02 and 2002-03 respectively; compared to the 
baseline in 1996-97 (McBean et al. 2005). An evaluation carried out after 7 years of 
the introduction of PCV7 has shown 45% reduction of invasive infection caused by 
all serotypes of pneumococci. Whereas, the incidence of invasive pneumococcal 
diseases caused by serotypes included in the PCV7 had declined by 94% (Pilishvili 
et al. 2010). PCV7 has also been shown to confer very good protection (74% 
efficacy) in HIV-infected adults from the vaccine serotypes and a vaccine related 
serotype, 6A (French et al. 2010). 
PCV7 was designed for the markets in the industrialised countries. The serotypes 
incorporated in the vaccine were the most prevalent in USA. Some of the common 
invasive serotypes (like 1 and 5), prevalent in developing countries are not included 
into it. Another important drawback of PCV7 was evident in countries, where it was 
introduced for routine vaccination. The initial magical success of PCV7 had been 
overshadowed by the reports of replacement diseases with serotypes not included in 
the vaccine (O'Brien et al. 2007b; Singleton et al. 2007).  
Thus, the serotype replacement and emergence of newer invasive serotypes has 
become the matter of new concern. One of the possible solutions could be 
broadening of the serotype coverage. It is not an easy task to incorporate more 
serotypes; as the serotype distribution around the world is quite diverse. Moreover, 
conjugation of additional serotypes in the PCV is technically challenging. 
Nevertheless, up-gradation of pneumococcal conjugate vaccine with incorporation of 
additional serotypes continued.  
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At first, a 9-valent formulation including serotypes 1 and 5 with PCV7 was 
developed (Mbelle et al. 1999). This vaccine was found to be effective in reduction 
of overall pneumococcal burden, although there was still an indication of increasing 
infection by non-vaccine serotypes (Klugman et al. 2003). Later, trial with an 11-
valent conjugate vaccine adding two more serotypes 3 and 7F showed promising 
prospect (Prymula et al. 2008). Relentless efforts to broaden the serotype coverage of 
the conjugate vaccine went on to develop a 13-valent PCV including two extra 
serotypes 6A and 19A. After a successful safety and efficacy trial of this 13-valent 
conjugate vaccine (PCV13) (Dinleyici and Yargic 2009); it was licensed for routine 
immunisation of children in the USA in February 2010 (CDC 2010b). Shortly after 
that, PCV13 has been introduced in many other developed countries including UK, 
replacing PCV7 for routine immunisation (van Hoek et al. 2012). The PCV13 
formulation (Prevnar 13, Wyeth Pharmaceuticals Inc.) contains capsular 
polysaccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 
23F; all of them individually conjugated to CRM197 carrier protein (CDC 2010b). A 
study in USA carried out before the licensure revealed that 64% of invasive 
pneumococcal diseases (IPD) was caused by serotypes included in PCV13; the 
additional six serotypes (than PCV7) accounted for 95% (60% of total) of them 
(CDC 2010a).  
1.7.4 Cellular Immune Mechanisms of PPSV and PCV  
The pneumococcal polysaccharide vaccine induces type-specific antibodies, which 
activate complement complex and promote bacterial opsonisation and phagocytosis 
(CDC 1997). Pneumococcal capsular polysaccharides are large, complex molecules 
composed of repeating immunogenic epitopes. They are recognised by the B cell 
receptors (BCR) and trigger the signal transduction for clonal expansion of serotype-
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specific B cells. The activated B cells are converted to plasma cells secreting type 
specific antibodies. These antigens are capable of stimulating the B lymphocytes 
directly, without getting broken-down and presented by the antigen presenting cells 
(APCs). As these antigens are recognised without the intervention of helper T cells, 
they are termed as T-independent (TI) antigens (Käyhty et al. 1984).  
Multivalent pneumococcal conjugate vaccines (PCV) are prepared by the covalent 
coupling of the capsular polysaccharides to a protein carrier. The protein conjugated 
polysaccharides also stimulate the BCR in an identical way. Additionally, the 
conjugated carrier proteins are processed by the antigen presenting cells (APC); and 
presented to the CD4
+
 helper T cells. These T cells offer so-stimulatory signals for 
an enhanced primary antibody response. They also initiate a memory B cell and T 
cell response resulting in a quicker and stronger secondary response (Mazmanian 
and Kasper 2006).  
The immune response induced by pneumococcal conjugate vaccine is stronger than 
that of polysaccharide vaccine. Particularly, it is highly effective in infants, young 
children, the elderly and immunodeficient persons. Moreover, the conjugate proteins 
prime memory B cells and T cells, which results in immune enhancement on a 
booster dose or subsequent exposure to infection (Mazmanian and Kasper 2006).  
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Figure-1.7.4: The immune responses to (a) polysaccharide only vaccine and (b) 
conjugate vaccines (Mazmanian and Kasper 2006).  
1.7.5 Advantages and Disadvantages of PPSV and PCV 
Despite a huge success in controlling pneumococcal diseases, the PPSV23 failed to 
become a universal choice, due its poor immunogenicity in infant and young 
children. The B cells of new-born children and infants respond poorly to these 
polysaccharide antigens (Barrett et al. 1984). With further maturation of immune 
system, antibody response start to develop slowly after the first year but protective 
efficacy remains unsatisfactory in children younger than 2 years. Moreover, these 
antigens do not induce a memory response; hence there is no immune enhancement 
on revaccination (Dintzis 1992). As there is no memory, periodic revaccination with 
polysaccharide vaccine is necessary. But there is evidence that, pneumococcal 
polysaccharide vaccine develops immune tolerance on repeated exposures (O'Brien 
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et al. 2007a). PPSV23 does not provide protection against mucosal infection, and 
thus has little effect on reducing nasopharyngeal carriage of pneumococci.  
The immune response induced by pneumococcal conjugate vaccine is stronger than 
that of polysaccharide vaccine. Particularly, it is effective in infants, young children, 
the elderly and immunodeficient persons. Moreover, the conjugate vaccine can 
induce mucosal immunity, which plays an important role in the protection against 
extracellular bacteria. PCV induced production of antibodies (by NALT) in the 
nasopharyngeal mucosa can prevent pneumococcal colonisation (Nieminen et al. 
1999). This ability to inhibit nasopharyngeal colonisation is another key advantage 
of conjugate vaccine over the polysaccharide vaccine (Dagan et al. 1996). The 
protection against pneumococcal carriage not only limits its progression to an overt 
infection in that individual, but also reduces the possibility of transmission of the 
organism to others. Indeed, vaccination of children with a conjugate vaccine has 
been shown to reduce pneumococcal transmission in adults also, thus creating ‘herd 
immunity’ in a community (Millar et al. 2008; Hammitt et al. 2006).  
PPSV23 includes more serotypes than that covered by PCV13. These additional 
serotypes account for 23% of the invasive pneumococcal diseases (IPD) among 
high-risk children of 6–18 years (CDC 2013). It is evident that, even after 
introduction of a PCV with relatively extended serotype coverage (PCV13), 
protection against the full spectrum of invasive pneumococcal serotypes is not 
achievable. While the burden of invasive infections has been dramatically reduced 
with the introduction of PCV, their impact on non-invasive diseases is difficult to 
assess, due to lack of confirmatory diagnosis and/or reporting. Moreover, the 
licensing of PCV13 was based on immunogenicity studies, not on clinical efficacy 
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trials (CDC 2010a). It remains to be seen the full effect of PCV13 on pneumococcal 
disease burden and on serotype replacement.   
Another disadvantage of conjugate vaccine is their high price, which makes them 
impracticable for global use. The expense of inclusion of PCV13 (multiple doses) in 
the national immunisation programme is far beyond the affordability of the 
countries, which harbour the highest pneumococcal burden. There are some other 
relevant issues to consider, such as; standardisation of dose schedule, duration of 
protective response, justification of a booster dose and its timing. Nevertheless, 
PCV13 is the best available option in the market so far, especially for the children 
immunisation.  
Vaccination with a conjugate vaccine, followed by a polysaccharide vaccine could 
provide an enduring immunity against pneumococcal disease. It has been shown to 
maintain a protective level of antibody with broader serotype coverage (de Roux et 
al. 2008). Immunisation with a conjugate vaccine induces a T cell-dependent 
memory response which is boosted by a dose of polysaccharide vaccine. Boosting 
may also happen in response to a subsequent natural exposure. Priming of the 
immune system with PCV13 followed by a single dose of PPSV23 seems to be an 
effective option (Paradiso 2012). In many countries, combined use of PCV13 and 
PPSV23 has been recommended for high risk population to overcome the 
shortcoming of each other. In the USA, one dose of PPSV23 is recommended for 
following-up after PCV13 vaccination in older children (6-18 years) and adults (19-
64 years) with increased risk of pneumococcal infection; and for all senior citizens 
(≥65 years) (CDC 2013; CDC 2012).  
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1.7.6 Development of Protein Based Vaccines for Pneumococcus 
Pneumococcal infections remain on the top of the fatal diseases list. Limitations of 
the capsular polysaccharides and conjugate vaccines have driven the initiatives for 
finding alternative vaccination strategies. Not surprisingly, development of effective 
protein vaccines has been one of the priorities in pneumococcal vaccine research. 
Protein antigens induce a T cell-dependent response and induce memory. If a protein 
antigen is found to be effective and safe, production would be relatively simple. 
Commercial production of such a vaccine by recombinant DNA technology would 
be efficient.   
The essence of vaccinology relies on the production of antibodies, which can either 
inhibit the virulence factors by direct neutralisation or promote opsonophagocytosis 
by host immune cells. Understandably, pneumococcal virulence factors, if 
sufficiently immunogenic, could potentially be suitable vaccine candidates.  That is 
why the pneumococcal proteins involved in disease pathogenesis, especially those 
acting as adhesins are being thoroughly investigated. The efficacy of a protein 
vaccine depends on its ability to induce a strong antibody response together with a 
good immunological memory, and be protective against colonisation and/or 
infection.   
1.7.7 Current Development of Protein-based Vaccines  
Several pneumococcal surface proteins are being evaluated as vaccine candidate.  
Among the adhesins, pneumococcal LPXTG proteins (PavB, PfbA, PclA, PsrP, 
RrgA, RrgB, RrgC, PitA and PitB), pneumococcal choline-binding proteins (PspA, 
CbpA, CbpD, LytA, Pce), lipoproteins (PsaA, PiaA, PiuA and SlrA), pneumococcal 
histidine triad proteins (PhtA, PhtB, PhtC, PhtD and PhpA), and other surface-
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exposed proteins (PavA, PppA, PcsB and StkP) were shown to possess good 
immunogenicity (Gámez and Hammerschmidt 2012). Apart from these adhesins, 
pneumococcal virulence factors (pneumolysin and/or its derivatives) were also found 
to be highly immunogenic (Briles et al. 2003; Zhang et al. 2006b).  Some of these 
proteins are well conserved among pneumococcal serotypes. Hence, the vaccines 
developed with these are expected to confer serotype-independent protection (Tai 
2006; Gámez and Hammerschmidt 2012).  
Pneumococcal choline-binding proteins are extensively studied for immunogenicity.  
Subcutaneous vaccination with pneumococcal surface protein A (PspA) protected 
experimental mice from pneumonia (Briles et al. 2003). Pneumococcal choline 
binding protein A (CbpA or PspC) was also found to be protective against 
nasopharyngeal carriage and fatal sepsis (Glover et al. 2008), whereas pneumococcal 
surface adhesin A (PsaA) showed protective response against carriage only (Briles et 
al. 2000). Another lipoprotein, the putative proteinase maturation protein A (PpmA), 
was found to be immunogenic in humans, and this immune response was protective 
in mice (Ling et al. 2004).  
Among the LPXTG adhesins, immunogenicity of pneumococcal adherence and 
virulence factor B (PavB) was assumed by detection of PavB-specific antibodies in 
human convalescent sera (Jensch et al. 2010). Another protein of this group, the 
pneumococcal serine-rich repeat protein (PsrP) also showed protective immune 
response in experimental mice following intranasal challenge (Shivshankar et al. 
2009). Immunisation with pneumococcal pilus-1 subunit proteins (RrgA and RrgB) 
protected experimental mice; and increased their survival following lethal intra-
peritoneal challenge (Gianfaldoni et al. 2007). The immunogenicity of two other 
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LPXTG proteins PrtA (Pneumococcal protease A) (Bethe et al. 2001), and SpuA 
(surface-located pullulanase) was also documented (Bongaerts et al. 2000).  
Two other pneumococcal surface proteins, PcsB (protein for cell wall separation of 
group B streptococcus) and StkP (serine-threonine protein kinase), identified by 
genomic scale antigenic fingerprinting of pneumococcus were found to elicit a 
strong functional antibody response in human (Giefing et al. 2008). Pneumococcal 
protective protein A (PppA) was shown to induce sufficient antibody responses to 
inhibit pneumococcal carriage in mice nasopharynx (Green et al. 2005). 
Another important group of pneumococcal proteins capable of inducing immune 
response are the pneumococcal histidine triad proteins: PhtA, PhtB and PhtD. These 
proteins are well conserved; especially PhtD appears to be present in all of the 
currently identified serotypes of S. pneumoniae (Hamel et al. 2004). The protective 
capacity of these histidine triad proteins against pneumococcal sepsis were 
documented in experimental mice (Adamou et al. 2001). Safety and efficacy of a 
vaccine produced with PhtD was promising (Seiberling et al. 2012). A combination 
of CbpA and PhtD also showed a good safety and efficacy profile in human (Bologa 
et al. 2012). In another phase I randomized study with a detoxified form of 
pneumolysin (PlyD1), it was found to be quite safe and highly immunogenic in 
human (Kamtchoua et al. 2013). 
It is clear from the above discussion that, pneumococcal toxins and several surface-
expressed proteins are strongly immunogenic. Combination of different protein 
antigens resulted in a more robust response; and their permutation-combination 
yielded better options in achieving specific targets, such as protection against 
invasive infection, nasopharyngeal carriage, development of herd immunity (Briles 
et al. 2000; Ogunniyi et al. 2007). 
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1.7.8 Prospect of a Mucosal Protein Vaccine for Pneumococcus 
All available pneumococcal vaccines are designed for intramuscular administration. 
These vaccines predominantly induce systemic immunity to prevent invasive 
infections. Nasopharyngeal colonisation is the prerequisite for pneumococcal 
diseases. Therefore, local immunisation via nasal spray could be an effective 
alternative vaccination strategy. This could potentially be protective against local 
nasopharyngeal carriage and also be effective against invasive disease. Intranasal 
immunisation against influenza in humans was shown to be safe and very effective 
(Belshe et al. 2004). Unlike injectable vaccines, the immune response induced by 
mucosal vaccines closely resembles natural immunity (Cox et al. 2004). Studies in 
mice using intranasal immunisation of pneumococcal protein antigens (PsaA) has 
shown to induce a strong immune response in both mucosal and systemic 
compartment, which successfully protected against nasopharyngeal colonisation 
(Oliveira et al. 2006; Xu et al. 2011). Intranasal vaccination with another 
immunogenic protein (PspA) has been shown to protect mice against invasive 
pneumococcal infection (Ferreira et al. 2009). 
1.8 Pilus Protein Antigens as Vaccine Candidate – Current Data 
All of the three pilus-1 subunit proteins (RrgA, RrgB and RrgC) have been shown to 
induce protective immune response in murine model (Gianfaldoni et al. 2007). Mice 
intraperitoneally immunised with recombinant RrgA, RrgB and RrgC produced 
substantial amount of antibodies against them, which were sufficient to protect them 
on subsequent challenge with a pilus-1 expressing strain. Intraperitoneal 
administration of a previously tested lethal dose of TIGR4wt strain (expressing 
RrgA, RrgB and RrgC) resulted in a lower level of bacteraemia and higher survival 
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rates in immunised mice than controls. Protection was also conferred upon passive 
immunisation with antibodies specific to these pilus-1 antigens. Transfer of mouse 
antisera raised against Recombinant RrgA, RrgB and RrgC protected naive mice 
form pneumococcal TIGR4wt challenge. Anti-RrgA showed the strongest response 
with only one mice out of eight (1/8) became bacteraemic and all (8/8) of them 
survived following intraperitoneal bacterial challenge. With the transfer of anti-
RrgB, two mice (2/8) became bacteraemic and all (8/8) of them survived. Three out 
of eight (3/8) mice had bacteraemia and one (1/8) died after passive transfer of anti-
RrgC serum. These results suggested that these pilus-1 subunit proteins are capable 
of inducing an efficient antibody-mediated protective response against 
pneumococcus (Gianfaldoni et al. 2007).   
RrgA is an adhesin, which mediates pneumococcal attachment to host respiratory 
epithelium (Nelson et al. 2007). Using human embryonic kidney cell (HEK) line, 
researchers have shown that a TLR2-dependent interaction of RrgA triggers a robust 
inflammatory response (Basset et al. 2013). During an episode of colonisation by a 
piliated strain of pneumococcus, interaction of RrgA with host immune system 
generates a protective antibody response (Nelson et al. 2007). RrgA has also been 
shown to be associated with rapid dissemination of S. pneumoniae in circulation by 
its interaction with complement receptor 3 (Orrskog et al. 2013). RrgA has two 
variants (clade I and II), based on the sequence variation in its terminal end. Both 
variants possess similar binding capacity to ECM components; like collagen, laminin 
and fibronectin. Importantly, both of them are able to produce cross protective 
immunity. Mice passively-immunised with antibodies developed against either of 
these variants has shown to be protected in subsequent challenge with pneumococcal 
strains expressing both variants (Moschioni et al. 2010b).  
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The major structural component, RrgB has also shown to induce a strong antibody 
response in mice. Passive transfer of anti-RrgB antibody in experimental mice 
efficiently protected them from invasive infection and increased their survival upon 
pneumococcal challenge. Molecular structural analysis has revealed three variants of 
RrgB (Clade I, II and III) (Moschioni et al. 2008). Unlike, anti-RrgA, passive 
immunisation of experimental mice with antisera raised against each of these RrgB 
variants showed clade-specific protection. However, a fusion of these three variants 
(RrgB321) exhibited efficient opsonophagocytic killing of piliated pneumococcal 
strains (Harfouche et al. 2012).  
The other ancillary component, RrgC is reported to be the most conserved protein of 
pneumococcal pilus-1 structure (Moschioni et al. 2008). Antigenic properties of 
RrgC have also been documented, although its protective efficacy seems to be 
inferior to both RrgA and RrgB (Gianfaldoni et al. 2007). RrgC is located in the 
basal part of the pilus shaft; and might not interact sufficiently with the host immune 
system to generate a robust antibody response (Nelson et al. 2007). Possibly for this 
reason, immunogenic potential of RrgC has been the least studied, despite being 
highly conserved among pilus-1 expressing pneumococci.  
Pneumococcal type-1 pilus subunits RrgA and RrgB have been shown to be strongly 
immunogenic in experimental mice. Immunisation with both of these proteins has 
shown to protect mice from subsequent challenge from pilus-1 expressing strains of 
pneumococcus. However, their immunogenic potential in human remains 
unexplored. So far, there is not much information regarding the role of pilus protein-
specific antibodies in protective immunity against pneumococcal carriage. A good 
understanding of the natural immune response induced by these pilus-1 proteins in 
humans and its relationship with pneumococcal carriage is necessary to evaluate 
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their protective efficacy. The currently offered conjugate vaccination with PCV13 is 
expected to protect against both pilus-1 and pilus-2 expressing serotypes (Kulohoma 
et al. 2013). Yet information regarding the immunogenicity of pilus-1 components in 
human could be valuable for planning future strategies.  
1.9 Hypothesis 
We hypothesize that pilus-1 subunit RrgA, as an adhesin might interact extensively 
with host respiratory mucosa during an episode of colonisation. Therefore, natural 
colonisation or infection with a pilus-1 expressing pneumococcus is likely to induce 
a strong mucosal immune response against it. Similarly, the major structural unit of 
pilus-1, RrgB is also expected to have a considerable interaction with the host 
mucosa to induce a substantial immune response. Considering their ability to induce 
a protective antibody response in mice, it would be valuable to study whether these 
two proteins induce antibody and Th17-mediated immune response in humans and 
whether the immune responses to RrgA or RrgB can protect against 
colonisation/carriage.  
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1.10 Aims/Objectives of the Thesis 
The aims of this thesis are 
1. To investigate the prevalence of pilus-1 genes among pneumococcal isolates 
colonising a cohort of healthy children in the UK by culturing nasal swab 
samples in blood agar plates and conventional PCR for detection of pilus-1 
gene among the isolates. 
2. To evaluate the naturally developed immune response against pneumococcal 
type-1 pilus proteins RrgA and RrgB by analysing circulating antibodies to 
these proteins in serum samples. 
3. To study whether previous colonisation/infection primes for immunological 
memory to pneumococcal RrgA and RrgB antigens in NALT (adenotonsillar 
MNC) by B cell ELISpot and in vitro antibody production assay. 
4. To examine the ability of these antigens to induce CD4+ T cell and Th17 cell-
mediated immune responses in peripheral blood and NALT by (CFSE 
labelled) cell proliferation assay and cytokine ELISA. 
5. To investigate whether the naturally developed antibody and/or cell mediated 
immune response to these proteins are protective against pneumococcal 
carriage, and 
6. To evaluate the potential of these proteins (RrgA and RrgB) as mucosal 
vaccine candidate in children. 
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Chapter 2 
Materials and Methods 
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2.1 Subjects and samples 
2.1.1    Subjects 
The subjects included in this study were patients who underwent tonsillectomy and 
adenoidectomy due to upper airway obstruction or tonsillitis from Alder Hey 
Children’s Hospital and Royal Liverpool and Broadgreen University Hospitals. 
Informed written consent was obtained in all cases from the patients or their legal 
guardians. Patients who received antibiotics or systemic steroids within 3 weeks of 
surgery, or who had any known immunodeficiency were excluded from the study. 
2.1.2 Patients Samples 
2.1.2.1  Adenotonsillar Tissues 
Immediately after surgical removal, adenotonsillar tissues were transferred into a 
25ml universal tube, containing 10ml Hank’s Balanced Salt Solution (HBSS) (Sigma 
Aldrich, UK) supplemented with 10μg/ml gentamycin (Sigma) and 1% L-glutamine 
(Sigma). The tissues were then transported to the laboratory for processing. 
2.1.2.2  Peripheral Blood 
Before operation, a 2-5ml peripheral blood sample was collected into a 25ml 
universal tube containing anticoagulant (heparin 100μl, LEO Pharma, UK); and 
transported to the laboratory. 
2.1.2.3  Nasopharyngeal Swabs 
Nasopharyngeal swabs were collected into a sterile vial containing 1ml Skim milk-
Tryptone-Glucose-Glycerol (STGG) broth (Appendix-I) as described previously 
(O'Brien et al. 2001). Briefly, immediately before the operation (while patient is 
under general anaesthesia), the nasopharyngeal swab was collected from patients 
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using a sterile Dryswab™ (Medical Wire & Equipment, UK). The swab was then 
inoculated to a vial containing STGG, and the shaft was cut off at the top level of the 
vial. Then the screw-cap of the vial was tightened and transported into the 
laboratory, where it was stored in a -80°C freezer before analysis. 
2.1.2.4  Saliva 
Before operation, a sample of unstimulated saliva was collected with a sterile 
‘Oracol’ sponge swab (Malvern Medical Developments Limited, UK). The 
absorbent sponge swab was inserted into the oral cavity and left at the side of mouth 
for about 1 minute to soak with saliva. Once saturated, the saliva swab was then 
replaced into the test tube and transported to the laboratory; where the saliva samples 
were squeezed out into 1.5ml eppendorf tubes by the help of 20ml plastic syringes 
and immediately stored in a -80°C freezer.  
2.2 Processing and/or Storage of Samples  
2.2.1  Isolation of mononuclear cells (MNC) from adenotonsillar tissues 
Adenotonsillar tissues were processed within a class-II Bio-safety cabinet following 
methods as previously described (Zhang et al. 2006b). At first, tissue samples were 
rinsed with 10ml of fresh HBSS and transferred into petri-dishes. With the help of a 
sterile pair of forceps, the tissues were minced by a scalpel to release cells into the 
medium. With a sterile Pasteur pipette, the cell suspension was filtered through a 
70μm cell strainer (BD biosciences, USA). The cells were then layered carefully on 
to 15ml Ficoll-Paque (GE Healthcare Life Sciences, UK) and isolated by gradient 
centrifugation (400×g for 30 min). After washing with sterile PBS (400xg for 10 
min), the cells were resuspended in 5ml RPMI (Sigma) supplemented with 10μg/ml 
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gentamycin (Sigma), 1% L-glutamine (Sigma) and 10% FBS (Sigma); and counted 
in an automated cell counter (BioRad, UK). 
2.2.2  Collection of serum and isolation of peripheral blood mononuclear cells 
(PBMC) 
After centrifugation of a peripheral blood sample (at 400xg for 10 min), serum was 
collected into a 1.5ml eppendorf tube  and stored in a -80°C freezer. For isolation of 
PBMC, the peripheral blood sample was diluted with HBSS and layered onto 10ml 
Ficoll-Paque (GE Healthcare Life Sciences, UK). The mononuclear cells were 
isolated by gradient centrifugation (400×g for 30 min); and washed with sterile PBS 
(400xg for 10 min). The cells were resuspended in 1ml RPMI-1640 (supplemented 
as above); and counted in an automated cell counter (BioRad, UK). 
2.3 Bacteriological Culture of Nasopharyngeal Swabs 
Nasopharyngeal swabs were cultured on blood agar (BA) plates (Oxoid, UK) 
following a standard procedure as described previously (O'Brien and Nohynek 
2003). Briefly, 40μl of broth from the swab containing vials was pipetted into a 
blood agar plate, and streaked with a sterile 5μl plastic loop (Technical Service 
Consultants Ltd, UK) using standard inoculating procedure. The inoculated plates 
were incubated overnight at 37°C, in 5% CO2. On the following day, the plates were 
observed for typical α-haemolytic colonies. Greenish α-haemolytic colonies with 
typical central depression were identified as possible Streptococcus pneumoniae 
(Pneumococcus). Each suspected α-haemolytic growth was subcultured and 
confirmed by standard optochin disc inhibition test, before being confirmed as 
pneumococcus. The density of bacterial load was measured semi-quantitatively 
following the methods described in (O'Brien and Nohynek 2003). The first 
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inoculation on the plate was considered as Quadrant 1, from where it was streaked 
into all four quadrants. The growth was termed as 4+ if >10 colonies were in 
Quadrant 4; growth was 3+ if <10 colonies were in Quadrant 4 and >10 colonies in 
Quadrant 3; growth was labelled 2+ if there were <10 colonies in Quadrant 3 and 
>10 in Quadrant 2; finally, 1+ growth was noted if there were <10 in Quadrant 2 
with growth in Quadrant 1. 
 
Figure-2.3: Growth of Streptococcus pneumoniae on blood agar plates; (a) typical 
‘Draughtsman’s’ colonies of pneumococci with 3+ growth, (b) mucoid α-haemolytic 
colonies (1+ growth). 
2.3.1  Optochin Susceptibility Test  
Typical pneumococcal colonies were picked up very carefully and streaked on BA 
plates in confluent lines with 5μl plastic loops. Using a pair of steel forceps 
(sterilized with red flame) 5µg optochin disk with 6mm diameter (Oxoid, UK) were 
placed on to the streaked area, at the intersection of first and second streaking. These 
plates were then cultured overnight (at 37°C, 5% CO2), and observed for optochin 
disk inhibition (Gardam and Miller 1998). The organism was identified as optochin 
susceptible if the zone of inhibition was ≥14 mm (Chandler et al. 2000). Isolates 
susceptible to optochin were confirmed as Streptococcus pneumoniae. 
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Figure 2.3.1: Optochin susceptibility tests of pneumococcal isolates; (a) on a typical 
‘Draughtsman’s’ colony; and (b) on a mucoid α-haemolytic colony. 
2.3.2  Storage of Streptococcus pneumoniae Isolates  
The confirmed isolates of Streptococcus pneumoniae were subcultured on blood agar 
plates at 37°C, in 5% CO2 overnight. A loop-full of organism from each pure culture 
was picked with a sterile 5μl plastic loop, and inoculated into screw capped Protect 
Plus bacterial preservative vials (Technical Service Consultants Ltd, UK), by 
rubbing gently against the hollow beads within those vials. The vials were then 
stored in -80°C for future analysis.  
2.4 Preparation of Pneumococcal CCS 
Pneumococcal strains used in this study included a pilus expressing strain of 
Streptococcus pneumoniae serotype 4 (TIGR4) (Tettelin et al. 2001); and its isogenic 
RrgA
-
/
- 
and RrgB
-
/
- 
mutant strains (Hilleringmann et al. 2009). Concentrated culture 
supernatants (CCS) from these strains were prepared using a procedure as described 
previously (Zhang et al. 2002). Briefly, these pneumococcal strains were cultured 
(37°C, 5% CO2) overnight on blood agar plates (Fisher Scientific, Loughborough, 
UK). On the following day, typical pneumococcal colonies from each strain were 
cultured (37°C, 5% CO2) again in Todd-Hewitt broth (Oxoid, Basingstoke, UK) with 
0.5% yeast extract (THYB) (appendix-I). The cultures were continued until it 
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reached the exponential phase (OD 0.4-0.5 at 620nm, approximately 108cfu/ml) of 
growth. They were then centrifuged at 3000×g for 30 min; and the supernatants were 
filtered through a 0.45mm sterile filter. The filtrate was filtered again through a 
0.2mm sterile filter; before concentrated by centrifugation (3000×g for 30 min) in 
Vivaspin15 (MWCO5000) concentrator (Sartorius Stedim Biotech, Germany). The 
centrifugation process was repeated 2/3 times until a ten-fold concentration of the 
supernatants was achieved. These CCS were then aliquoted into 1.5ml 
microcentrifuge tubes and stored in -80°C freezer. 
2.4.1 Measurement of protein concentration in pneumococcal CCS 
The protein concentrations of these CCS were measured by Bradford protein assay, 
using Bradford protein dye reagent (Sigma), following the manufacturer's 
instructions. The protein standard was prepared from bovine serum albumin (BSA) 
by seven serial (double) dilutions, starting with 2mg/ml. CCS solutions were assayed 
in duplicate and in three different concentrations (neat, 1:10 and 1:100). Firstly, 
250μl of dye reagent was dispensed into a 96-well Costar plate. Thereafter, 5μl of 
standards and samples were added to them and mixed thoroughly. The plate was 
incubated at room temperature in dark for 5 min. Absorbance was measured at 
595nm wavelength using a microtiter plate reader (Opsys MR, Thermo labsystems, 
UK). A standard curve was produced from the absorbance of BSA standards and the 
concentration (mg/ml) of each sample was calculated against the standard curve, 
with the help of microplate analysis software DeltasoftPC (Biometallics Inc., USA).  
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Figure-2.4.1: Standard curve of Bradford protein assay 
Table-2.4.1: Concentration of the pneumococcal CCS measured by protein assay 
Pneumococcal CCS Conc. (mg/ml) Conc. used to stimulate cells 
TIGR4wt 0.571 1μg/ml 
RrgB
-
/
-
 0.587 1μg/ml 
RrgA
-
/
-
 0.527 1μg/ml 
 
2.5 Western Blotting 
2.5.1 Principle of the assay 
In this method, proteins are separated electrophoretically on sodium dodecyl 
phosphate- polyacrylamide gels (SDS-PAGE), according to their molecular weight. 
Then these proteins are electrphoretically transferred into a nitrocellulose or PVDF 
membrane. After that, non-specific binding capacity on the membrane is blocked 
with bovine milk (skimmed) proteins. Thereafter, the target protein is probed with a 
specific primary antibody, which is then detected by chemiluminescence with an 
enzyme conjugated secondary antibody allowing it to react with its substrate. 
2.5.2 Western Blotting of Pneumococcal CCS  
Immunostaining of RrgA and RrgB proteins in pneumococcal CCS was performed 
following Western blotting protein transfer using rabbit anti-RrgA and anti-RrgB 
antisera (Novartis vaccine, Sienna, Italy) to confirm the presence of RrgA and RrgB 
54 
 
pilus proteins in the TIGR4wt CCS and the absence of RrgA protein in RrgA
-
/
- 
mutant strain and RrgB protein in RrgB
-
/
- 
mutant strain.  
2.5.2.1 Gel Electrophoresis 
Samples were prepared in Laemmli reducing Buffer (1:2 dilutions) and then heated 
on a heat block at 100°C for 5 min. After that, 20μl of CCS (derived from TIGR4wt, 
RrgB
-
/
- 
or RrgA
-
/
-
 strain) and 5μl of precision plus protein kaleidoscope ladder (Bio-
Rad, UK) were loaded into a 12% mini protean precast TGXTM gels (BioRad). The 
gel was run for 1 hr at a constant 250v in 50mA.  
2.5.2.2 Protein Transfer by Western blotting 
Western blotting transfer of protein was performed using a Transblot Turbo
TM
 
transfer system (BioRad) into a 0.2μm nitrocellulose membrane (Transblot turbo 
transfer pack). After gel electrophoresis, the gel was carefully placed onto a 
nitrocellulose membrane and then placed on to the bottom ion reservoir (anode) 
stack. The top ion reservoir (cathode) stack was then laid over the gel, and run for 10 
min at a constant 25v in 1000mA. 
2.5.2.3 Detection of RrgA and RrgB proteins in pneumococcal CCS 
Following Western blot transfer, the nitrocellulose membrane was blocked with 5% 
skimmed milk in TBS containing 0.05% Tween20 (TBS-T) (appendix I) for 2 hr at 
room temperature (RT). After washing 3 times in TBS-T, rabbit anti-RrgA and anti-
RrgB antiserum, diluted 1:10,000 in blocking solution were added. The membrane 
was incubated in room temperature for 2 hr at RT. After, washing for 5 times in 
TBS-T, the membrane was incubated with secondary antibody (donkey anti-rabbit 
IgG-HRP) for 1 hr at RT. The secondary antibody was prepared by adding 2μl 
donkey anti-rabbit IgG-HRP (1:30,000) (Santa Cruz Biotechnology, Germany), to 
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visualise the ladder 2μl Streptactin-HRP (1:30,000) (Bio-Rad) and to reduce 
background 30μl normal donkey serum (Sigma) into 60 ml blocking solution. The 
membrane was washed 5 times in TBS-T and then in PBS, before the addition of 
substrate to the membranes. Western Blot substrate was prepared by adding equal 
volume (1:1) of Immun-star WesternC chemiluminescence reagent A and B 
(BioRad). The membrane was incubated with the prepared substrate solution for 5 
min in the dark. Finally, the membranes were imaged in the Chemi-DocXRS system 
(BioRad), after removal of excess substrate with PBS.  
 
Figure 2.5.2.3: Western blot analysis of pneumococcal CCS (TIGR4wt, RrgB
-/-
 and 
RrgA
-/-
). (a) Nitrocellulose membrane blotted with pneumococcal CCS were immunostained 
with rabbit anti-RrgA antiserum showing that, RrgA band is present in TIGR4wt and RrgB
-/-
 
CCS but absent in RrgA
-/- 
mutant CCS. RrgA band shows a higher molecular mass (∼120 
kDa) than predicted from its sequence (92.7 kDa) (LeMieux et al. 2008). (b) Blotted with 
rabbit anti-RrgB antiserum showing that, RrgB band (~50 kDa) is present in TIGR4wt and 
RrgA
-/-
 CCS but absent in RrgB
-/- 
mutant CCS.  
2.5.2.4 Western blotting of recombinant pilus proteins (rRrgA and rRrgB) 
Western blotting and immunostaining of recombinant pilus (rRrgA and rRrgB) 
proteins (Gianfaldoni et al. 2007) were also performed with rabbit anti-RrgA and 
anti-RrgB antisera (Novartis vaccine, Sienna, Italy). This was later used as the 
standard control in the detection of pilus-specific antibodies in serum samples using 
Western blotting. Samples for this purpose was prepared by adding 5μl of 
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recombinant proteins (rRrgA and rRrgB) to 95μl of Laemmli reducing Buffer 
(appendix-I), to make a 1:20 dilutions. After heating on a heat block at 100°C for 5 
min, 5μl of these mixtures were loaded into the gel. The rest of the Western blot 
procedure was the same as that of the pneumococcal CCS, as described earlier.  
 
Figure 2.5.2.4: Western blotting of recombinant RrgA (rRrgA) and RrgB (rRrgB) 
proteins. (a) Probing with rabbit anti-RrgA antiserum showing the (~100 kDa) RrgA band. 
(b) Probing with rabbit anti-RrgB antiserum showing the (~ 50 kDa) RrgB band.  
 2.5.2.5 Serum Western Blotting for detection of pilus-specific antibodies 
Serum anti-RrgA and anti-RrgB antibodies were also analysed by Western blotting. 
Recombinant pilus proteins (rRrgA and rRrgB) were mixed with Laemmli reducing 
buffer (1:20) and heated at 100°C for 5 min. The mixtures were loaded into a mini 
protean TGX gel (BioRad, UK), and run for 1 hr at a constant 250v in 50mA. 
Transfer of protein to a 0.2μm nitrocellulose membrane was performed with a 
Transblot turbo transfer system (BioRad). The membrane was then blocked with 5% 
skimmed milk TBS-T for 2 hr. The membrane was then probed with serum samples 
(1:10,000 in blocking solution) for 2 hr. After washing, murine anti-human IgG-HRP 
(Sigma) and Streptactin-HRP (BioRad), both diluted (1:10,000) in blocking solution 
were added and incubated for 1 hr.  The membrane was imaged on Chemi-DocXRS 
system (BioRad), 5 min after the addition of 1:1 mixture of Immun-star WesternC 
chemiluminescence reagent A and B (BioRad). 
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Figure 2.5.2.5: Western blotting of recombinant RrgA and RrgB proteins with 
patients’ sera. Figure shows the MW marker ladder in lane 1, positivity of anti-RrgA in 
lane 2 and positivity of anti-RrgB in lane 3 in a representative serum sample.  
2.6 Measurement of In vitro Antibody Production in NALT  
2.6.1 Preparation of adenotonsillar MNC for culture 
Mononuclear cells isolated from adenotonsillar tissue were resuspended at a 
concentration of 4×10
6
/ml, in RPMI-1640 medium supplemented with HEPES 
(Sigma), 10μg/ml gentamycin (Sigma), 1% L-glutamine (Sigma), 10% FBS (Sigma) 
and 2.5μg/ml amphotericin B (Sigma).  
2.6.2 Stimulation of adenotonsillar MNCs 
1ml of diluted (4×10
6) cells were stimulated with (1μg/ml) of pneumococcal CCS 
(TIGR4 wt, RrgA
-
/
-, 
RrgB
-
/
-
). As a positive control, some cells were stimulated with 
a polyclonal B cell activator CpG-ODN (1μg/ml) (InvivoGen, USA). An 
unstimulated (only the RPMI culture medium) control was included in each 
experiment. To exclude any non-specific stimulation from components of Todd-
Hewitt-Yeast broth (THYB) media, some cells were co-incubated with this media; 
concentrated following the same procedure as in pneumococcal CCS preparation. 
Some samples were also stimulated with recombinant pilus (rRrgA and rRrgB) 
antigens alone or in combination with the respective mutant (RrgA
-
/
-, 
RrgB
-
/
-
) CCS.  
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2.6.3 Culture of adenotonsillar MNCs 
After stimulation, the cells were added into a 96-well culture plate (Corning Inc., 
USA). The plate was then incubated in a CO2 incubator (at 37°C, 5% CO2). Culture 
supernatants were collected on day 7 and day 14 of the incubation from each well. 
They were then centrifuged at 5,000xg for 5 min, and the supernatants were stored at 
-80°C until further analysis by ELISA. 
2.7 Enzyme-Linked Immunosorbent Assay (ELISA) 
2.7.1 Detection of serum pilus-specific IgG antibodies by ELISA 
Pilus specific antibodies (anti-RrgA and anti-RrgB) were detected in serum by 
ELISA using the following protocol. Coating solutions (1µg/ml) were prepared from 
recombinant RrgA (2.7mg/ml) and RrgB (2.7mg/ml) stock solutions, by adding 3.7μl 
of antigens into 10ml of sterile PBS. A 96-well flat-bottom, high binding Costar EIA 
plate (Corning) was coated with 100μl of coating solution per well. The plate was 
then incubated overnight in 4°C. On the following morning, the plate was washed 5 
times with PBS containing 0.05% Tween20 (PBS-T). The plate was then blocked 
(150μl/well) with blocking buffer (10% FBS in PBS) at 37°C for 1 hr. In the 
meantime, samples and standards were prepared by diluting them (1:100) in blocking 
buffer. Human immunoglobulin (sandoglobulin, Sandoz, UK), containing high IgG 
antibody titers to pilus antigens, was used as a reference standard for measurement of 
IgG antibodies; and the dilution standard series was constructed by 8 serial dilutions, 
starting with 1:50. Diluted samples and standards (50μl in each well) were added to 
the plate in duplicate; and incubated at RT for 2 hr. At the end of this incubation, the 
plate was washed 5 times with PBS-T; and 50μl of alkaline phosphatase-conjugated 
mouse anti-human IgG (1:2000 dilutions) (Sigma) was added into each well. Then 
the plate was incubated at room temperature for 2 hr. Thereafter, the plate had been 
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washed 5 times with PBS-T, before 50μl of freshly prepared PNPP substrate was 
added into every well (appendix-I). Then the plate was incubated at RT for 15 
min protecting it from direct light. Finally, the absorbance (OD) was measured using 
a microtiter plate reader (Opsys MR, Thermo labsystems, UK) at 405nm. The 
concentration (units/ml) of each sample was calculated against the standard curve 
constructed with serial dilution of Sandoglobulin, with the help of microplate 
analysis software DeltasoftPC (Biometallics, Inc., USA). 
Before starting the ELISA analysis of the test samples, the antibody titre of the 
reference standard (sandoglobulin) for both RrgA and RrgB was determined by the 
following method. Twelve dilutions (1:50, 1:100, 1:200, 1:400, 1:600, 1:800, 
1:1000, 1:1200, 1:1400, 1:1600, 1:1800, and 1:2000) of the standard was analysed. 
The plates were coated with rRrgA (1µg/ml) and rRrgB (1µg/ml) as usual; and the 
ELISA procedure was followed as described previously. The optical density (OD at 
405 nm) was measured after 30 min of adding the substrate solutions. The anti-RrgA 
and anti-RrgB titre of sandoglobulin was assigned as the reciprocal dilutions at 
which their corresponding OD reached to 1.00 at that time point. Based on this, the 
stock solution of Sandoglobulin was assigned to an antibody titre of 1000 units/ml 
for anti-RrgA and 1400 units/ml for anti-RrgB. 
2.7.1.1 Specificity of Serum Pilus-specific Antibody ELISA  
The specificity of the ELISA measuring anti-pilus antibodies was confirmed by 
antigen-specific inhibition ELISA assays. Each recombinant protein (rRrgA and 
rRrgB) was added in following concentrations (0.3125, 0.625, 1.25, 2.50, 5.0 and 
10.0 μg/ml) to the serum sample. They were then incubated for 30 min at RT to 
adsorb the specific antibodies present in each sample. To measure both anti-RrgA 
and anti-RrgB antibody titres in these samples, ELISA assays were carried out, 
following the above mentioned procedures.  
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2.7.1.2 Detection of pilus-specific IgG subclasses in serum  
Serum IgG subclasses (IgG1, IgG2, IgG3 and IgG4) to RrgA and RrgB were also 
measured by ELISA. The above mentioned protocol was followed for IgG 
subclasses, except alkaline phosphatase-conjugated mouse monoclonal anti-human 
IgG1 (Southern Biotech, UK), IgG2 (Southern Biotech), IgG3 (Southern Biotech) or 
IgG4 (Southern Biotech), all diluted 1:500 in 10% FBS-PBS were added as 
conjugates respectively. Also, after adding PNPP substrate, the plates were incubated 
for 3 hr at RT before reading the OD at 405nm. 
2.7.1.3 Detection of pilus-specific IgM antibodies in serum 
Serum IgM antibodies to RrgA and RrgB were also measured by ELISA following a 
procedure similar to serum IgG measurement, except alkaline phosphatase-
conjugated mouse anti-human IgM (1:1000 dilution) (Sigma) was used as conjugate. 
In the absence of a reference standard, results were expressed as the optical densities 
(OD at 405nm) 30 min after the addition of substrate solution. 
2.7.2 Measurement of pilus-specific antibodies in cell culture supernatants 
Pilus specific (anti-RrgA and anti-RrgB) antibodies were detected in cell culture 
supernatants by ELISA using the same procedure followed for serum antibody 
measurement; except samples (cell culture supernatants) were used in 1:10 dilution 
and 8 serial dilutions of standard (sandoglobulin) was used starting from 1:200 on 
the top. Also, after adding PNPP substrate, the plates were incubated for 2 hr at RT 
(protecting it from direct light) before reading the OD at 405nm. 
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2.7.3 Measurement of total IgG, IgM and IgA in cell culture supernatants 
Production of total IgG, IgM and IgA by adenotonsillar MNC was measured in cell 
culture supernatants by ELISA using the following protocol. Cell culture 
supernatants from pneumococcal TIGR4wt CCS stimulated and unstimulated 
(medium control) samples were analysed for this purpose. Culture supernatants 
stimulated with a polyclonal B cell activator CpG-ODN (InvivoGen, USA) were 
used as positive control. The ELISA procedure was similar to the previously 
described procedure for pilus-specific antibody detection, except for the coating 
antigens, standards and conjugate preparations described below. 
2.7.3.1 Measurement of total IgG  
For total IgG measurement, coating solution was prepared using Fab specific anti-
human IgG (Sigma) which was diluted at 1:1,000 in PBS. The standard for this total 
IgG assay was purified IgG from human serum (Sigma). The concentration of the 
stock solution was 4.8mg/ml. A concentration of 1µg/ml was obtained by adding 1μl 
of the stock solution to 4.8ml of blocking buffer (10% FBS-PBS). The series of 
standards were constructed by 8 serial dilutions; starting with 0.5µg/ml. Samples for 
this assay were prepared as 1:100 dilutions of the cell culture supernatants in 
blocking buffer. Following an incubation of 2 hr in RT, 50μl of alkaline 
phosphatase-conjugated mouse anti-human IgG (1:2000 dilution) (Sigma) was added 
into each well of the plate and incubated for 2 hr at RT. After final washes, PNPP 
substrate was added and absorbance was measured after 5 min by a microtiter plate 
reader (Opsys MR), at 405nm. The concentration (μg/ml) of each sample was 
calculated against the standard curve, with the help of microplate analysis software 
DeltasoftPC (Biometallics). 
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2.7.3.2 Measurement of total IgM  
For total IgM measurement, coating solution was prepared with polyclonal rabbit 
anti-human-IgM (Dako, Denmark) which was diluted at 1:1,000 in PBS. The 
standard for this total IgM assay was purified human serum IgM (Sigma), with a 
stock solution concentration of 0.9mg/ml. A concentration of 1µg/ml was obtained 
by adding 1μl of the stock solution to 900μl of blocking buffer (10% FBS-PBS). 
Rest of the ELISA procedure was exactly same as the total IgG measurement, 
described earlier, except 50μl of alkaline phosphatase-conjugated mouse anti-human 
IgM (1:1000 dilution) (Sigma) was used as conjugate.  
2.7.3.3 Measurement of total IgA 
For total IgA measurement, coating solution was prepared with polyclonal rabbit 
anti-human-IgA (Dako) which was diluted 1:1,000 in PBS. The standard for this 
total IgA assay was prepared from human colostrum IgA (Sigma). The concentration 
of the stock solution was 1.6mg/ml. A concentration of 1µg/ml was prepared by 
adding 1μl of the stock solution to 1.6ml of blocking buffer (10% FBS-PBS). Rest of 
the ELISA procedure was exactly same as the total IgG measurement, described 
earlier, except 50μl of alkaline phosphatase-conjugated mouse anti-human IgA 
(1:1000 dilution) (Sigma) was used as conjugate.  
2.7.4 Measurement of salivary IgG and IgA antibodies  
For salivary ELISA, saliva samples were prepared as follows. After thawing in RT 
for 15-20 min, they were centrifuged at 10,000xg for 10 min. The supernatants were 
collected into appropriately labelled microcentrifuge tubes; and used for the 
subsequent analysis. 
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2.7.4.1 Measurement pilus-specific IgG antibody in saliva 
Pilus specific IgG antibodies were detected in saliva using the following an ELISA 
procedure similar to that used for the detection of RrgA- and RrgB-specific IgG in 
adenotonsillar cell culture supernatants described previously, except for the saliva 
samples were used in a dilution of 1:50, and measurement of absorbance was done 
after 1 hr incubation with the PNPP substrate.  
2.7.4.2 Measurement pilus-specific secretory component (S-IgA) in saliva 
Pilus specific secretory component (S-IgA) was measured in saliva using the 
following procedures. Plates were coated with rRrgA or rRrgB antigen at 1µg/ml, 
incubated overnight in 4°C and then blocked at 37°C for 1 hour as described 
previously. After that, 50µl of samples (1:50 in blocking buffer) was added to each 
well in duplicate in the plate, and incubated for 2 hr at RT. After washing, 50µl of 
murine monoclonal anti-human IgA secretory component (1:1,000) (Sigma) was 
added into each well and incubated for 2 hr at RT. 50µl of (1:1,000) alkaline 
phosphatase conjugated goat anti-mouse IgG (Sigma) as then added into each well 
and incubated overnight at RT. The subsequent procedure was the same as the IgG 
assay as described above.  
2.7.4.3 Measurement of total IgG and IgA in saliva 
Measurement of total IgG and IgA in saliva was performed using the same procedure 
as above for the measurement of total IgG and IgA in the cell-culture supernatants, 
except that saliva samples were diluted 1:200 for these assays. 
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2.7.5  Measurement of cytokine production in cell culture supernatants 
2.7.5.1 Measurement of IL-17A  
In vitro IL-17A production in adenotonsillar MNC and PBMC cultures was 
measured with human IL-17A ELISA Ready-Set-Go® set (eBioscience, UK), 
following manufacturer’s instructions. 96-well Costar plates were coated with the 
capture antibody which was prepared by adding 44μl of purified anti-human IL-17A 
into 11ml carbonate buffer (1:250 dilutions). 100μl of the capture antibody solution 
was added into each well of the plates and incubated overnight at 4°C. In the 
following morning, the plate was washed 5 times with PBS-T. After blocking with 
1x assay diluent (200μl/well), the plate was incubated at RT for 1 hr. Then the plate 
was washed 5 times with PBS-T. In the meantime, the top concentration (500pg/ml) 
of the standard was prepared by adding 5μl human IL-17A recombinant protein into 
10ml of 1x assay diluent. The samples were also prepared (1:20 dilution) in 1x assay 
diluent. After blocking for 1 hr, the plate was washed 5 times with PBS-T. 
Thereafter, the standards and samples (100μl/well) were added to the plate. A total 
of 8 standards were prepared by 2-fold serial dilutions from the top standard. The 
plate was then incubated at RT for 2 hr. In the meantime, detection antibody was 
prepared by adding 44μl of purified anti-human IL-17A Biotin into 11ml 1x assay 
diluent (1:250 dilutions). At the end of the incubation, the plate had been washed 5 
times with PBS-T, before adding 100μl of detection antibody to each well. Then the 
plate was incubated at RT for 1 hr, and then washed 5 times with PBS-T. Thereafter, 
100μl of Avidin-HRP (diluted 1:250) was added to each well; and incubated at RT 
for 30 min. After washing 5 times with PBS-T, 100μl of TMB substrate solution was 
added to each well, and incubated at RT for 15 min in dark. Then, 50μl of stop 
solution (1M H2SO4) was added to each well. Finally, the plate was read at 450nm, 
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and the concentration (pg/ml) of each sample was calculated against the standard 
curve, with the help of DeltasoftPC software (Biometallics). 
2.7.5.2 Measurement of IL-17F  
In vitro IL-17F production in adenotonsillar MNC and PBMC cultures was measured 
with human IL-17F ELISA Ready-Set-Go® set (eBioscience), following 
manufacturer’s instructions. The capture antibody was prepared by adding 44μl of 
purified anti-human IL-17F into 11ml coating buffer (1:250 dilutions). The top 
concentration (500pg/ml) of the standard was prepared by adding 5μl human IL-17F 
recombinant protein into 10ml of 1x assay diluent. The detection antibody was 
prepared by adding 44μl of anti-human IL-17F Biotin into 11ml 1x assay diluent 
(1:250 dilutions). The rest of the procedure was the same as described for IL-17A 
measurement. 
2.7.5.3 Measurement of IL-22 
In vitro IL-22 production in adenotonsillar MNC cultures and PBMC was measured 
with human IL-22 ELISA Ready-Set-Go® set (eBioscience), following 
manufacturer’s instructions. The capture antibody was prepared by adding 44μl of 
purified anti-human IL-22 into 11ml coating buffer (1:250 dilutions). The top 
concentration (500pg/ml) of the standard was prepared by adding 5μl human IL-22 
recombinant protein into 10ml of 1x assay diluent. The detection antibody was 
prepared by adding 44μl of Biotin conjugated anti-human IL-22 into 11 ml 1x assay 
diluent (1:250 dilutions). The rest of the procedure was the same as described for IL-
17A measurement. 
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2.8 Enzyme Linked Immuno Spot (ELISpot) Assay 
2.8.1 Principle of the test 
A solid phase (membrane) is pre-coated with an antigen of interest. Then B 
Lymphocytes are incubated with that membrane. Upon stimulation, B cells produce 
antigen-specific antibodies that bind to the antigen in the vicinity of the cells 
secreting them. These captured antibodies are visualised by a secondary antibody-
enzyme conjugate and its reaction with the substrate, which results in the 
development of visible spots. Each spot represents an antibody secreting cell.  In the 
current project, ELISPOT assay was used to measure the frequencies of memory B 
cells specific to pneumococcal pilus-1 proteins, RrgA and RrgB. Following 
preparation of freshly isolated adenotonsillar MNC, they were stimulated with 
pneumococcal TIGR4wt CCS (1μg/ml). Pilus-1 antigen-specific memory B cells 
were activated to differentiate into plasma cells and produce specific antibodies; 
which were then enumerated by ELISpot assay. 
2.8.2 Culture of adenotonsillar MNCs  
Mononuclear cells isolated from adenotonsillar tissue were resuspended in RPMI-
1640 medium (4×10
6
/ml) and stimulated with TIGR4wt CCS (1μg/ml) and CpG-
ODN (1μg/ml) (InvivoGen, USA) as described previously (Zhang et al. 2006b) for 
antibody production. Equal volume of unstimulated cells was incubated as medium 
control. The cells were incubated in a 24-well cell culture plate (Corning Inc., USA) 
at 37°C, in 5% CO2 for 5 days. Thereafter, the cells were harvested and washed with 
sterile PBS with 1% BSA followed by centrifugation at 400xg for 10 min. The 
pellets were then resuspended in RPMI-1640 medium to a final cell concentration of 
4×10
6
/ml. 
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 2.8.3 Plate coating  
One day before the cells were harvested, a filtered 96 well ELISpot plate (Millipore, 
UK) were coated with different antigens. For detecting pneumococcal pilus-1 
specific memory B cells, plates were coated with recombinant RrgA and RrgB 
antigens. Coating solutions were prepared by adding 3.7μl of RrgA (2.7mg/ml) and 
RrgB (2.7mg/ml) antigens into 5ml of PBS to get 2µg/ml concentrations. For 
enumeration of total IgG, IgA and IgM spots as  positive controls, the plate was also 
coated with capture anti-IgG, -IgM and -IgA antibody in 1:1000 dilutions. Fab 
specific anti-human IgG (Sigma), polyclonal rabbit anti-human-IgM (Dako) and 
polyclonal rabbit anti-human-IgA (Dako) were used for this purpose. Before coating, 
each well was pre-wet with 15μl of 35% ethanol for 1 min. The wells were washed 
three times with 150μl of PBS. After coating, the plate was incubated overnight at 
4°C. 
2.8.4 Incubation of cells in the ELISpot plate  
On the following morning, the plate was washed 3 times with PBS-T. Then the plate 
was blocked with 150μl of RPMI-1640 media with 10% FCS for 1 hr at RT.  In the 
meantime, adenotonsillar cells were harvested from the incubation as described 
earlier. 100μl of cell suspension was added into each of the designated wells in 
triplicate. Cell concentration used for different antigens were: 4x10
6
/ml (stock 
suspension) for RrgA and RrgB; 4x10
5
/ml for total IgM and IgA (1:10 dilution of 
stock) and 2x10
5
/ml for total IgG (1:20 dilution of stock). Only RPMI-1640 media 
(no cell) was added into the wells designated as negative controls (at least one well 
for each antigen). The plate was then incubated overnight at 37°C in 5% CO2 
incubator. 
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2.8.5 ELISpot assay procedure  
The plate was washed 3 times with PBS-T. 50μl of biotin conjugated anti-human 
antibodies was then added into the designated wells followed by incubation for 30 
min at RT. Goat anti-human IgG (H+L) biotin (Invitrogen, USA), Goat anti-human 
IgM (Fab)2 biotin (Invitrogen) and Goat anti-human IgA (Fab)2 biotin (Invitrogen) 
were used in 1:2,000 dilutions respectively.
  
At the end of incubation, the plate was 
washed 3 times with PBS-T, followed by the addition of 50μl of (1:10,000 dilutions) 
Horseradish peroxidase Avidin D (Vector laboratories Inc., USA). The plate was 
then incubated for 30 min at RT. After washing 3 times with PBS-T, 50μl of freshly 
prepared AEC substrate was added into each well. The substrate was prepared with 
0.5 ml 3-amino-9 ethylcarbazole into 9.5 ml acetate buffer (appendix-I); adding 25 
μl of H2O2 immediately before use. The plate was then incubated in dark for 15-20 
min at RT. The reaction was stopped with cold water and both sides of the plate were 
washed with running tap water. Finally, the plate was blotted gently with adsorbent 
paper to remove the excess water and allowed to dry for 2-3 hr.  
2.8.6 Counting of ELISpots  
The spots were imaged by Chemi-doc XRS system, and analysed with NIST’s 
Integrated Colony Enumerator (NICE) software (Version 1.2.1, National Institute of 
Standards and Technology, USA). The result was expressed as number of 
ASC/million of lymphocytes. For antigen-specific ASC (RrgA and RrgB), the 
average spot counts were multiplied by 2.5 to get this result. This calculation was 
obtained by dividing 1x10
6
 (one million) by 4x10
5 
that was the number of cells in 
100μl of (4x106) cell suspension, which was put into each wells. Similarly, for total 
IgM and IgA the result was obtained by multiplying the spot counts with 25; and for 
total IgG 50 time multiplication of the average spot count was performed. 
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2.9 Flow Cytometric Analysis of Cells   
2.9.1 Principle of the test 
The flow cytometry analyses the optical properties of the fluorocrome-labelled cells 
passing through a focused laser beam. In this process the cells disrupt and scatter the 
laser signals as the forward and side scattered light.  Forward scatter (FSC) is related 
to cell size, distributing the larger cells more scattered in its axis. Whereas, side 
scatter (FSC) is an indicator of cells internal complexity or granularity, distributing 
the more granular cells more scattered. A combination of FSC and SSC 
characteristically distribute different subsets of cells in sample containing a mixed 
population. The FSC is also used to distinguish the dead cells (with low FSC 
distribution) from the viable cells. Apart from these scatters, flow cytometry also 
measures fluorescence parameters to detect other structural and functional properties 
of cellular subsets (Goetzman 1993).  
Flow Cytometric analyses in this project were carried out on BD FACS Calibre (BD 
Biosciences) and BD AccuriV6 flow cytometers (BD Biosciences). Different subsets 
of lymphocyte were defined with multiple parameters, including FSC and SSC based 
gating. Fluorescence emissions of different fluorocromes were measured at different 
wavelengths; FITC or Alexafluor488 in FL1 at 519nm, PE in FL2 at 578nm, 
PerCPCy5.5, PECy5 or PECy7 in FL3 at 695nm, and APC or Alexafluor660 in FL4 
at 660nm. For BD FACS Calibre, data were acquired with Cell Quest software (BD 
Biosciences) and analysed with WinMDI 2.9 software. For BD AccuriV6, CFlow 
plus software (BD Biosciences) was used for both flow cytometer data acquisition 
and analysis. 
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2.10  T cell Proliferation Assay  
2.10.1 Principle of the Assay 
Carboxyfluorescein diacetate succinimidyl ester (CFDASE), a fluorescein derivative 
is initially non-fluorescent and highly permeable across the cell membrane. After it’s 
uptake into the cell the acetate groups are cleaved by cellular esterase to form 
carboxyfluorescein succinimidyl ester (CFSE). The removal of these acetate groups 
makes the CFSE molecule highly fluorescent and impermeable to plasma membrane. 
The succinimidyl group reacts with amino groups, forming a highly stable covalent 
bond. Although a small amount of these fluorescent conjugates decays or leaks out 
of the cells, most of them are retained within the cell for a long time. These 
remaining dyes are evenly distributed among the dividing daughter cells. This 
dilution of fluorescence in the offspring cells is used to measure the cell proliferation 
by flow cytometry. Other cellular properties of the dividing cells can be detected by 
using other fluorocromes, which are compatible with fluorescein (Quah et al. 2007). 
2.10.2 Labelling of adenotonsillar MNCs and PBMCs with CFSE  
At first, the adenotonsillar MNC and/or PBMC were washed with PBS at 400xg for 
10 min, to get rid of protein containing media (RPMI); and the cell pellet was 
dissolved in 3ml sterile PBS. In the meantime, a working concentration of CFSE 
(50μM) was prepared by adding 5μl of CFSE to 10ml of sterile PBS. 3 ml of this 
freshly prepared CFSE solution was added to the cell suspension; and mixed 
thoroughly by vortexing at high speed. The cells were then incubated at 37°C for 8 
min. Then, the reaction was quenched by adding 15ml of ice-cold RPMI-1640 
media. Thereafter, the cells were centrifuged at 400xg for 10 min; and the pellet was 
dissolved in RPMI-1640 medium supplemented with HEPES (Sigma), 10μg/ml 
gentamycin (Sigma), 1% L-glutamine (Sigma) and 10% FBS (Sigma). For 
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adenotonsillar MNC, 4x10
6
cells/ml suspension was prepared; and for PBMC, 
2x10
6
cells/ml suspension was used. 500μl of these cell suspensions was stimulated 
with different concentrations of recombinant pilus (rRrgA and rRrgB) antigens and 
pneumococcal CCS (TIGR4wt, RrgA
-
/
-, 
RrgB
-
/
-
). Three controls were used with each 
set of samples; two without any stimulation (one for unstained and one for CD4-PE 
stained negative control), and a positive control stimulated with anti-CD3 antibody 
(4μl/ml). The cells were then added into a 96-well cell culture plate (Corning); and 
incubated at 37°C in 5% CO2 for 4-5 days.  
2.10.3 Staining of the CFSE labelled cells for FACS analysis 
At the end of incubation, the cells were harvested and washed with FACS staining 
buffer (PBS with 0.02% BSA), by centrifuging at 500xg for 8 min. The pellets were 
resuspended and 2.5μl of CD4-PE (BD bioscience) was added into all the tubes 
except the unstained negative control. Then the tubes were vortexed and incubated in 
dark at 4°C for 30 min. Thereafter, the tubes were washed (500xg for 8 min) with 
1ml of FACS staining buffer. The pellets were resuspended in 400μl of FACS 
staining buffer; and the tubes were kept in dark at 4°C, until analysed in the BD 
FACS Calibre (BD bioscience). 
2.11 Intracellular Cytokine Staining for Th1/Th2/Th17 Phenotyping  
Phenotyping of different T helper cell subsets were performed by intracellular 
cytokine staining with Human Th1/Th2/Th17 Phenotyping kit (BD Bioscience, UK), 
following the manufacturer’s instruction. 
 2.11.1 Cell stimulation 
For cell stimulation 500μl of cell suspension (4X106/ml) was incubated at 37°C for 
24hr in 5% CO2, for each antigen and a medium control. A positive control was also 
stimulated with Ionomycin (1µg/ml) and PMA (20ng/ml). After 24hr, 0.5µl 
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(1.0µl/ml) of a protein transport inhibitor, BD GolgiStop  (monensin) was added to 
each samples; and incubated at 37°C in 5% CO2 for 6hr. After that, the incubation 
was stopped, wrapped with cellophane and kept at 4°C for overnight. 
2.11.2 Cell harvest, fixation and permeabilization 
In the following morning cells were harvested and washed with FACS staining 
buffer (0.02% PBS-BSA) by centrifugation (500xg for 8 min). The pellets were 
resuspended and fixed with 1ml cold BD Cytofix™ (4% paraformaldehyde in PBS). 
The cells were then incubated in dark, at RT for 20 min; after washing (500xg for 8 
min), the pellets were resuspended with 1ml of 1x Perm/Wash™. The cells were 
then incubated in dark, at RT for 20 min. 
2.11.3 Intracellular cytokine staining 
After washing (500xg for 8 min), the pellets were resuspended with 50µl of 1x 
Perm/Wash™. Then 20µl fluorochrome-labeled antibody cocktail for detection of 
intracellular cytokines was added to each samples; and incubated in the dark at RT 
for 30 min. After that, 1ml of Perm/Wash™ was added to each tube. After washing 
(500xg for 8 min), the stained cells were resuspended in 400μl of FACS staining 
buffer; and analysed on a flow cytometer.  
2.12 Depletion of adenotonsillar MNCs for obtaining T helper cell subsets 
To evaluate the proliferative and cytokine production response of different subsets of 
T helper (Th) cell repertoire, effector memory (CD45RO
+
) and activated (CD69
+
) 
cells were depleted from the adenotonsillar MNC with the help of magnetic beads 
(Miltenyi Biotech, Germany), magnetic column (Miltenyi Biotech), and a MACS 
magnet (Miltenyi Biotech). Usually the PBMC sample volumes were small; hence 
depletion of PBMC was not done.  
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2.12.1 Principle of the MACS separation 
Firstly, the cells to be depleted (CD45RO
+
 or CD69
+
) are magnetically labelled with 
the specific micro-beads binding with the target surface molecules (CD45RO or 
CD69). Thereafter, the cell suspension is allowed to pass through a MACS LD 
column, placed within the magnetic field of a MACS separator. The unlabelled cells 
(not expressing the target molecules) run through the column. These depleted cells 
are collected in a tube placed underneath the column. The process is known as 
negative selection. The magnetically labelled cells (those expressing the target 
molecules) are retained within the column.  
2.12.2 Depletion of CD45RO
+
 Cells 
CD45RO is expressed on memory CD4
+
 and CD8
+
 T cells. It is also present on 
CD4
+
 effector T cells, monocytes, macrophages and granulocytes. Depletion of 
CD45RO
+
 cells with CD45RO microbeads yields a naive T cell population, from 
which naive CD4
+
 cells can be analysed by flow cytometry. 
2.12.2.1 Magnetic labelling and depletion  
Approximately, 50x10
6
 cells were resuspended in 400μl (80μl/107cells) of depletion 
buffer (0.5% BSA in PBS); and 100μl (20μl/107cells) of CD45RO magnetic beads 
(Miltenyi Biotech) was added into them. After thorough vortexing, the cells were 
incubated at 4˚C for 15 min. After that, the cells were washed with 10ml 
(2ml/10
7
cells) of depletion buffer (400xg for 10 min). The cell pellet was 
resuspended in 250μl (50μl/107cells) of depletion buffer; and magnetic separation 
was carried out in a class-II bio-safety cabinet. The MACS LD column (Miltenyi 
Biotech) was placed inside the magnet groove; and primed by adding 2ml buffer 
avoiding any bubbles. Then the cell suspension was added to the column and 
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allowed to pass through. After that, 2ml buffer was added to the column and allowed 
to pass through. The naive (CD45RO
+ 
depleted) T cells, obtained by this process 
were resuspended into RPMI medium to a concentration of 4x10
6
cells/ml. CFSE 
labelling, stimulation with antigens and FACS analysis were done following the 
same techniques, described previously for undepleted lymphocytes. 
2.12.3 Depletion of CD69
+
 Cells 
CD69, a member of C-type lectin family is expressed on activated T cells, B cells, 
NK cells, macrophages, neutrophils, eosinophils and platelets. It is the earliest 
inducible cell surface marker of lymphoid activation. It acts as a signal transmitting 
receptor for cellular activation (Santis et al. 1994). Depletion of CD69
+
 cells with 
CD69 microbeads gets rid of already activated T cells in a population, from which 
the resting CD4
+
 cells can be analysed by flow cytometry. 
2.12.3.1 Magnetic labelling and depletion  
Approximately, 50x10
6
 cells were taken for this depletion. The cells were washed 
with PBS (400xg for 10 min); and the cells were resuspended in 200μl 
(40μl/107cells) of depletion buffer (0.5% BSA in PBS). After that, 50μl 
(10μl/107cells) of CD69-biotin (Miltenyi Biotech) was added into the tube and 
vortexed thoroughly. Then the cells were incubated at 4˚C for 15 min. At the end of 
the incubation, 100μl (20μl/107cells) of CD69 magnetic beads (Miltenyi Biotech), 
and 150μl (30μl/107cells) of depletion buffer were added into the cells. After 
vortexing thoroughly, the cells were incubated again at 4˚C for 15 min. After that the 
cells were washed with 10ml (2ml/10
7
cells) buffer solution at 400xg for 10 min. 
Finally, the pellet was resuspended into 250μl (50μl/107cells) buffer solution. 
Magnetic separation of these cells was carried out in a class-II bio-safety cabinet as 
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described above for CD45RO depletion. The resting (CD69
+ 
depleted) T cell 
populations, obtained by this process were resuspended into RPMI medium to a 
concentration of 4x10
6
cells/ml. CFSE labelling, stimulation with antigens and FACS 
analysis were done following the same techniques, described previously for 
undepleted lymphocytes.  
2.13 PCR of Pilus 1 Islet and Pneumolysin Genes  
2.13.1 Principles of the Assay 
Polymerase Chain Reaction occurs in three major steps. First step is the 
denaturation, when the double stranded DNA is split into two single strands at 94°C. 
The second step, annealing occurs at 56°C, when two (forward and reverse) primers 
are attached with each of the strands. The final step is the extension of the DNA 
templates at 72°C, producing two double stranded DNAs. After that, the first cycle is 
completed. Repeating of such cycles many (30 or 40) times, produces more than a 
billion copies of the template DNA. The amplified DNA can be detected by various 
methods, after electrophoresis in agarose gel. 
2.13.2  PCR of pilus 1 islet and pneumolysin genes in pneumococcal isolates 
The primers were designed to amplify the three genes in the rlrA pathogenecity islet 
(PI-1) that encode proteins constituting the pneumococcal pilus-1 (Basset et al. 
2007b). As a positive control for pneumococcus, amplification of ply gene (encoding 
pneumolysin) was done in each of the isolates with primers described in previous 
studies (Regev-Yochay et al. 2010, Whatmore et al. 1999). All the primers were 
validated by NCBI primer BLAST. Also the size of each amplicon was determined 
by aligning the forward and reverse primer sequences with that of each respective 
gene (rrgA, rrgB, rrgC and ply) in the Streptococcus pneumoniae (TIGR4) genome 
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(ftp://ftp.tigr.org/pub/data/Microbial_Genomes/s_pneumoniae_tigr4/annotation_dbs/
s_pneumoniae_tigr4.seq). The amplicon sizes were calculated as; rrgA 2550 Kb, 
rrgB 1850 Kb, rrgC 1056 Kb and ply 1191 Kb. Detailed information of the primers 
(ordered from Sigma Aldrich, UK) are mentioned in table-2.13.2. 
Table-2.13.2: Primers used for the PCR detection of PI-1 and Ply genes in 
pneumococcal isolates 
Oligo Primer Primer sequence (5′-3′) Tm° nmol GC% Reference 
rrgA Forward AAGATATTTCAGAAGGCAGTTGCA 64.7 47.3 37.5 (Basset et al. 2007b) 
rrgA Reverse TTCTCTCTTTGGAGGAATAGGTTC 62.6 37.4 41.6 (Basset et al. 2007b)374 
rrgB Forward CTTGCTGCCTTATTACTGA 55.6 39.5 42.1 (Basset et al. 2007b) 
rrgB Reverse GATAGTGATTTTTTTGTTGAC 52.9 105.3 28.5 (Basset et al. 2007b) 
rrgC Forward GCTCTGTGTTTTTCTCTTGTATGG 62.8 57.9 41.6 (Regev-Yochay et al. 2010) 
rrgC Reverse ATCAATCCGTGGTCGCTTGTTATTTTTA 69.8 49.5 35.7 (Regev-Yochay et al. 2010) 
ply Forward TTGTTGTTATCGAAAGAAAGAAGCGGA 69.7 44.0 37.0 (Whatmore et al. 1999) 
ply Reverse AAACCGTACGCCACCATTCCCA 72.9 46.2 54.5 (Whatmore et al. 1999) 
2.13.3 DNA extraction 
The S. pneumoniae isolates were streaked on blood agar plates and then incubated 
overnight at 37°C and 5% CO2. Then 8-10 pure colonies of the bacteria were picked-
up with a sterile loop and dissolved in a sterile 1.5ml eppendorf tube containing 
500μl sterile PBS. They were centrifuged at 1000xg for 10 min; and the supernatants 
were aspirated carefully. The pellets were resuspended into 100μl of 1x ThermoPol 
buffer (New England Biolabs, USA); and boiled for 10 min at 94°C. Then they were 
centrifuged at 1000xg for 5 min; and cooled on ice. The DNA concentration and 
purity were measured with a nanodrop apparatus using 2μl supernatants from these 
boilates. 
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2.13.4 PCR amplification 
1μl of the supernatant of the boiled bacteria was used as DNA template. A final 
volume of 25μl was prepared by adding 12.5μl BioMix Red reaction mix (Bioline, 
UK), 2.5μl of each forward and reverse primer (conc. 0.3μM) and 6.5μl ddH2O. In 
each set of PCR assay a sample of TIGR4wt pneumococcus was run as a positive 
control; and a sample of ddH2O was run as a negative control.  For detection of ply 
(pneumolysin) and rrgC genes; reaction conditions consisted of 30 cycles of 94°C 
for 30 sec, 55°C for 30 sec and 72°C for 1 min, followed by 5 min at 72°C. Reaction 
conditions for detection of rrgA and rrgB genes consisted of 30 cycles of 94°C for 
30 sec, 55°C for 30 sec and 72°C for 2 min, followed by 5 min at 72°C. 
2.13.5. Gel running and visualisation 
Before loading into a 0.75% agarose gel, 1μl Ultrasafe BlueTM (Syngene, UK) was 
added to 10μl of each PCR products and a 1 kb DNA ladder (Invitrogen, UK). The 
gel was run in 1x TBE buffer at constant 100v for 1 hr. It was then visualised in a 
ChemiDoc XR system (BioRad, UK), over a blue filter tray.  
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2.14 Statistical Analysis 
Data were analysed using SPSS statistics version 20 and GraphPad Prism version 5. 
At first the data were tested for normality with D’Agostino and Pearson omnibus 
normality test. Further analyses of the data that did not pass the normality test were 
done by nonparametric test; and the data that pass the normality test were analysed 
by parametric test. In some cases, log transformation of data was done before 
analysing by parametric statistical methods. Differences between two groups (i.e., 
carrier and non-carriers) were analysed by Student’s t (parametric) or Mann-Whitney 
(non-parametric) test. Differences between CCS stimulated and unstimulated 
samples in the same group of subjects were analysed by paired t (parametric) or 
Wilcoxon matched-pairs signed rank (non-parametric) test. One way analysis of 
variance (ANOVA) was performed to evaluate the effects of age and nasopharyngeal 
carriage status on the antibody titre. Association between two factors was analysed 
by Chi square (χ2) test. Correlation between two factors was analysed by Pearson’s 
(parametric) or Spearman’s (non-parametric) correlation test. A p value of <0.05 was 
taken as a level of statistical significance.  
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Chapter 3 
Nasopharyngeal Carriage of Streptococcus 
pneumoniae and Prevalence of Pilus-1 Gene 
among The Carriage Isolates 
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3.1 Introduction 
Human nasopharynx is the ecologic niche for a number of mucosal pathogens, from 
where they escape into the adjacent sites or spread to close contacts via droplet and 
respiratory secretions (Hill and Virji 2003). Streptococcus pneumoniae is one of the 
important members of this microbial flora. Despite being a very common event in 
early childhood, pneumococcal carriage remains asymptomatic most of the time. 
Occasionally, the bacteria disseminate to the sterile sites causing overt infections 
(Austrian 1986).  
Usually, pneumococcal acquisition in the human nasopharynx occurs in the first year 
of life (O'Brien and Nohynek 2003). The onset of this acquisition shows wide 
geographical variation; which usually occurs at an earlier age in the developing 
countries than in the developed world. A longitudinal study in Papua New Guinea 
showed over 60% of the neonates were colonised by 1 month of age (Gratten et al. 
1986). In a study in Bangladesh, 50% of the new-born children were reported to 
experience at least one episode of pneumococcal colonisation within 8 weeks, which 
surpassed 90% within 21 weeks (Granat et al. 2007). A similar trend was observed in 
neighbouring India, where 50% of the new-borns were colonised by pneumococcus 
before the age of 2 months and 80% before 6 months (Coles et al. 2001). A South 
African study showed a comparatively delayed onset of acquisition; which was 30% 
in 6 weeks, 44% in 10 weeks, 51% in 14 weeks and 61% in 9 months of age (Mbelle 
et al. 1999). In developed countries, pneumococcal acquisition starts around 6 
months of age, which peaks on the following 6 months (WHO 2009). In USA, the 
onset of carriage varied between 4 days to 18 months, with a mean age of about 6 
months (Gray et al. 1980). A study in Swedish children showed a much slower 
acquisition, 12% at the age of 2 months and 30% at the 6 months (Aniansson et al. 
1992).  
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The high carriage rate in the early childhood gradually declines with increasing age 
(Bogaert et al. 2004b). A study carried out in the UK before the introduction of 
conjugate vaccination showed that the average prevalence of pneumococcal carriage 
rates dropped from over 50% in children <2 years to less than 10% in adults 
(Hussain et al. 2005). Not only the frequency of pneumococcal carriage, but also the 
incidence of diseases caused by them shows a decreasing trend as the children grow 
older. This decline is thought to be mediated by the naturally acquired or vaccine 
induced immunity (O'Brien and Nohynek 2003).   
Geographical variations in the serotypes colonising human nasopharynx is relatively 
small (Bogaert et al. 2004a), and the most commonly isolated carriage serotypes are 
6, 14, 19 and 23 (Ghaffar et al. 1999). Risk factors for higher pneumococcal carriage 
include ethnicity, over-crowding, surrounding environment, and socioeconomic 
conditions (Bogaert et al. 2004a). Indigenous people in the developed countries, such 
as Apache and Navajo (USA), Eskimo (Alaska), Aborigines (Australia) and African 
American are among the highly susceptible ethnic groups for pneumococcal 
colonisation and diseases (Bogaert et al. 2004a; Mackenzie et al. 2010). Most 
important socioeconomic condition affecting pneumococcal carriage is the number 
of family members (older siblings in particular) (Petrosillo et al. 2002). 
Environmental factors potentiating colonisation include overcrowding and smoking 
(Ghaffar et al. 1999). Higher carriage was reported in children attending day-care 
centres (Bogaert et al. 2001) and living in orphanages (Raymond et al. 2000). Apart 
from these, carriage rate increases in winter. This may be associated with a 
preceding viral infection, and closer contact with other people or sharing warm 
clothing (Ghaffar et al. 1999). 
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Several factors are involved in facilitating pneumococcal colonisation and invasion. 
Biochemical structure of polysaccharide capsules is an important factor affecting 
pneumococcal carriage, and serotypes producing capsules are more likely to colonise 
and survive neutrophilic killing in the nasopharynx (Weinberger et al. 2009). 
Colonisation by a particular pneumococcal serotype also differs owing to its phase 
variation, yielding either transparent or opaque phenotypes of colonies (Weiser et al. 
1994). Transparent varieties, with thinner polysaccharide capsules are more likely to 
colonise the nasopharynx. On the other hand, the opaque varieties having thicker 
capsules are more resistant to phagocytosis and more likely to cause invasive 
infections (Kim et al. 1999).  
Capsulated bacteria express adhesins on their surface to augment their attachment in 
the respiratory mucosa (Carbonnelle et al. 2009). Pneumococci are decorated with a 
number of adhesins, which help them to colonise the nasopharynx. They include, 
phosphorylcholine (ChoP), choline binding protein A (CbpA), neuraminidase 
(NanA), β-galactosidase (BgaA), β-N-acetylglucosaminidase (StrH), hyaluronate 
lyase (Hyl), pneumococcal adhesion and virulence factor A (PavA), and enolase 
(Eno) (Kadioglu et al. 2008). Some pneumococcal strains express another important 
ECM-binding adhesin on their surface, known as pilus (Barocchi et al. 2006).  
Bacterial pili are hair-like surface projections, helping them to adhere with the host 
epithelium (Schwarz-Linek et al. 2004). Besides facilitating adhesion to host 
mucosal surface, Gram-negative pili have diverse biological functions; as for 
example, meningococcal pili contribute to bacterial motility and facilitate uptake of 
genetic material (Hill et al. 2010). On the contrary, Gram-positive pili are thinner 
and primarily involved in cell attachment (Proft and Baker 2009). Their adhesive 
function is mediated by interaction with adhesive matrix molecules (MSCRAMM) in 
the host mucosa (Schwarz-Linek et al. 2004). 
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Streptococcus pneumoniae expresses two types of pili. Type-1 pilus is composed of 
three subunit proteins; RrgA, RrgB and RrgC. The backbone of pilus shaft is formed 
by RrgB, anchoring RrgA at the tip and RrgC at the base (Hilleringmann et al. 
2009). On the other hand, the type-2 pilus is composed of only a core structural 
protein, PitB (Bagnoli et al. 2008). Compared to their non-piliated variants, pilus-
expressing pneumococci are more efficient to colonise and cause invasive infections; 
and associated with an enhanced host inflammatory response in experimental mice 
(Barocchi et al. 2006). Genes encoding pneumococcal type-1 pilus (known as pilus 
islet 1 or PI-1), are located in the rlrA pathogenicity islet. This islet is composed of 
seven genes; a regulatory gene rlrA, three structural genes (rrgA, rrgB, rrgC) 
encoding subunit proteins, and three sortase genes (srtB, srtC, and srtD) encoding 
catalytic enzymes (Hava et al. 2003).  
Type-1 pilus islet is clonally inherited by pneumococcal strains and exists in three 
variants, clade I, II and III (De Angelis et al. 2011). Not all pneumococcal strains 
containing PI-1 islet necessarily express pilus. Biphasic expression of pilus-1 has 
been observed even in a single clonal population of pneumococci; showing both high 
pilus expression (HPE) and low pilus expression (LPE) phenotypes (Basset et al. 
2011; De Angelis et al. 2011). This variability of pilus-1 has been reported to be 
positively regulated by an endogenous promoter (rlrA) and negatively regulated by 
one of the pilus-1 subunit (RrgA) proteins (Basset et al. 2011). A complex regulatory 
mechanism of pilus-1 expression has been described by studies identifying some 
other negative regulators (MgrA, HK343, MerR, CbpS, TCS08, mntE, PsaR) 
(Hemsley et al. 2003; Rosch et al. 2008; Song et al. 2009). 
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Based on the sequence variation in the terminal end, RrgA has two clades (clade I 
and II) (Moschioni et al. 2010b); and RrgB has three variants (clade I, II and III) 
corresponding the clonal variation of pilus-1 operon (Moschioni et al. 2008). 
Although definite function of RrgC is yet to be established (Hilleringmann et al. 
2009); rrgC has been shown to be the most conserved at the DNA level (Moschioni 
et al. 2008). For this reason detection of rrgC gene is considered as the marker of 
positivity for pilus-1 positivity (Basset et al. 2007b; Regev-Yochay et al. 2010). 
Prevalence of pilus islets (PI) in pneumococcal strains is not very common. PI-1 has 
been reported to be present in 30-50% of the pneumococcal strains. Importantly, 
their prevalence is higher among antibiotic resistant strains of vaccine serotypes 4, 
6B, 9V, 14, 19F and 23F (Aguiar et al. 2008, Moschioni et al. 2010a, Moschioni et 
al. 2010b, Regev-Yochay et al. 2010). PI-1 has also been detected in some vaccine-
related (6A and 23A/B) and non-vaccine serotypes (11A and 17F) (Regev-Yochay et 
al. 2009). Prevalence of PI-2 is even rarer than PI-1; and mostly associated with 
emerging serotypes (1, 2, 7F and 19A). Co-existence of both pilus islets has been 
reported in some of the pneumococcal strains (Bagnoli et al. 2008). 
This study focuses on the nasopharyngeal carriage of pneumococci in a cohort 
(patients undergoing routine adenoidectomy/tonsillectomy) of UK population. We 
also investigated the prevalence of PI-1 genes in these carriage isolates. Studies in 
animal model have shown that pneumococcal pili facilitate their adherence to the 
respiratory epithelium (Barocchi et al. 2006). So far, there is no information 
regarding their contribution to nasopharyngeal colonisation in humans.   
3.2 Aims of Study 
To investigate pneumococcal colonisation rate in children and adults; to isolate the 
carriage strains and analyse the prevalence of pilus-1 genes among these isolates. 
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3.3 Experimental Design 
1. Bacteriological culture of nasopharyngeal swab samples was done for detection of 
pneumococcal carriage. 
2. Streptococcus pneumoniae was isolated from these cultures and stored for further 
analyses. 
3. PCR amplification of genes (rrgA, rrgB and rrgC) in the PI-1 operon was 
performed to detect the prevalence of type-1 pilus among these isolates. 
4. Data were analysed to see whether there is any association between PI-1 genes 
and density of pneumococcal growth in the nasopharyngeal swab culture. 
3.3.1 Culture of nasal swabs for Streptococcus pneumoniae  
Detailed procedure of culture for pneumococcus from nasopharyngeal swabs is 
described in the methods chapter-2. Briefly, swabs were collected in vials containing 
1ml Skim milk-Trypone-Glucose-Glycerine (STGG) broth, and stored at -70°C. 
After thawing and vortexing 40μl of broth were inoculated on Columbia blood-agar 
plates (Oxoid, UK), following a standard technique (O'Brien and Nohynek 2003). 
The plates were incubated overnight at 37°C, in 5% CO2; and observed for α-
haemolytic colonies of pneumococcus, which were then confirmed by optochin disc 
inhibition tests (Chandler et al. 2000). The density of bacterial load was measured 
semi-quantitatively following a standard method (O'Brien and Nohynek 2003). The 
first inoculation on the plate was considered as Quadrant 1, from where it was 
streaked into all four quadrants. The growth was termed as 3+ if <10 colonies were 
in Quadrant 4 and >10 colonies in Quadrant 3; growth was labelled 2+ if there were 
<10 colonies in Quadrant 3 and >10 in Quadrant 2; finally, 1+ growth was noted if 
there were <10 in Quadrant 2 with growth in Quadrant 1. 
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 Figure 3.3.1: Growth of Streptococcus pneumoniae on blood agar plates; (a) 
Pneumococcal colonies (3+ growth) and (b) their Optochin susceptibility. 
3.3.2. PCR for detection of pilus islet 1 (PI-1) in pneumococcal isolates 
Detailed procedure for detection of pilus-1 operon (PI-1) by PCR in pneumococcal 
isolates from nasopharyngeal swabs is described in the methods chapter-2.  Briefly, 
DNA was extracted by boiling the bacterial cells (10 min at 94°C) in 1× Thermo Pol 
buffer (New England Biolabs, USA). For the PCR reaction, 1μl of the DNA template 
was used in a final volume of 25μl reaction mix, prepared by adding 12.5μl BioMix 
Red reaction mix (Bioline, UK), 2.5μl of each forward and reverse primers (0.3μM) 
(obtained from Sigma Aldrich, UK) and 6.5μl ddH2O. The reactions were carried out 
in a Techne Flexigene Thermal Cycler (Techne, UK). The reaction conditions for 
rrgC and ply consisted of 30 cycles of 94°C for 30 seconds, 55°C for 30 seconds and 
72°C for 1 min, followed by 5 min at 72°C. For rrgA and rrgB same conditions were 
applied, except a longer extension phase 72°C for 2 min. Primer sets used for these 
reactions are listed in table 3.3.2 with references. After the amplification 10μl of 
each PCR products were run into 1.0% agarose gel with 1μl Ultrasafe Blue 
(Syngene), and then visualised in a ChemiDoc XR (BioRad), over a blue filter tray. 
Pneumococcal isolates carrying rrgC gene was considered as pilus positive, since it 
is highly conserved within the PI-1 islet (Moschioni et al. 2008; Basset et al. 2007b). 
Presence of pneumolysin (ply) confirmed the isolate as pneumococcus (Regev-
Yochay et al. 2010). 
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Figure-3.3.2: Detection of PI-1 and pneumolysin (ply) genes in pneumococcal isolates. 
Figure shows the a) ply (1191 Kb), b) rrgC (1056 Kb), c) rrgA (2550 Kb) and d) rrgB 
(1850) genes.  
3.3.3  Statistical analysis 
Data were analysed using IBM SPSS statistics (version 20.0). Mean age differences 
between PI-1 positive and negative groups was analysed by Student’s t-test. 
Association of PI-1 gene positivity in the pneumococcal isolates and the density of 
growth in nasal swab culture was analysed by Chi square (χ2) test. A p value of 
<0.05 was taken as a level of statistical significance.  
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3.4  Results 
3.4.1 Pneumococcal carriage rate declines with increasing age  
A total of 295 subjects were included in the study among whom 195 were children 
(age <16 years, Mean±SEM = 6.04±0.259), and 100 were young adults (age 16-30 
years, Mean±SEM = 21.72±0.39). Pneumococcal carriage was assessed by culturing 
nasopharyngeal swabs. As expected, there was an age-related decrease in carriage 
rate, with more than 50% in <3 years old children to 3% in young adults (table-1). 
There was no significant difference between carriage rates in male and female 
patients. 
Table-3.4.1: Demography of the study subjects and nasopharyngeal carriage of 
pneumococcus 
 
n (% colonised) 
Age group Male Female Total 
1-3 yrs. 32 (56.3) 24 (54.2) 56 (55.4) 
4-6 yrs. 40 (37.5) 40 (32.5) 80 (35.0) 
7-9 yrs. 11 (27.3) 13 (38.5) 24 (33.3) 
10-15 yrs. 9 (22.2) 26 (15.4) 35 (17.1) 
16-30 yrs. 24 (4.2) 76 (2.6) 100 (3.0) 
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3.4.2 Prevalence of pilus-1 gene (PI-1) among the carriage isolates  
To investigate the prevalence of pilus-1 genes among the pneumococcal isolates 
obtained from nasal swab culture of study subjects, PCR amplification was 
performed for rrgA, rrgB and rrgC genes. Among the total 76 isolates, 8 were 
positive for rrgC gene. Only 2 of these strains were positive for rrgA and rrgB 
genes. All of these strains were positive for ply gene, which was amplified to 
confirm them as pneumococci. The isolates carrying the rrgC gene was considered 
as pilus-1 positive, which has been reported to be highly conserved within the pilus 
islet 1 (PI-1). Based on rrgC positivity, the overall of prevalence PI-1 among the 
isolates in our study was about 10.6% (figure 3.4.2). Colonisation by pilus-1 positive 
strains was highest (19.4%) in children younger than 3 years, followed by 7.1% in 
the 3-6 years age group. None of older children and adults was colonised with a pilus 
1 positive strain (Figure-3.4.2). 
 
 
 
 
 
 
Figure-3.4.2: Prevalence of PI-1 genes among the pneumococcal isolates from 
nasopharyngeal swab samples in different age groups. Figure shows the total number of 
pneumococcal isolates recovered from nasal swab culture (bar diagram) with the relative 
share of PI-1 positive (blank area) and negative (shaded area) strains.  
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The mean age (2.88±0.29) of children colonised with PI-1 positive strains was 
significantly lower than that of (5.1±0.36) children colonised by PI-1 negative strains 
(Figure-3.4.3, p=0.0383).  
 
 
 
 
 
 
Figure-3.4.3: Mean age of children colonised by PI-1 negative and positive 
pneumococcal strains. The scatter plot shows the age distribution of children (n=73) 
colonised by PI-1 negative (blank circles) and positive strains (filled circles) of 
pneumococcus, with mean age ± SEM (error bars) and significance level *p<0.05.  
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3.4.4 Relationship of pneumococcal density on nasal swab and patients’ ages 
Semi-quantitative estimation of the density of the pneumococcal growth in the nasal 
swab culture was performed, which roughly represented the bacterial load in the 
nasopharynx. As a whole, the distribution of pneumococcal growth densities (1+, 2+ 
and 3+) was (43%, 32% and 25% respectively) (Figure-3.4.4). These densities were 
analysed in relation to different age groups of the colonised subjects. More than two-
thirds (71%) of the <3 years children yielded higher pneumococcal growth density 
(2+ and 3+). In the 4-6 years age group, this percentage was 53%, which dropped to 
35% in older subjects (Figure-3.4.4).  
   
 
 
 
 
 
 
Figure-3.4.4: Density of pneumococcal growth on nasal swab culture in different age 
groups of colonised subjects. Figure shows the density of pneumococcal growth among 
different age groups in colonised subjects (n=76).  Result represents 1+ growth (blank bars), 
2+ growth (shaded bars) and 3+ growth (black bars) of pneumococcus during nasal swab 
culture on blood agar.  
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3.4.5 PI-1 positive pneumococcal strains are associated with higher density of 
pneumococcal growth in nasal swab culture  
To investigate whether there was any association between bacterial growth density 
and the pilus-1 positivity in pneumococcal isolates; Chi-square (χ2) test was 
performed (table-3.4.5); which showed that presence of PI-1 gene was associated 
with a higher pneumococcal growth density on nasal swab culture (n=76, Pearson 
χ2=9.01, DF=2, p=0.011).   
Table-3.4.5: Association of PI-1 positivity with density of pneumococcal growth in the 
nasal swabs from the carriers  
  Density of pneumococcal growth    
PI-1 gene  1+ 2+ 3+ Total 
Negative 33 21 14 68 
Positive 0 3 5 8 
Total 33 24 19 76 
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3.5 Discussion 
In this study, nearly half of the children aged less than six years were found to be 
colonised by pneumococcus. This finding was consistent with the colonisation rate 
among UK children of this age group, as reported in other studies (Roche et al. 
2007). As expected, pneumococcal colonisation rate showed an age-dependent 
decline in our study population (table-3.4.1). This finding was in agreement with the 
results of a previous study among a similar cohort of UK children showing that 
carriage rates peaked in 2 years then declined steadily and reached to ~30% beyond 
3 years (Zhang et al. 2006b). The pattern is similar among the children of other 
European countries. A carriage study in healthy Dutch children reported peak 
incidence (55%) at the age of 3 years, then declined gradually to around 10% beyond 
age of 10 years (Bogaert et al. 2006). Whereas, in Switzerland colonisation rate in 
children aged <4 years was reported to be 48%, which then gradually declined 
throughout the childhood (Mühlemann et al. 2003).  
Children at their early childhood are not only at greater risk of pneumococcal 
colonisation, but also more likely to carry them for longer duration of time (Högberg 
et al. 2007). This might be the reason for higher density of bacterial growth in 
younger children on nasal swab culture as observed in our study. We observed an 
age-dependent decrease in the percentage of children with higher bacterial growth 
density on nasal swab culture (figure-3.4.4). This may be due to the natural 
immunity developed during previous exposures.  
Serotyping of the colonizing isolates in our study was not performed. Therefore, we 
are unable to comment about serotype prevalence among the population. However, 
we have analysed the prevalence of pilus-1 positive strains among these isolates. 
Only 10.6% of the isolates in our study population was positive for rrgC gene. The 
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positivity of rrgA and rrgB genes, which encode the other two pilus-1 component 
proteins was even lower (2.6%). This might be due to the fact that RrgA and RrgB 
has different clades (two and three respectively). 
The positivity rate of PI-1 (rrgC) genes among the isolates in our study population 
was lower than previous studies, which showed that 25% to 50% of pneumococcal 
strains possess PI-1 genes (Aguiar et al. 2008; Moschioni et al. 2010a; Basset et al. 
2007b); and the prevalence was similar in both human carriage and invasive strains 
(Basset et al. 2007b). This low positive rate of PI-1 genes in our study is likely to be 
associated with the introduction of pneumococcal conjugate vaccines in the UK, as it 
happened in the years immediately after introduction of PCV7 in USA (Regev-
Yochay et al. 2010). PCV7 was introduced for routine vaccination in the UK in 
2006, which was replaced by PCV13 in 2010. Serotypes included in the 
pneumococcal conjugate vaccines are more likely to carry the rrgC gene than the 
non-vaccine serotypes (Basset et al. 2007b). As shown in a study on children (<7 
years) in USA, the prevalence of pilus-1 positive strains among nasopharyngeal 
isolates dropped from ~25% to 15% after 3 years of introduction of PCV7. 
Interestingly, they observed the prevalence to rise again in  seven years (~26%) 
matching that of the pre-vaccination era; which was most likely due to colonisation 
by non-vaccine serotypes (Regev-Yochay et al. 2010). However, the contribution of 
vaccination to this low prevalence of pilus-1 gene positive isolates in our study was 
unknown, as the percentages of vaccine and non-vaccine serotypes were not 
analysed.  
In this study, PI-1 gene could be detected only in a small fraction of strains isolated 
from young children (<6 years); not in the isolates recovered from the older children 
or adults. The study subjects included in our study were individuals undergoing 
routine elective adenotonsillectomy and they were otherwise healthy and not 
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immunodeficient. It is assumed that pneumococcal colonisation rate and pilus-1 
positivity rate among the isolates would be similar in normal healthy population. The 
mean age of children colonised with a PI-1 positive strain was significantly lower 
than that of children colonised with a PI-1 negative strain (Figure-3.4.3, p=0.0383). 
It has been shown previously that pneumococcal colonisation is a dynamic process, 
with most young children (<2 years) colonised serially with single or even multiple 
serotypes of the pneumococcus (Syrjänen et al. 2001). So it is possible that older 
children or adults included in this study had been exposed to pilus-1 expressing 
strains previously. Such case of a colonisation event is likely to induce a natural 
immune response to the pilus-1 components, which are known to be potently 
immunogenic in animal models (Gianfaldoni et al. 2007). This natural immunity 
resulting from a previous exposure to one of the pilus-1 expressing stains might also 
contribute to their overall low prevalence, particularly in the older children and 
adults (Regev-Yochay et al. 2010).  
Pneumococcal colonisation triggers a natural immunising process conferring 
protection against future colonisation and diseases. This protection is not strictly 
confined to that particular colonizing serotype; and has been shown to cover other 
serotypes as well (Ferreira et al. 2013). It is possible that children, who were 
colonised by piliated strains of pneumococci, developed a protective immune 
response. They were therefore protected from any subsequent carriage episode by 
these strains. As many protein antigens in the piliated strains are shared with other 
pneumococcal strains, there is a high possibility of developing cross-protective 
immunity. In general, colonisation by any pneumococcal strains in the early 
childhood reduces the likelihood of colonisation by the piliated strains in later life. 
While this explains the absence of pilus positive pneumococci among the carriage 
isolates from older children and adults, their prevalence among the strains colonizing 
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<1 year children remains unknown, as our study population did not include any 
children of this age group. These children may carry pneumococci, with a higher 
percentage of pilus-1 gene positivity, as expected by the trend we observed in our 
study (figure-3.4.2).  
Studies in animal models suggest pneumococcal pili contribute to mucosal 
colonisation (Barocchi et al. 2006). So far, there is no information regarding their 
role in colonising human nasopharynx. To establish human carriage models for this 
purpose is beyond the scope of our study. However, analysis of culture densities of 
piliated and non-piliated pneumococci in nasal swabs may indicate their capacity to 
colonise. Our findings suggest that PI-1 positive isolates were associated with higher 
colonisation densities than those of the PI-1 negative strains (table-3.4.5).  
It can be debated whether the higher bacterial density yielded in the nasal swab 
culture of piliated strains is attributable to pilus expression only, as it could also be 
related to the younger age of the children. Our findings suggest that both the 
pneumococcal strains (piliated or not) and the age of the carrier could contribute to 
the higher bacterial load in the nasopharynx, similar to their effect on the duration of 
carriage (Högberg et al. 2007). The younger children are less likely to develop a 
strong immune response to clear the colonizing bacteria early (Granat et al. 2009); 
and therefore may carry a higher bacterial load. On the other hand, expression of pili 
is likely to facilitate pneumococcal adhesion to nasopharynx (Nelson et al. 2007); 
and may contribute to the higher density of pneumococcal growth on nasal swab 
culture.  
The pneumococcal genome is highly diverse with more than 50% of it is composed 
of accessory genetic regions varying in different strains (Hiller et al. 2007). 
Expression of these genes affects the virulence of pneumococcal strains from 
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different genetic background. Pilus islet-1 (PI-1) is one of these accessory genetic 
components, likely to be acquired for facilitating pneumococcal adherence and 
survival on mucosal surfaces (Henriques-Normark et al. 2008). PI-1 is present in a 
limited number of pneumococcal clones, and can be divided into three different 
clades, mostly contributed by the main pilus subunit RrgB (Moschioni et al. 2008). 
Pneumococcal pili enhance bacterial adhesion to human respiratory epithelium, 
promote colonisation in mice and facilitate in vitro biofilm formation (Nelson et al. 
2007; Barocchi et al. 2006; Muñoz-Elías et al. 2008). Despite these advantages of 
piliated strains in colonisation and invasion, acquisition of both pilus islets (PI-1 and 
PI-2) in pneumococcal strains is not very common. One of the reasons limiting a 
widespread selection of the pilus-1 genes in pneumococci could be the strong 
immunogenicity of its components (Gianfaldoni et al. 2007), which is likely to 
induce a protective response against colonisation.  
PI-1 positive pneumococci exist in two phenotypically distinct (pilus-expressing and 
non-expressing) forms (Basset et al. 2011; De Angelis et al. 2011), which probably 
helps them to evade the host immune response. These phases are interchangeable, 
with reversion of pilus-high to pilus-low expression state and vice versa. A complex 
interaction between RlrA (positive regulator) and a number of negative regulators 
determines the fraction of cells in each phenotype (Basset et al. 2012). Bacterial 
phase variation can be considered as their evolutionary survival mechanism in the 
face of the host immune response. Phase variation is more common among the 
structures expressed on bacterial surface and therefore exposed to the immune 
system (van der Woude and Bäumler 2004). Variation of pilus expression has been 
reported in meningococci as well (Virji et al. 1992), which affects their interaction 
with host respiratory epithelium (Hill et al. 2010).  
98 
 
Several mechanisms are accounted for bacterial variable protein expression. There 
might be changes at genetic level due to genetic rearrangement or DNA 
modification; or it might result from epigenetic phenotypic variation without 
affecting the DNA sequence (van der Woude and Bäumler 2004). The biphasic 
expression of pneumococcal pilus-1 has been reported to be mediated by the later 
cause. Comparison of PI-1 islet from both pilus-high and pilus-low expression 
populations of three different strains has revealed no difference in their genomic 
sequence. There was no indication that their biphasic expression pattern resulted 
from genetic mutation or recombination events PI-1 operon (De Angelis et al. 2011). 
While evidence suggesting that this phenotypic variability in the pneumococcal pilus 
is not due to change at genetic level, it is likely to be controlled by the positive-
feedback from RlrA, which is also encoded within the same PI-1 islet (Basset et al. 
2012, De Angelis et al. 2011). 
Prevalence of pneumococcal piliated strains drastically dropped immediately after 
the introduction of the pneumococcal conjugate vaccine in USA, which went up 
again to the pre-vaccination level after a short interval (Regev-Yochay et al. 2010). 
This re-emergence of pilus-1 in pneumococcal populations suggests that it can offer 
significant selective advantages in bacterial colonisation and invasion. The biphasic 
expression pattern pneumococcal pilus-1 enables them to survive under different 
challenging conditions. Considering the fact that the regulators of the expression are 
located within the same islet encoding the pilus-1 genes, acquisition of the PI-1 islet 
would easily spread them to non-piliated pneumococcal strains. The association of 
pilus-1 and antibiotic resistance could be a matter of great concern in this regard 
(Moschioni et al. 2010a; Selva et al. 2012).  
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In summary, pneumococcal carriage is common in young children, which gradually 
decreases with advancing age. The presence of type-1 pilus is rare among these 
carriage strains in our population. This low prevalence could be associated with the 
introduction of pneumococcal conjugate vaccine, which covers the common piliated 
serotypes. It might also be contributed by the acquisition of natural immunity 
developed during colonisation episodes by piliated or non-piliated (sharing other 
common epitopes) strains. It will be interesting to investigate whether a re-
emergence of piliated pneumococcal strains follows this initial decline in our 
population as it happened in USA. Although the presence of pilus-1 genes is not 
widespread among pneumococcal strains, its association with antibiotic resistance 
and relatively higher prevalence among carriage isolates in younger children may 
have clinical implications. 
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Chapter 4 
Naturally Developed Serum and Salivary 
Antibodies to Pneumococcal RrgA and RrgB 
Antigens in Children and Adults 
 
 
 
 
 
 
101 
 
4.1 Introduction 
The naturally developed antibody responses to polysaccharide capsules are induced 
by the exposure to the pneumococcus during nasopharyngeal carriage which is 
common in younger children (Regev-Yochay et al. 2004). Natural antibody 
responses also develop against other pneumococcal targets, particularly to the 
surface expressed proteins (Jódar et al. 2003). Pneumococcal colonisations induce 
antibody responses to both capsular and non-capsular antigens in the local mucosal 
sites also. Following an exposure to pneumococcus, salivary IgA antibodies to the 
capsular polysaccharides develops more rapidly than the serum IgG (Simell et al. 
2002). Local production of salivary IgA antibodies to pneumococcal surface proteins 
(PsaA, Ply, and PspA), following pneumococcal carriage or episodes of acute otitis 
media was also reported (Simell et al. 2001).   
Several pneumococcal cell-surface or secreted proteins have been identified, which 
induce substantial antibody responses. Antibodies to some of these protein antigens 
showed good protective efficacy in experimental mice models (McCool et al. 2002; 
Briles et al. 2000). A combination of these antigens enhanced their antibody 
responses. For achieving specific targets; such as protection against invasive 
infection, nasopharyngeal carriage, development of herd immunity, a permutation-
combination of these antigens was found to be useful (Briles et al. 2000).  
Subsequent studies in humans also suggested the possible protective role of these 
non-polysaccharide antibodies. An experimental carriage model in healthy adults 
showed pre-existing antibodies to pneumococcal surface protein A (PspA) was 
protective against pneumococcal colonisation (McCool et al. 2002). These antibodies 
appear quite early in childhood, achieving a good titre before the second birthday, as 
evidenced in a Finnish study (Rapola et al. 2000) and a Kenyan study (Ellis and 
Beaman 2004). Considering the fact that, anti-capsular antibodies start to develop 
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during the second and third year of life; antibodies to protein antigens could play a 
crucial protective role in young children (Lipsitch et al. 2005). 
The antibody levels to these proteins in humans increase with age, while 
pneumococcal carriage rates decrease. Moreover, higher antibody levels to certain 
protein antigens were observed in culture-negative children than those who were 
colonised (Zhang et al. 2006b, Vukmanovic-Stejic et al. 2006). The inverse 
relationship between the magnitude of immune responses and pneumococcal 
carriage, suggests that naturally developed immunity to these protein antigens might 
be protective against pneumococcal carriage.  
All three subunits of pneumococcal pilus-1 were found to be immunogenic in 
experimental mice (Gianfaldoni et al. 2007). Intraperitoneal immunisation of mice 
with recombinant pilus subunits (RrgA, RrgB and RrgC) and heat-inactivated pilus-1 
expressing strain (TIGR4) produced specific serum antibodies detectable by ELISA. 
The antibody responses to all three proteins were sufficient to protect these 
immunised mice on subsequent intraperitoneal challenge with a TIGR4 strain in a 
lethal dose, showing lower level of bacteraemia and higher survival rates than 
controls. Moreover, passive transfer of mouse antisera raised against recombinant 
pilus antigens was able to protect previously unexposed mice (Gianfaldoni et al. 
2007).   
RrgA mediates pneumococcal adhesion to host respiratory epithelium. During 
colonisation with a piliated strain RrgA interacts with the host immune system, and 
elicits a strong host immune response (Nelson et al. 2007). Based on the sequence 
variation in the terminal end, two variants of RrgA (Clade I and II) were reported. 
Passively-immunised mice with antibodies developed against either of these variants 
showed cross-protection in subsequent challenge with pneumococcus (Moschioni et 
al. 2010b). Based on the molecular structural analysis, three variants of RrgB (Clade 
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I, II and III) were reported (Moschioni et al. 2008). Passive immunisation of 
experimental mice with antisera raised against each of these variants showed clade-
specific protection; but a fusion of these three variants (RrgB321) has been shown to 
be protective against piliated pneumococcal strains (Harfouche et al. 2012).  
Data on the immunogenicity of pneumococcal pilus-1 proteins in humans are 
limited. Little information is available with regard to the role of pilus-1 specific 
antibodies in protective immunity against pneumococcal carriage. Understanding the 
naturally developed immunity to pilus-1 proteins in humans and its relationship with 
carriage may provide valuable information to future vaccination strategy against 
pneumococcal infection. We hypothesize that, RrgA being an adhesin plays an 
important role in the bacterial interaction with host respiratory mucosa. Therefore, 
natural colonisation and/or infection with pilus-1 expressing pneumococci, is 
expected to induce systemic and mucosal antibody response against it. RrgB, the 
major structural unit of pneumococcal type-1 pilus may also induce protective 
antibody response. If these antibody responses are sufficiently strong, they might 
protect against subsequent colonisation and infection.  
4.2 Aims of Study 
To study naturally developed pneumococcal RrgA and RrgB antigen-specific 
antibodies in serum and saliva samples; and their relationship to nasopharyngeal 
carriage of pneumococcus in children and adults. 
4.3 Experimental Design 
1. An ELISA based method was established to measure pilus-1 antigen (RrgA and 
RrgB) specific antibodies in serum and saliva. The specificity of this method was 
ascertained by antigen-specific inhibition ELISA.  
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3. Serum and salivary antibodies to RrgA and RrgB was measured in children and 
adults by ELISA and Western blot. 
4. The relationship between the antibody levels and nasopharyngeal carriage of 
pneumococcus was analysed. 
4.3.1 Recombinant RrgA and RrgB Antigens  
Purified His-tagged recombinant RrgA and RrgB proteins from Streptococcus 
pneumoniae serotype 4 TIGR4 strain; obtained from Novartis Vaccines, Sienna, Italy 
(Gianfaldoni et al. 2007) were used for detection of anti-RrgA and -RrgB antibodies 
by ELISA and Western Blot.   
4.3.2 ELISA Assay 
ELISA assay was performed as described in methods (chapter 2). In brief, ELISA 
plates were coated with individual recombinant RrgA and RrgB antigens, and 
incubated overnight at 4°C. After washing, plates were blocked with 10% FBS-PBS 
followed by incubation of serum and saliva samples. Thereafter, alkaline 
phosphatase conjugated anti-human IgG (Sigma) was incubated before addition of 
PNPP substrate. Optical density was measured at 405 nm and data were analysed 
using DeltasoftPC microplate analysis software (BioMetallics) (for details see 
materials and methods chapter 2). 
Pooled human immunoglobulin (Sandoglobulin, Sandoz, UK) was used as the 
reference standard. The antibody titre of sandoglobulin for both RrgA and RrgB was 
determined by using a serial dilution of the immunoglobulin followed by the same 
ELISA procedure as described previously. The anti-RrgA (1000 units/ml) and anti-
RrgB (1400 unit/ml) titre of sandoglobulin was assigned as the reciprocal dilutions 
(1:1000 and 1:1400 respectively) at which their OD (at 405 nm) reached to 1.00, 30 
minutes after adding the substrate solutions. 
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4.3.3. Western Blot detection of anti-RrgA and anti-RrgB  
Western Blot detection of anti-RrgA and -RrgB antibodies are described in details in 
the methods chapter 2. Briefly, recombinant proteins (rRrgA and rRrgB), mixed with 
Laemmli reducing buffer were loaded and run into a mini protean TGX
TM
 gel 
(BioRad). Thereafter, the protein bands were transferred to a 0.2μm nitrocellulose 
membrane by a Transblot Turbo
TM
 transfer system (BioRad). After blocking with 
5% skimmed milk in 0.1% TBS-Tween20 for 2 hr, the membrane was blotted with 
serum samples (1:10,000 in blocking solution) for 2 hr. After washing, murine anti-
human IgG-HRP (Sigma) and Streptactin-HRP (BioRad), were added and incubated 
for 1 hr. The membrane was imaged on Chemi-DocXRS system (BioRad), 5 minutes 
after adding Immun-Star WesternC Chemiluminescence reagent A and B (BioRad). 
The densities of positive bands were measured semiquantitively using Image Lab 
software version 4.0.1 (BioRad).  For details procedures please see the materials and 
methods in chapter 2. 
4.3.4  Statistical analysis 
Statistical analysis was performed using IBM SPSS Statistics (version 20). Log 
transformation of data was done before analysing by parametric statistical methods. 
Differences in antibody titres between groups were analysed by analysis of variance 
and Student's t-test. One way analysis of variance (ANOVA) was performed to 
evaluate the effects of age and nasopharyngeal carriage status on the antibody titre. 
Association between two factors was analysed by Spearman’s correlation. A p value 
of <0.05 was considered statistically significant. 
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4.4 Results 
4.4.1 Establishment of ELISA for measuring RrgA and RrgB Specific antibodies 
ELISA assay was designed and established to measure pneumococcal RrgA and 
RrgB -specific antibodies. Each set of experiment was performed after optimisation 
for antigen coating concentration, sample dilution, conjugated-antibody 
concentration and incubation conditions. Standard curves were constructed for anti-
RrgA and anti-RrgB titres of test samples based on a reference standard 
sandoglobulin. As shown in figure (4.4.1) standard curve was obtained to calculate 
concentration of antigen-specific antibody levels. The optical densities (OD) of test 
samples within the standard curve were analysed. Samples with OD higher than the 
topmost standard were repeated with higher dilution. 
 
Figure 4.4.1: Establishment of standard curve after performing ELISA. Following the 
ELISA analysis of the reference standard and samples, standard curves were constructed 
based on the optical densities (OD at 405nm) and the antibody titres assigned to the serially 
diluted standard, using the DeltasoftPC microplate analysis software (BioMetallics, USA). 
4.4.2 Specificity of pneumococcal pilus-1 specific antibody ELISAs 
The specificity of the ELISA measuring anti-pilus antibodies was confirmed by 
antigen-specific inhibition ELISA assays adopted from (Zhang et al. 2000) with 
some modifications (details see chapter 2 materials and methods). 
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4.4.2.1 Specificity of anti-RrgA ELISA  
Three serum samples with high anti-RrgA titres were used and prepared (1:100 
dilutions). Recombinant RrgA were co-incubated with the serum samples in the 
following concentrations (0.3125, 0.625, 1.25, 2.50, 5.0 and 10.0) μg/ml, to adsorb 
the antibodies present in the serum. The percentage of inhibition was 20% at 
0.2μg/ml of RrgA antigen, and reached to about 100% with 2.5μg/ml rRrgA antigen. 
The mean concentration of the RrgA corresponding 50% inhibition of antibody 
activity was 0.3125μg/ml. The inhibition curve with increasing RrgA concentrations 
ascertains the specificity of anti-RrgA ELISA (Figure-4.4.2.1a). The failure of 
inhibition by adsorption by a heterologous antigen, recombinant RrgB, also 
supported the specificity of this assay (figure 4.4.2.1b). 
 
Figure-4.4.2.1a: Inhibition of Anti-RrgA IgG ELISA by recombinant RrgA. Anti-RrgA 
titre in the serum decreased with increasing concentration of the adsorbent recombinant 
RrgA antigen in a dose dependent manner confirming the specificity of the ELISA assay 
(one of three representative samples is shown). 
 
Figure 4.4.2.1b: Failure of inhibition of anti-RrgA IgG ELISA by recombinant RrgB. 
Serum samples were adsorbed by recombinant RrgB antigen showing no inhibition on the 
anti-RrgA titres in the serum samples (one of three representative samples is shown). 
108 
 
4.4.2.1 Specificity of anti-RrgB ELISA  
Three serum samples with high anti-RrgB titres were used and prepared (1:100 
dilutions). Recombinant RrgB were co-incubated with the serum samples in the 
following concentrations (0.3125, 0.625, 1.25, 2.50, 5.0 and 10.0) μg/ml, to adsorb 
the antibodies present in the serum, before ELISA assay for anti-RrgB antibody. The 
mean concentration of the RrgB corresponding to 50% inhibition of antibody activity 
was 2.5μg/ml. The inhibition curve of anti-RrgB antibody with increasing RrgB 
concentration (Figure-4.4.2.1c), and the failure of inhibition by a heterologous 
antigen, recombinant RrgA, supported the specificity of this assay (Figure-4.4.2.1d). 
 
Figure-4.4.2.1c: Inhibition of Anti-RrgB IgG ELISA by recombinant RrgB. Anti-RrgB 
titres detected in the serum sample decclined with increasing concentration of the adsorbent 
recombinant RrgB antigen in a dose dependent manner supports the specificity of the ELISA 
assay (one of three representative samples is shown). 
 
Figure 4.4.2.1d: Failure of inhibition of anti-RrgB IgG ELISA by recombinant RrgA. 
Serum samples adsorbed by recombinant RrgA antigens show no inhibition on anti-RrgB 
titres of the samples (one of three representative samples is shown). 
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4.4.3  Association of serum anti-RrgA and anti-RrgB IgG titres with age 
To investigate if there is any association between RrgA and RrgB -specific IgG 
antibody titres and age, serum samples from 195 children (<16 years) and 109 adults 
(>16 years) were measured for these antibodies using ELISA and analysed in 
association with age. Both anti-RrgA and –RrgB antibody titres were higher in adults 
than in children (Figure-4.4.3a, p<0.0001). 
  (a) 
 
 
 
 
 
 
 
Figure-4.4.3a: Serum anti-RrgA and anti-RrgB IgG titre in children and adults. Serum 
antibody titre was measured by ELISA in 195 children (n=195) and 109 adults (n=109). The 
results expressed as the geometric mean titre (GMT) ± 95% confidence interval (CI). 
Significance level (***p<0.0001) was compared between adult and children in student’s t 
test.  
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The age-related increase of anti-RrgA antibody is presented in figure 4.4.3b. As 
shown in the figure, anti-RrgA antibody could be detected in early childhood before 
the age of three years old. The antibody titre increased with age until around the age 
15 years, followed by a drop of in those aged between 16 and 30 years. One way 
ANOVA showed significant difference of anti-RrgA titre among the age groups 
(F=12.19, p<0.0001). In post hoc tests, the antibody titre in the age group of 10-15 
years was found to be significantly higher than that of 1-3, 4-6 and 16-30 years 
group. The titre of age group 16-30 years was higher than that of 1-3 and 4-6 years 
age groups (Figure 4.4.3b).   
  (b) 
 
 
 
 
 
 
Figure-4.4.3b: Serum anti-RrgA IgG titre in different age groups. Serum anti-RrgA 
titres at different age groups are shown. A total of 295 samples (n=295) are analysed 
including:  1-3 years (n=56), 4-6 years (n=80), 7-9 years (n=24), 10-15 years (n=35) and 16-
30 years group (n=100). The results are expressed as the geometric mean titre (GMT) ± 95% 
confidence interval (CI). Statistical differences (***p<0.0001, **p<0.01, and *p<0.05) 
between different groups were calculated by one way ANOVA with post hoc test.  
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The age-related increase in anti-RrgB antibody titres is presented in figure 4.4.3c. 
Anti-RrgB antibody titres were low in early childhood, which appeared to rise after 
the age of 6 years. Similar to anti-RrgA antibody, anti-RrgB antibody increased with 
age until around 15 years and then there was a decline in those aged 16-30 years. 
One way ANOVA showed difference in anti-RrgB titres among the age groups 
(F=12.71, p<0.0001). In post hoc tests, the antibody titre in the age groups of 7-9, 
10-15 and 16-30 years were higher than that of 1-3 and 4-6 years group (Figure 
4.4.3c).   
 (c) 
 
 
 
 
 
 
 
Figure-4.4.3c: Serum anti-RrgB IgG titre in different age groups. Serum anti-RrgB titres 
at different age groups are shown. A total of 295 samples (n=295) are analysed including 
age groups, 1-3 years (n=56), 4-6 years (n=80), 7-9 years (n=24), 10-15 years (n=35) and 
16-30 years group (n=100). The results are expressed as the geometric mean titres (GMT) ± 
95% confidence intervals (CI). Statistical differences (***p<0.0001 and *p<0.05) between 
different groups were calculated by one way ANOVA with post hoc test.  
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4.4.4 IgG subclasses of serum anti-RrgA and anti-RrgB antibodies 
To investigate which types of IgG subclasses are contributing to the antibody 
responses against the pilus-1 proteins, serum anti-RrgA and anti-RrgB IgG 
subclasses were also measured by ELISA. A total of 129 samples were analysed, of 
whom, 64 were children and 65 were adults. The predominant subclass for both 
antibodies was found to be IgG1 followed by IgG3 then IgG2, and IgG4 was the 
lowest. One way ANOVA showed significantly higher level of IgG1 for both anti-
RrgA and -RrgB than all three other subclasses (Figure-4.1.2.1, a+b). In case of anti-
RrgB, a significant difference between IgG3 and IgG4 was also observed (Figure-
4.4.4, a+b). 
(a)                                                                (b) 
 
 
 
 
 
 
 
 
 
Figure-4.4.4a+b: IgG subclasses of serum anti-RrgA and anti-RrgB antibodies. IgG 
subclasses of antibodies to RrgA and RrgB were analysed. Result shows OD (at 405 nm) of 
IgG subclasses for (a) anti-RrgA and (b) anti-RrgB antibodies. Statistical differences 
(***p<0.0001 and *p<0.05) between different subclasses were calculated by one way 
ANOVA with post hoc test. 
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4.4.5 Detection of serum anti-RrgA and anti-RrgB antibodies by Western 
blotting 
To confirm the presence or absence of RrgA- and RrgB-specific antibodies in serum 
samples, Western blot assay was also performed by immunoblotting serum samples 
against recombinant RrgA (~120kD) and RrgB (~50kD) proteins (Figure-4.4.5a). A 
total of 33 randomly selected serum samples (16 adults, 17 children) were tested, 
among them 19 were anti-RrgA positive and 24 were anti-RrgB positive. The 
detection of anti-RrgA and -RrgB antibodies in the serum samples by Western 
blotting confirm the presence of the antibodies detected by ELISA. The results from 
the Western blot analysis was applied to construct receiver operating characteristic 
(ROC) curves to set arbitrary cut-off values for positivity of serum anti-RrgA and -
RrgB titres (measured by ELISA). 
  (a) 
 
Figure-4.4.5a:  Detection of serum anti-RrgA and -RrgB antibodies by Western 
blotting. The presence or absence of anti-RrgA (lane 2, 4 and 6) and anti-RrgB (lane 3, 5 
and 7) in serum samples was detected by western blot technique. Blotting of three different 
serum samples were shown, first (lane 2, 3) and second (lane 4, 5) were positive for both 
RrgA and RrgB, third (lane 6, 7) was double negative. Lane 1 shows the molecular weight 
marker. 
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The densities of western blot bands were measured semiquantitively with Image Lab, 
version 4.0.1 (BioRad, UK). These relative densities analysed by Western blotting 
were shown to be well correlated with the antibody titres measured by ELISA for 
both anti-RrgA (p<0.05) and -RrgB (p<0.05) (Figure-4.4.5b+c).  
(b)                                                        (c) 
 
 
 
 
 
Figure-4.4.5b+c: Correlations of serum antibodies measured by ELISA and Western 
Blotting. Correlation between the densities of antibody bands by Western blotting and the 
serum antibody titres measured by ELISA are shown. (b) Anti-RrgA (n=19) measured by 
these two methods were correlated (*p<0.05) in Pearson’s correlation analysis; (c) anti-RrgB 
(n=24) measured by these two methods were also well correlated (*p<0.05) in Pearson’s 
test.  
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4.4.5.1 Calculation of a cut off value for serum anti-RrgA positivity measured by 
ELISA 
Based on the antibody positivity by western blot analysis, a receiver operating 
characteristic (ROC) curve was constructed for setting an arbitrary cut-off value of 
serum anti-RrgA titre (Figure-4.4.5.1). The area under the curve (±SE) was 
0.959±0.031. By the help of this ROC curve, the cut-off value for serum anti-RrgA 
was set as 100units/ml, with sensitivity of 84.2% and specificity of 92.9%. Using 
this cut-off, among the 304 patients studied, 61.5% of serum samples (56.9% of 
children and 69.7% of adults) were considered as serum positive for anti-RrgA. 
 
 
Figure-4.4.5.1: The ROC curve for setting anti-RrgA cut-off. The ROC curve for 
determining the cut-off value for positivity of serum anti-RrgA titre was constructed by the 
western blot analysis of 33 samples (n=33) of which 19 showed positive bands and 14 
negative. The area under curve (±SE) calculated by both logistic predicted probability and 
discriminant predicted a probability was 0.959 (±0.031), and the 95% CI (lower bound-
upper bound) was 0.899 -1.00 with asymptomatic significance ***p<0.0001. 
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4.4.5.2 Calculation of a cut off value for serum anti-RrgB positivity measured by 
ELISA 
Based on the antibody positivity by western blot analysis, a ROC curve was also 
constructed for setting an arbitrary cut-off value of serum anti-RrgB (Figure 4.4.5.2). 
The area under the curve (±SE) was 0.921 (±0.054). With the help of this ROC 
curve, the cut-off value for serum anti-RrgB was set at 100units/ml and that gave 
sensitivity of 87.5% and specificity of 77.7%. Among the 304 patients studied, 
58.2% of serum samples (51.8% of children and 69.7% of adults) were considered as 
serum positive for anti-RrgB antibody. 
 
 
Figure-4.4.5.2: The ROC curve for setting anti-RrgB cut-off. The ROC curve for 
determining the cut-off value for positivity of serum anti-RrgB titre was constructed by the 
western blot analysis of 33 samples (n=33), of which 24 showed positive bands and 9 
negative. The area under curve (±SE) calculated by both logistic predicted probability and 
discriminant predicted a probability was 0.921 (±0.054); and the 95% CI (lower bound-
upper bound) was 0.816 -1.00 with asymptomatic significance ***p<0.0001. 
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4.4.5.3 Antibody positivity by Western blot in different age groups 
The antibody positivity determined by the cut-off values calculated from Western 
blot analysis also showed an age-dependent increase. Both anti-RrgA and -RrgB 
positivity was less than 50% in 1-3 years children. Anti-RrgA positivity appeared to 
be higher in early childhood (<6 years), but anti-RrgB seemingly predominated in 
older children (>7 years) and adults. Positivity for both anti-RrgA and -RrgB peaked 
(>80%) at the age group of 10-15 years,  In 16-30 years group it was around 70% 
(Figure 4.4.5.3).   
 
 
 
 
 
 
 
 
 
 
 
 
Figure-4.4.5.3: Antibody positivity by Western blot in different age groups. The 
antibody positivity rates (determined by the cut-off values of 100units/ml based on Western 
blotting) in different age groups are shown. A total of 295 samples (n=295) were analysed 
including 1-3 years (n=56), 4-6 years (n=80), 7-9 years (n=24), 10-15 years (n=35) and 16-
30 years group (n=100). The results are expressed as the percentage (%) of antibody 
positivity. 
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4.4.6  Association of serum anti-RrgA and anti-RrgB IgM titres with age 
Pilus -1 (RrgA and RrgB) antigen-specific IgM antibodies in serum were analysed in 
70 children (<16 years) and 66 adults (>16 years) by ELISA. In the absence of a 
reference standard, results were expressed as the optical densities (OD at 405nm) 30 
min after the addition of substrate solution.  The mean OD for both anti-RrgA and -
RrgB IgM were significantly higher in children compared to those in the adults in 
independent sample t test (Figure-4.4.6, p=0.006 and p=0.008 respectively).  
 
 
 
 
 
 
 
 
 
Figure-4.4.6: Serum anti-RrgA and anti-RrgB IgM titre in children and adults. Serum 
IgM titre was measured by ELISA in children (n=70) and adults (n=66). The results are 
shown as the mean OD ± 95% confidence interval (CI). Significance (**p<0.001) compared 
with adults in Student’s t test.  
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4.4.7 Association of serum antibody titres with pneumococcal carriage  
To investigate whether there is any relationship between antibody levels and 
pneumococcal carriage, serum anti-RrgA and anti-RrgB IgG antibody titres were 
analysed in association with the presence/absence of nasopharyngeal carriage of 
pneumococcus. When all children and adults samples were included in the analysis, 
both anti-RrgA and anti-RrgB antibody titres were found to be higher in 
pneumococcal culture-negative patients than in culture-positives (figure-4.4.7, 
p<0.0001).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure-4.4.7: Serum anti-RrgA and -RrgB titres in relation to pneumococcal carriage 
Mean concentration (units/ml) of antibodies to RrgA and RrgB antigens were analysed in 
culture negative and colonised subjects. Significance (***p<0.0001) were compared with 
colonised by Student’s t test. Results represent GMT ± 95% CI (error bars) of 304 study 
subjects, of whom 76 were colonised and 228 were negative for pneumococcal carriage.  
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4.4.7.1 Association of serum anti-RrgA titres with pneumococcal carriage in 
different age groups  
As the antibody levels were shown to be age-dependent, we analysed the individual 
effects of carriage and age on antibody levels using a general linear model of 
analysis of variance (GLM-ANOVA). It was observed that the effect of carriage 
status on serum anti-RrgA antibody levels was independent of age, i.e. both carriage 
status and age were determinant factors of anti-RrgA antibody titres (p<0.007 and 
p=0.034 respectively). The geometric mean titres of anti-RrgA IgG antibodies in 
culture-negative patients were significantly higher than those of culture-positives in 
all age groups (p = 0.0048, <0.0001, <0.0001, <0.0001 and 0.0049 respectively, 
Figure-4.4.7.1). The number of culture-negative and colonised patients in 1-3 years 
groups were 25 and 31; in 4-6 years 52 and 28; in 7-9 years 16 and 8; in 10-15 years 
29 and 6; and in 16-30 years were 97 and 3.  
 
 
 
 
 
 
 
 
 
 
Figure-4.4.7.1: Serum anti-RrgA titre in different age groups and pneumococcal 
carriage. Anti-RrgA titres were analysed in relation to nasopharyngeal carriage of 
pneumococcus in different age groups. Results represent GMT ± 95% CI (error bars) of anti-
RrgA (units/ml) in culture negative and colonised subjects. Statistical difference 
(***p<0.0001, **p<0.01) was compared with colonised in Student’s t test.  
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4.4.7.2 Association of serum anti-RrgB titres with pneumococcal carriage in 
different age groups  
Unlike anti-RrgA, anti-RrgB titres were very low children younger than 6 years, and 
no difference was found between culture- and culture+ patients in these children. 
However, there appeared to be a differences between culture – and culture+ subjects 
in 7-9 and 10-15 years age groups (p<0.0001, Figure-4.4.7.2). Figure 4.4.7.2 shows 
the geometric mean titres of anti-RrgB IgG antibodies in culture-negative and 
culture-positive patients in different age groups. However, GLM-ANOVA analysis 
showed no independent effect of carriage status on anti-RrgB antibodies, as it was 
for age (p=0.065 and p=0.028 respectively). The number of culture-negative and 
colonised patients in 1-3 years groups were 25 and 31; in 4-6 years 52 and 28; in 7-9 
years 16 and 8; in 10-15 years 29 and 6; and in 16-30 years were 97 and 3.  
 
 
 
 
 
 
 
 
 
 
Figure-4.4.7.2: Serum anti-RrgB titre in different age groups and pneumococcal 
carriage. Anti-RrgB titres were analysed in relation to nasopharyngeal carriage of 
pneumococcus in different age groups. Results represent GMT ± 95%CI (error bars) of anti-
RrgB (units/ml) in culture- and culture+ subjects. Statistical difference (***p<0.0001) was 
compared with colonised in Student’s t test.  
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4.4.7.3 Association of IgG subclasses with pneumococcal carriage  
Anti-RrgA and -RrgB IgG subclasses were also analysed in relation to 
nasopharyngeal carriage of pneumococcus. The titre of IgG1 subclass for both 
antibodies was found to be significantly higher in pneumococcal culture-negative 
patients than in culture-positives (Figure 4.4.7.3a+b, p=0.022 and <0.001 
respectively). No significant difference was found in other subclasses (IgG2, IgG3 
and IgG4) for both anti-RrgA and -RrgB. (Figure 4.4.7.3a+b, p>0.05). 
 
 
(a)        (b) 
 
 
 
 
 
 
 
 
 
Figure-4.4.7.3a+b: IgG subclasses and pneumococcal carriage. The IgG subclasses for 
(a) anti-RrgA and (b) anti-RrgB antibodies were analysed in relation to pneumococcal 
carriage. Significance levels (**p<0.0001 and ** p<0.01) for the particular subclass were 
compared between culture-negative (n=103) and culture-positive (n=26) patients in 
Student’s t test.   
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4.4.7.4 Association of serum IgM titres with pneumococcal carriage  
Serum anti-RrgA and anti-RrgB IgM titres in children were also analysed in 
association with the presence/absence of nasopharyngeal carriage of pneumococcus. 
As the IgM titres were low in the adults, who also had a lower carriage rates, only 
children samples were analysed for association of carriage and IgM titre.  Both anti-
RrgA and anti-RrgB antibody titres were found to be higher in pneumococcal 
culture-positive than in culture-negative children (Figure-4.4.7.4, p=0.002 and 
p<0.0001 respectively).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure-4.4.7.4: Serum IgM in children in relation to pneumococcal carriage. IgM 
antibodies to RrgA and RrgB were analysed in culture negative and colonised children. 
Statistical significance (**p<0.01, ***p<0.0001) was compared with colonised in Student’s t 
test. Results represent mean OD ± 95% CI (error bars) of 70 children, of whom 34 were 
colonised and 36 were negative for pneumococcal carriage.  
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4.4.8 Salivary IgG and secretory IgA antibodies to RrgA and RrgB antigens  
Salivary anti-RrgA and anti-RrgB IgG antibody levels were measured by antigen-
specific ELISA. For the antigen-specific salivary IgG assays, pooled human serum 
immunoglobulin (Sandoglobulin) was used as the reference standard in a similar way 
it was used for serum IgG assays; and the results were expressed as units/ml. The 
salivary IgG antibodies to RrgA and RrgB antigens were analysed in relation to the 
corresponding serum IgG titres. A good correlation was found between serum and 
salivary IgG antibody titres to both RrgA and RrgB (Figure-4.6.2a+b, n=84, 
r=0.6121, P<0.0001; and n=84, r=0.7900, p<0.0001 respectively) in nonparametric 
(Spearman’s) correlation test. 
(a)          (b) 
 
  
 
 
 
 
 
Figure-4.4.8a+b: Correlation of serum and salivary IgG antibodies to RrgA and RrgB. 
Correlation between serum and salivary IgG antibodies to RrgA and RrgB in 84 samples 
(n=84); showing significant correlation for both (a) Serum and salivary anti-RrgA IgG and 
(b) Serum and salivary anti-RrgB IgG. 
To analyse the secretory IgA in saliva samples, anti-RrgA and anti-RrgB secretory 
component that represents secretory IgA (S-IgA) was also measured by antigen-
specific ELISA. In the absence of reference standard, the optical density (OD at 
405nm) 30 min after the addition of substrate solution was analysed.  
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4.4.8.1 Salivary RrgA and RrgB specific IgG in relation to pneumococcal carriage 
Salivary anti-RrgA and anti-RrgB IgG titre were analysed in relation to 
nasopharyngeal carriage of pneumococcus. Salivary antibody was measured in a 
total of 85 patients among them 47 were children and 38 were adults. None of the 
adults (n=38) were colonised. For this reason only children’s saliva samples (n=47) 
were included in the comparative analysis to investigate whether there was any 
association or relation to pneumococcal carriage with the antibody titres.   
Both salivary anti-RrgA and -RrgB IgG levels was found to be higher in culture-
negative children than in those who were culture-positive (Figure 4.4.8.1, p=0.0081 
and p=0.0478 respectively).  
  
 
  
 
 
 
 
 
 
 
Figure-4.4.8.1: Relationship between levels of salivary IgG antibodies and 
pneumococcal carriage. Salivary anti-RrgA and anti-RrgB IgG were analysed in culture 
negative (n=27) and culture positive (n=20) children. Results expressed as the geometric 
mean ± 95% confidence interval (CI) of antigen (RrgA and RrgB) specific IgG (units/ml). 
Statistical significance (*p<0.05 and **p<0.01) was compared with culture-positive children 
in Student’s t test.  
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4.4.8.2 Salivary anti-RrgA and RrgB S-IgA antibodies in relation to pneumococcal 
carriage 
Salivary anti-RrgA and anti-RrgB secretory IgA (S-IgA) levels were analysed in 
relation to nasopharyngeal carriage of pneumococcus. As described previously, only 
children’s saliva samples were included in this analysis. 
Both salivary anti-RrgA and anti-RrgB S-IgA levels were lower in the culture-
negative children than those who were colonised (Figure-4.4.8.2, p=0.0042 and 
p=0.0228). 
 
 
 
 
 
 
 
 
 
 
Figure-4.4.8.2: Relationship between salivary S-IgA antibodies and pneumococcal 
carriage. Salivary anti-RrgA and anti-RrgB S-IgA were analysed in culture negative (n=27) 
and culture positive (n=20) children. Results expressed as the geometric mean ± 95% 
confidence interval (CI) of antigen (RrgA and RrgB) specific S-IgA (OD at 405 nm). 
Statistical significance (**p<0.01 and *p<0.05) was compared to culture-negative children 
in Student’s t test.  
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4.5 Discussion  
Pneumococcus is a major human pathogen often colonises the human nasopharynx 
asymptomatically (Bogaert et al. 2004a). Pneumococcal infection is particularly 
common in young children and a major contributor of high mortality for children 
under five years (Obaro 2009). The incidence of invasive pneumococcal diseases 
gradually decreases with progression of age (Jódar et al. 2003). Nasopharyngeal 
carriage also declines in an age-dependent manner (Bogaert et al. 2004a). This 
decreased susceptibility to colonisation or infection is likely to be associated with the 
development of natural immunity to pneumococcus. Development of antibodies to 
pneumococcal capsular polysaccharides and surface proteins is a very important 
component of natural immune response to pneumococcus. Antibodies to capsular 
polysaccharides efficiently protect against subsequent carriage or infection by the 
corresponding serotypes (Shapiro et al. 1991). Similarly, antibodies against protein 
antigens also possess protective efficacy (Kamtchoua et al. 2013).  
Measurement of antibodies in serum (or in other body fluids, such as saliva, 
bronchoalveolar lavage) is an important parameter of assessing naturally or vaccine-
induced immune response to pneumococcal antigens. The most commonly used 
technique for measuring these antibodies is ELISA. ELISA based detection of anti-
pneumococcal capsular polysaccharide-specific antibodies became the choice of 
techniques in earlier 1980s, replacing the previously practiced radioimmunoassay 
(RIA). ELISA provided several advantages over RIA, including requirement of less 
sample volumes and avoidance of handling radioactive substances. However, earlier 
generation of ELISA lacked specificities, and after several modifications a third 
generation of ELISA had been standardised, which was universally adopted in a 
meeting of experts held at WHO headquarter in 2000 (Wernette et al. 2003).  
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ELISA based techniques are widely used for detection of antibodies to 
pneumococcal protein antigens also. Gianfaldoni et al, (2007) used an ELISA 
technique to measure antibodies to pilus-1 (RrgA, RrgB and RrgC) subunit proteins 
in mouse serum (Gianfaldoni et al. 2007). A modification of that ELISA procedure 
for analysis of RrgA- and RrgB-specific antibodies in human serum was applied in 
this study. The solution used for blocking ELISA plates, and diluting samples, 
standards and conjugates was 10% FCS in PBS. The presence of fibronectin in the 
FCS, which might bind to the adhesin RrgA, could potentially lead to non-specific 
background in the ELISA assay. However, this effect may be minimal, if present, as 
the negative control wells showed low background colour development. Another 
limitation of this ELISA was the use of a recombinant RrgB antigen from a single 
clade (clade-1) of pilus-1, which might result in a lower than estimated prevalence of 
serum anti-RrgB positivity 
Specificities of these assays were confirmed by inhibition ELISA.  Anti-RrgA 
ELISA was inhibited by adsorption of the serum antibodies after incubating with 
recombinant RrgA, but not with recombinant RrgB. Vice versa, anti-RrgB ELISA 
was inhibited by adsorption of the serum antibodies after incubating with 
recombinant RrgB, but not with recombinant RrgA.  
An in house modification of Western blot technique was also developed to further 
confirm the presence of pilus-1 specific antibodies. Indeed, Western blotting 
confirmed the presence of these antibodies in serum samples with antibody titres 
above certain threshold levels. This has provided supportive evidence of specificity 
for the antibodies detected by ELISA. It has enabled us to determine detection limits 
for the antibody positivity from antibody titres measured by ELISA.  
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In this study, we detected significant levels of serum anti-RrgA and RrgB antibodies 
in large number of patients (both children and adults), which were likely to be 
derived from previous colonisation of pneumococcus expressing pilus. To the best of 
our knowledge, this is the first report of naturally developed antibodies to 
pneumococcal RrgA and RrgB antigens in humans.  In general, the antibody titres to 
both RrgA and RrgB were higher in older children and adults than in children 
(Figure-4.4.3a). This may be a common phenomenon seen in antibodies to other of 
pneumococcal protein antigens including pneumolysin, PsaA, CbpA and PspA 
(Brandileone et al. 2004). Based on the cut-off value (100units/ml) calculated by the 
ROC curves constructed from western blot analysis, 61.5% of total serum samples 
were estimated to be positive for anti-RrgA, and 58.2% estimated to be positive for 
anti-RrgB antibodies.  
RrgA is the major contributor to the interaction of pneumococcal pilus-1 with host 
immune system (Nelson et al. 2007). This could be the reason why antibodies to 
RrgA appeared to develop earlier in childhood than that to RrgB, as shown in our 
study. Although an age-dependent increase in antibody levels for both serum anti-
RrgA (Figure-4.4.3b) and anti-RrgB (Figure-4.4.3b) IgG titres was observed, the 
titre of anti-RrgB was very low in general before the age of 6 years. However, anti-
RrgB titres elevated rapidly in children older than 6 years and reached similar levels 
to anti-RrgA antibody in older children (Figure-4.4.3c). The titres of both these 
antibodies were highest in adolescents and appeared to decline to some extent in the 
16-30 years old subjects (Figure-4.4.3b and 4.4.3c).    
The development of RrgA- and RrgB-specific antibodies in the serum could be 
considered as part of natural immune response in humans, induced by exposure to 
these proteins during colonisation or infection. Detection of anti-RrgA and -RrgB in 
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a large  proportion of sera (in both children and adults) suggests that pilus-1 
expressing pneumococcal strains may frequently colonise children during early 
childhood, despite the prevalence of pilus-expressing strains has been estimated to be 
around only 30% (Barocchi et al. 2006). It has been shown previously that 
pneumococcal colonisation is a dynamic process; and most young children (<2 
years) are colonised serially with single or even multiple serotypes of the 
pneumococcus (Syrjänen et al. 2001). So it is possible that children in this study had 
been exposed to pilus-expressing strains previously.  
As shown previously, antibodies to other pneumococcal proteins including CbpA 
and pneumolysin (Zhang et al. 2006b), IgG1 was the predominant subclass to RrgA 
and RrgB antigens (Figure-4.4.4, a+b). This was typical for antibody responses to 
protein antigens, with the predominance of IgG1 followed by IgG3 and with minimal 
levels of IgG2 and IgG4 (Hjelholt et al. 2013). Both IgG1 and IgG3 are potent 
complement activators (Ram et al. 2010). Therefore, the predominant generation of 
these two isotypes of antibodies to RrgA and RrgB protein antigens may be 
advantageous for their opsonophagocytic functionality, which contributes to the 
complement mediated phagocytosis of pneumococcus.  
When the antibody titres were analysed in all the patients samples in relation to 
pneumococcal carriage, both serum anti-RrgA and anti-RrgB IgG titres appeared to 
be higher in culture-negative patients than in those who were colonised (Figure-
4.4.7a). Detailed analysis in different age groups showed a consistently higher titre 
of anti-RrgA IgG antibodies in culture negative than in culture positive subjects in 
all age groups studied. This suggests that anti-RrgA antibodies may contribute to 
protection against pneumococcal carriage in humans. For anti-RrgB antibody, there 
appeared to be a difference between culture-negative and culture-positive subjects in 
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older children (7-15 years) (Figure-4.4.7.2) when the antibody titre reached higher 
level. This suggests that anti-RrgB antibody may also contribute to protection 
against carriage in older children and adults. 
Salivary IgG antibodies to both RrgA and RrgB were also detected in the study 
subjects. There was a significant difference in salivary anti-RrgA and -RrgB IgG 
titres between pneumococcal culture-negative and culture-positive patients, with 
higher titres in the former (Figure-4.4.8.1a). The higher salivary IgG in non-
colonised patients supports our hypothesis that it might significantly contribute in the 
protection against pneumococcal colonisation at the mucosal sites (figure-4.4.8.1a).   
There was a good correlation between the serum and salivary IgG antibodies for both 
anti-RrgA and anti-RrgB (Figure-4.4.8.1c+d), suggesting that the salivary IgG 
antibodies were mostly derived from serum leakage (Zhang et al. 2000), although 
local mucosal immune tissue NALT could also contribute to this local pool of 
antibodies (Ivarsson et al. 2004; Zhang et al. 2006b).  
On the other hand, the salivary secretory IgA (S-IgA) to both RrgA and RrgB were 
relatively higher in the colonised children compared to the non-colonised (Figure-
4.4.8.2). This increase of S-IgA in colonised patients could be explained by the fact 
that they are secreted from the local mucosal immune system (NALT), induced by 
recent colonisation. These locally produced S-IgA may contribute to protection 
against local invasion of pneumococcus to cause invasive disease, but may not be 
effective to clear pneumococcal carriage in the absence of an effective level of IgG.   
The primary antibody response to pathogens characteristically shows an early 
production of IgM antibodies, which later undergo affinity maturation and class-
switching to produce other antibody isotypes (Boes 2000). Following a recent 
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colonisation, the IgM antibodies rise quickly. That may explain the higher RrgA- 
and RrgB-specific IgM titres in colonised than in the non-colonised children (Figure-
4.4.7.4).    
One limitation of this study is the interpretation of association between antibody titre 
and carriage on the basis of a cross sectional data. A longitudinal follow-up of 
colonised patients to observe any subsequent rise of IgG titre and clearance of 
carriage would be helpful. Our cross sectional data suggests that recent 
pneumococcal colonisation induces a secretory IgA (in local mucosal sites, like 
saliva) and a systemic IgM (in serum) antibody responses to pneumococcal RrgA 
and RrgB proteins. These initial responses might not be sufficient to clear the 
nasopharyngeal carriage until a strong systemic IgG response develops, which 
potentially contributes to the eradication of carriage. This explanation is supported 
by the findings of a recent study where experimental human carriage induced strong 
mucosal and systemic antibody responses, which were protective against re-
colonisation or invasive pneumococcal disease (Ferreira et al. 2013).  
In summary, we show significant antibody levels to pilus RrgA and RrgB proteins 
developed from natural immunity in children and adults. There was an age-
dependent increase in serum antibody levels to both RrgA and RrgB. Notably, anti-
RrgA antibody starts to develop earlier in childhood than anti-RrgB antibody. Also, 
higher antibody levels, anti-RrgA antibodies in particular, were found in children 
who were culture-negative than in those who were culture-positive for 
pneumococcus in nasopharynx. These results suggest that naturally developed 
antibodies to pneumococcal pilus-1 proteins, particularly anti-RrgA might have a 
significant contribution in the protection against pneumococcal carriage in humans.  
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Chapter 5 
B cell Response to Pneumococcal RrgA and 
RrgB Antigens in Human Nasal Associated 
Lymphoid Tissues (NALT) 
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5.1  Introduction 
Streptococcus pneumoniae is a mucosal pathogen which frequently colonises the 
human nasopharynx. Although regarded as a precondition for disease causation, 
pneumococcal carriage can also be considered as a natural immunisation process 
(Ferreira et al. 2013). Pneumococcal carriage rates are highest in early childhood, 
which decline gradually in older children (Bogaert et al. 2004b). Priming of 
immunological memory to pneumococcal antigens occurs during the episodes of 
carriage in childhood, which may lead to the development of protective immunity in 
later life (Zhang et al. 2006b; Vukmanovic-Stejic et al. 2006). The nasal associated 
lymphoid tissues (NALT) play a crucial role in the induction of local mucosal 
immune response to pneumococcal protein antigens (Zhang et al. 2006b).  
Adenoids and palatine tonsils are major contributor of the human NALT (Brandtzaeg 
2003). These are the store houses for pathogen specific memory B and T cells 
(Passàli et al. 2003). Surgically removed adenotonsillar tissues were found to be rich 
in memory cells specific to pneumococcal protein antigens (Zhang et al. 2002). 
These memory cells are likely to be induced by previous colonisation by 
pneumococcus. Subsequent carriage enhances the magnitude of antigen specific 
antibody responses in these tissues, possibly by recalling these memory cells. 
Activation of these memory cells may mount a rapid and robust antibody response 
against pneumococcus (Zhang et al. 2002).   
Human adenoids and tonsils have structural and functional similarities. Unlike those 
in the other mucosal sites, adenotonsillar B cells are more of IgG secreting than of 
IgA. The IgA subclass produced in these tissues are mostly of IgA1 which is 
vulnerable to the degradation of IgA1 protease secreted by many respiratory 
pathogens, including pneumococcus. For this reason the IgG antibodies play a major 
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role in the protective response in these tissues (Boyaka et al. 2000). The abundance 
of B cells, together with the relative predominance of CD4
+
 T cells over CD8
+ 
cells 
(Passàli et al. 2003) supports the crucial role of the adenotonsillar tissues in the 
development of antigen-specific antibody response (Zhang et al. 2002). 
Pneumococcal protein antigens are capable of inducing antibody secreting cells 
(ASC) of different isotypes (IgG, IgM and IgA), with the predominance of IgG 
response in adenotonsillar tissues (Zhang et al. 2002). Adenotonsillar B cells express 
phenotypic properties of both mucosal and systemic compartments (Brandtzaeg 
2003). The mucosal phenotypes migrate preferentially in and around the upper 
respiratory tract (Johansen et al. 2005). Pneumococcal protein antigens stimulate 
both mucosal (expressing J chains) and systemic phenotypes of B cells in 
adenotonsillar MNC (Zhang et al. 2006b).  
Pneumococcal type-1 pilus subunits RrgA and RrgB showed good immunogenicity 
and protective capacity in experimental mice (Gianfaldoni et al. 2007). The subunit 
RrgA is an adhesin, which mediates the attachment of the bacteria and facilitates 
nasopharyngeal colonisation. It interacts extensively with the host mucosal cell 
adhesion molecules, and induces antibody responses in colonised children during 
this process (Nelson et al. 2007). Antibody response to subunit RrgB, the major 
structural component of pilus-1 was also reported. However, no data is available 
whether these proteins induce the local mucosal immunity in the human NALT. 
This study have investigated the antibody responses to RrgA and RrgB in the 
adenotonsillar MNC after in vitro stimulation with pneumococcal concentrated 
culture supernatant (CCS), containing both RrgA and RrgB proteins.  We examined 
the B cell responses to these RrgA and RrgB antigens in human NALT after 
stimulation with pneumococcal CCS or a polyclonal B cell activator CpG-ODN. 
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5.2  Aims of Study 
To investigate the B cell responses to pneumococcal RrgA and RrgB antigens in 
human nasal associated lymphoid tissues (NALT)  
5.3  Experimental Design 
1. Adenotonsillar MNC were stimulated with pneumococcal CCS or a polyclonal B 
cell activator (CpG-ODN) to induce B cell responses and in vitro production of 
antigen-specific or total antibodies.  
2. The B cell responses was analysed by enumerating RrgA- and RrgB-specific 
antibody secreting cells (ASC) by ELISpot assay. 
3. In vitro production of antigen-specific or total antibodies was measured by 
ELISA.  
4. Analyses were done to investigate whether current nasopharyngeal carriage of 
pneumococcus influences the in vitro antibody production or memory B cell 
responses to RrgA and RrgB. 
5.3.1  Patients and samples 
Surgically removed adenotonsillar tissues were obtained from both children and 
adults (1–30 years). A nasopharyngeal swab from each patient was obtained on the 
same day of operation. Patients who were known to be immunocompromised or had 
received antibiotics or steroids two weeks before surgery were excluded. The study 
was approved by the local ethics committee (Liverpool Paediatric Research Ethics 
Committee). An informed written consent was obtained from each patient/guardian 
as appropriate. 
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5.3.2  Pneumococcal Concentrated Culture Supernatant (CCS)  
Concentrated pneumococcal culture supernatant (CCS) used for in vitro stimulation 
of adenotonsillar mononuclear cells in this study was produced from a pilus-1 
expressing Streptococcus pneumoniae serotype 4 (TIGR4) strain (Tettelin et al. 
2001) following a previously described method (Zhang et al. 2006b). Detailed 
procedures for preparation of CCS from the TIGR4 wild type and its isogenic RrgA
-
/
- 
and RrgB
-
/
- 
mutants (Hilleringmann et al. 2009) was discussed in methods chapter-
2. Briefly, the CCS was prepared by concentrating the supernatants of pneumococcal 
broth cultures grown up to the exponential phase. The supernatant was removed 
following centrifugation (3000×g for 30 min). To get rid of any residual bacteria, the 
supernatant was filtered through a 0.2-mm sterile filter, and then concentrated 10-
fold before aliquoted for storage in the -80°C freezer. The protein concentrations of 
the CCS were measured by a Bio-Rad protein assay following the manufacturer's 
instructions (Sigma). Western blots of the CCS were performed with rabbit anti-
RrgA and anti-RrgB antisera to confirm the presence or absence of RrgA and RrgB 
proteins in the CCS from wild type TIGR4, RrgA
-
/
-
 and RrgB
-
/
- 
mutant strains.  
The choice of pneumococcal CCS for cell stimulations offers several advantages. 
First of all, it obviates the need for using live bacteria, therefore safe for handling. 
Secondly, the chance of cytotoxicity is less compared to live cells. Finally, it allows 
investigating the stimulatory effects of soluble proteins in their native form, 
excluding other structural components of pneumococcal cells. The effect of an 
individual protein may be assessed by comparing effect induced by CCS from the 
wild-type with the isogenic strains depleted of a particular protein. 
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5.3.3  Recombinant RrgA and RrgB Antigens  
Purified His-tagged recombinant RrgA and RrgB proteins from Streptococcus 
pneumoniae serotype 4 TIGR4 strain (obtained from Novartis Vaccines, Sienna, 
Italy) (Gianfaldoni et al. 2007) were used for detection of RrgA and RrgB-specific B 
cell response by ELISpot assay, and for measuring anti-RrgA and -RrgB antibodies 
by ELISA.   
5.3.4  Cell culture and stimulation by pneumococcal CCS 
Adenotonsillar MNC was cultured at 4x10
6
/ml in RPMI-1640 with or without 
pneumococcal CCS (1µg/ml). For enumerating the frequency of antibody secreting 
cells (ASC) by ELISpot assay, cells were incubated (at 37°C, in 5% CO2) for 5 days 
before being transferred to ELISpot plates. To analyse the in vitro antibody 
production after CCS stimulation, cell culture supernatants were collected at day 14 
and stored at –70°C until the antibody production was measured by ELISA. 
5.3.5  Measurement of B cell response by ELISpot assay 
B cell responses to pneumococcal RrgA and RrgB antigens were analysed using 
ELISpot assay. The detailed procedures are described in the methods chapter-2. 
Briefly, ELISpot plates (Millipore) were coated overnight with recombinant RrgA 
and RrgB antigens (5µg/ml). After blocking with RPMI (containing 10% FBS) at 
37°C for 2 hr, adenotonsillar MNC were added and incubated overnight at 37°C. 
After washing, biotinylated anti-human IgG antibodies (Invitrogen) were added and 
incubated for 30 min at RT. Thereafter, Avidin D-HRP conjugate (Vector 
Laboratories) was added and incubated for 30 min at RT. Coloured spots developed 
after addition of AEC substrate, which were imaged by Chemi-Doc XRS system, 
and analysed with NIST’s Integrated Colony Enumerator (NICE) software.  
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Figure-5.3.5:  ELISpot assay to enumerate antibody secreting B cell response showing 
number of RrgA- and RrgB-specific antibody secreting cells (ASCs) in TIGR4wt CCS 
stimulated samples compared to the corresponding medium controls. Total numbers of IgG 
secreting cells are shown on the right hand side column for each sample.   
5.3.6  ELISA Assay 
ELISA assay was performed as described in methods (chapter 2). In brief, ELISA 
plates were coated with individual recombinant RrgA and RrgB antigens (1µg/ml); 
and incubated overnight at 4°C. After washing, plates were blocked with 10% FBS-
PBS followed by incubation of cell culture supernatants. Thereafter, alkaline 
phosphatase conjugated antibodies were added and incubated before addition of p-
Nitrophenyl phosphate substrate. Optical density was measured at 405nm and data 
were analysed using DeltaSoft microplate analysis software (BioMetallics) (for 
details see materials and methods chapter 2). 
5.3.7  Statistical analysis 
Differences in B cell response or antibody titres between different groups were 
analysed by analysis of variance and Student's t-test. Association between two 
factors was analysed by Pearson’s correlation. A p value of <0.05 was considered 
statistically significant. Statistical analysis was performed using IBM SPSS Statistics 
(version 20). 
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5.4  Results 
5.4.1 Optimisation of pneumococcal CCS concentration for in vitro stimulation 
of adenotonsillar MNC 
The optimal concentration of pneumococcal CCS required for induction of antibody 
production to pilus-1 antigens in adenotonsillar MNC culture was obtained by 
stimulation of 5 samples with different concentrations (0.5, 1.0, 2.0 and 5.0µg/ml) of 
TIGR4wt CCS. One way ANOVA shows significant induction of both anti-RrgA 
and -RrgB production with all four concentrations of CCS compared to the 
unstimulated (0 µg/ml) controls (Figure-5.4.1). Antibody production to both antigens 
was highest when stimulated at CCS concentrations ≥1µg/ml (figure-5.4.1). This 
concentration (1µg/ml) was used to stimulate adenotonsillar MNC by all three CCS 
(TIGR4wt, RrgB
-/-
 and RrgA
-/-
) in subsequent experiments. 
 
 
 
 
 
 
Figure-5.4.1: Optimisation of TIGR4 CCS concentration for in vitro stimulation of 
adenotonsillar MNC for specific antibody response. Dose response of TIGR4wt CCS in 
the induction of RrgA- and RrgB-specific IgG production in adenotonsillar MNC cultures in 
5 patients are shown. Results are expressed as mean IgG titre (units/ml) + SEM (error bars). 
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5.4.2 Optimisation of the duration of adenotonsillar cell culture for specific 
antibody production  
Time-course of antibody production to pilus-1 antigens in adenotonsillar MNC 
culture following pneumococcal CCS stimulation was optimised. MNC culture 
supernatants were collected at different time points (1, 5, 7, 10 and 14 days) 
following stimulation with TIGR4wt CCS in 6 patients. Production of anti-RrgA was 
higher after 5 days of stimulation and onwards, when compared to day 1; whereas, 
anti-RrgB production was significant after 7 days of stimulation and onwards 
(Figure-5.4.2). The highest level was observed for both antibodies at day 14 (Figure-
5.4.2). In subsequent experiments, culture supernatants were collected at day 14 day 
of stimulation for measurement of antibody production by ELISA.    
 
 
 
 
 
 
Figure-5.4.2: Time course of antibody production after stimulation with pneumococcal 
CCS. Production of RrgA- and RrgB-specific IgG in adenotonsillar MNC culture was 
observed after 5-7 days of stimulation with TIGR4wt CCS and continues to increase until 
day 14. Results are expressed as mean IgG titre (units/ml) + SEM (error bars) of 6 patient 
samples. 
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5.4.3 Pneumococcal CCS stimulation induces anti-RrgA and anti-RrgB 
antibody responses in adenotonsillar MNC  
To investigate the in vitro production of antibodies to RrgA and RrgB by 
adenotonsillar MNC, antibody titres were measured in the cell culture supernatants. 
Cells were stimulated with an optimum concentration (1.0µg/ml) of pneumococcal 
CCS derived from TIGR4 wild type and its isogenic mutants (RrgA
-/-
 and RrgB
-/-
) 
for 14 days. Production of anti-RrgA and anti-RrgB antibodies in the MNC culture 
supernatants (n=58) was measured by ELISA. Stimulation with CCS derived from 
wild type pneumococcus (TIGR4wt) induced both anti-RrgA and anti-RrgB IgG 
antibody production (figure-5.4.3a+b, p<0.001 and P<0.01 respectively) compared to 
medium control. The CCS derived from RrgB
-/- 
mutant of TIGR4 strain induced anti-
RrgA IgG production, but there was no induction of anti-RrgB IgG production 
(figure-5.4.3a+b, p=0.0036 and p>0.05 respectively). The CCS derived from RrgA
-/- 
mutant of TIGR4 strain failed to induce anti-RrgA production; but it was able to 
induce production of anti-RrgB (figure-5.4.3a+b, p>0.05 and p=0.0032 respectively).  
(a)                                                             (b) 
 
 
 
Figure-5.4.3a+b: Induction of anti-RrgA and -RrgB antibody responses in 
adenotonsillar cells after pneumococcal CCS stimulation. (a) Anti-RrgA IgG (b) Anti-
RrgB IgG. IgG antibody response to RrgA and RrgB in adenotonsillar MNC cultures in 58 
patients with or without stimulation by CCS derived from three different pneumococcal 
strains (TIGR4wt, RrgB
-/-
 and RrgA
-/-
) are shown. Results are expressed as mean titre 
(units/ml) ± SEM (error bars). Significance (***p<0.001, ** p<0.001) was compared with 
the medium control in paired t test.  
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It has been shown that the protein-specific memory B cell antibody production is 
dependent on memory (CD45RO
+
) Th cells (Crotty and Ahmed 2004). To determine 
whether the pilus-1 specific antibody response was of memory type, in vitro 
antibody production in CD45RO
+
 cell depleted MNC were analysed and compared 
with unfractionated whole MNC in 4 samples. Production of both anti-RrgA and -
RrgB IgG antibodies following TIGR4wt CCS stimulation were markedly decreased 
in CD45RO
+ 
cell-depleted MNC compared to unfractionated MNC (Figure, 
5.4.3c+d, p=0.0094 and 0.0288 respectively). This suggests that the antigen specific 
antibody levels detected were most likely to derive from memory B cells.   
 
(b)      (d) 
 
 
 
 
 
Figure-5.4.3c+d: Effect of CD45RO
+
 cell depletion on the in vitro antibody production.  
Comparison of (c) anti-RrgA and (d) anti-RrgB IgG production by CD45RO
+
 cell-depleted 
MNC and unfractionated adenotonsillar MNC are shown (n=4). Antibody production in 
CD45RO
+ 
cell-depleted MNC was much lower than that of unfractionated whole MNC after 
stimulation with TIGR4wt CCS. Results are expressed as mean titre (units/ml) ± SEM (error 
bars); *p<0.05 **p<0.01 as compared between naïve (CD45RO
+
 depleted) and undepleted 
cells in paired t test. 
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5.4.4 Induction of antibody responses by Pneumococcal CCS is not a general 
polyclonal but antigen-specific 
To investigate whether the induction of in vitro antibody production by 
pneumococcal CCS results from a general polyclonal activation of adenotonsillar 
memory B cells or from a response specific to pneumococcal antigens, the total IgG, 
IgA and IgM antibodies production by adenotonsillar MNC were measured. The 
MNC were stimulated with a polyclonal B cell activator (CpG-ODN) and 
pneumococcal TIGR4wt CCS, and the cell culture supernatants collected after 8 days 
were analysed for total IgG, IgA and IgM production by ELISA. IgG titres following 
both stimulations were compared with unstimulated medium control in 24 patients 
(n=24). There was no increase in total IgG, IgA and IgM production in 
adenotonsillar MNC following stimulation by CCS. In contrast, CpG-ODN 
stimulation induced a marked increase of all 3 isotypes of immunoglobulins, i.e. total 
IgM, IgG and IgA (Figure-5.4.4, ***p<0.001, *p<0.05 and *p<0.05 respectively).  
 
 
 
 
 
Figure-5.4.4: Induction of total antibody production by pneumococcal TIGR4wt CCS 
and CpG-ODN. Pneumococcal CCS stimulation did not affect the total IgM, IgG and IgA 
concentration in adenotonsillar MNC culture, whereas significant increase in total 
immunoglobulin production (in all three isotypes) was observed following CpG-ODN 
stimulation. Results are expressed as mean antibody titre (units/ml) ± SEM (error bars) for 
total IgM, IgG and IgA in 24 patients (n=24); significance (*p<0.05 and ***p<0.001) was 
compared with the medium control in paired t tests. 
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5.4.5 Culture medium (THBY) alone does not induce antibody production 
Pneumococcal culture supernatants were produced by growing the organism in 
Todd-Hewitt Broth with 0.5% Yeast extract (THBY) medium. To determine whether 
there was any contribution of the THBY medium in the induction of the antibody 
responses by pneumococcal CCS, tonsillar MNC (n=21) were stimulated with this 
culture medium alone (concentrated in the same way as in the CCS) as a negative 
control. For both anti-RrgA and -RrgB IgG, addition of THYB culture medium alone 
did not induce any antibody response (Figure, 5.4.5a+b, p>0.05); whereas, all three 
CCS (TIGR4wt, RrgB-/- and RrgA-/-) induced specific antibody responses. CCS derived 
from RrgB
-/-
 induced anti-RrgA, CCS from RrgA
-/-
 induced anti-RrgB IgG and CCS from 
TIGR4wt induced both  (Figure, 5.4.5a+b, ***p<0.001). 
   (a)                                                                       (b) 
 
 
 
 
 
 
Figure-5.4.5a+b: Stimulation of adenotonsillar MNC with THYB medium; for (a) Anti-
RrgA IgG (b) Anti-RrgB IgG production. Addition of THYB medium alone is not sufficient 
to induce RrgA- and RrgB-specific antibodies. TIGR4wt CCS induces both anti-RrgA and -
RrgB, RrgB
-/-
 CCS induces anti-RrgA and RrgA
-/-
 CCS induces anti-RrgB IgG in 
adenotonsillar MNC cultures (n=21). Results showing mean IgG titre (units/ml) ± SEM 
(error bars); significance (***p<0.0001) was compared with the medium control in paired t 
test.  
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5.4.6 Recombinant antigen alone does not induce specific antibody response 
To investigate whether recombinant RrgA (rRrgA) or RrgB (rRrgB) protein induces 
antibody production in adenotonsillar MNC culture, tonsillar MNC (n=9) were co-
incubated with rRrgA (1μg/ml) or rRrgB (1μg/ml). Addition of either recombinant 
protein did not induce any significant antibody response (Figure, 5.4.6a+b, p>0.05). 
However, co-incubation of recombinant RrgA or RrgB with RrgA
-/-
 CCS or RrgB
-/-
 
CCS appeared to induce some anti-RrgA or -RrgB antibody production in 
adenotonsillar MNC culture (Figure, 5.4.6a+b, **p<0.01 and *p<0.05), although the 
magnitude of the antibody response was lower than that induced by TIGR4wt CCS. 
 
         (a)                                                            (b) 
 
 
   
 
 
 
 
Figure-5.4.6: Stimulation of adenotonsillar MNC with recombinant RrgA and RrgB 
antigens. Production of (a) anti-RrgA IgG and (b) anti-RrgB IgG after stimulation with CCS 
derived from TIGR4wt and isogenic mutant strains (RrgB
-/-
 and RrgA
-/-
); rRrgA or rRrgB 
alone (1.0μg/ml), or recombinant RrgA or RrgB together with RrgA-/-CCS or RrgB-/-CCS 
(rRrgA+RrgA
-/-
 and rRrgB+RrgB
-/-
) were analysed and compared with medium 
(unstimulated) control in 9 patient samples. Results showing mean IgG titre (units/ml)± 
SEM (error bars); significance (**p<0.01 and **p<0.05)  was compared with the medium 
control in paired t test.  
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5.4.7 Detection of antibody secreting cells (ASC) following stimulation by 
CpG-ODN and pneumococcal CCS. 
To analyse pilus-1 antigen specific B cell response in adenotonsillar MNC, ELISpot 
assay was performed. Firstly, memory B cell frequencies to RrgA and RrgB were 
enumerated after stimulation with a polyclonal B cell activator CpG-ODN. 
Significant memory B cell response (numbers of IgG ASC) were observed following 
CpG stimulation compared to the medium control (Figure-5.4.7a, ***p<0.001). 
Number of RrgA-specific IgG ASC (mean±SEM, 29.95±2.97) appeared to be higher 
than that of RrgB (mean±SEM, 16.08±5.7) (Figure-5.4.7a, *p<0.05).  
                (a) 
 
 
 
 
 
 
Figure-5.4.7a: Induction of RrgA and RrgB-specific B cell responses in NALT by CpG-
ODN. Numbers of RrgA- and RrgB-specific memory IgG cells ASC in adenotonsillar MNC 
were enumerated by ELISpot assay following CpG-ODN stimulation. Significant numbers 
of IgG ASC to RrgA and RrgB (***p<0.001) were observed after CpG-ODN stimulation 
(filled bars) compared with medium controls (open bars) paired t test. Data represent the 
mean±SEM (error bars) of number of antigen-specific ASC/10
6
 MNC (n=24). Also the 
frequency of RrgA-specific IgG ASC after CpG-ODN stimulation was significantly higher 
(*p<0.05) than that of RrgB in paired t test. 
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ELISpot assay was also performed to enumerate the numbers of RrgA- and RrgB-
specific B cell responses following stimulation by pneumococcal TIGR4wt CCS.  
Enumeration of antigen-specific ASC in adenotonsillar cells was done with or 
without TIGR4wt CCS stimulation in 58 patients (n=58). Significant numbers of IgG 
ASC to both RrgA and RrgB antigens were observed following CCS stimulation 
(mean±SEM, 20.55±2.67 and 13.56±1.69 respectively) compared to the medium 
control (mean±SEM, 5.39±0.69 and 5.09±0.60 respectively) (Figure-5.4.7b, 
***p<0.001). Number of RrgA ASC appeared to be higher than that of RrgB ASC 
(Figure-5.4.7b, *p=0.0291) 
                       (b) 
 
 
 
 
 
Figure-5.4.7b: Induction of RrgA and RrgB-specific B cell responses in NALT by 
TIGR4wt. Numbers of RrgA- and RrgB-specific IgG ASC in adenotonsillar MNC 
following TIGR4wt CCS stimulation (filled bars) were enumerated by ELISpot assay. 
Results expressed as the mean±SEM (error bar) of frequency of antigen-specific ASC/10
6
 
MNC (n=58); significance (*p<0.001) was compared with medium control (blank bars) in 
paired t test. Also the frequency of RrgA-specific IgG ASC after TIGR4wt stimulation was 
significantly higher (*p<0.05) than that of RrgB in paired t test. 
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The association between in vitro production of antibodies to pilus-1 antigens in 
adenotonsillar MNC culture supernatant and numbers of IgG ASC following 
stimulation by TIGR4wt CCS was examined in 33 patient’s samples. There was a 
good correlation between the two as shown in figure-5.4.7c+d.  
 
 (c) (d) 
 
 
 
 
 
 
 
Figure-5.4.7c+d:  Correlation between antibody levels in cell culture supernatant and 
numbers of ASC in adenotonsillar MNC after TIGR4wt CCS stimulation; (c) antibodies 
to RrgA, (d) antibodies to RrgB. In vitro antibody production was well correlated to the 
frequency of IgG ASC to both RrgA and RrgB (n=33) in Spearman’s correlation test; 
significance (***p<0.001).  
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Frequency of memory B cells is traditionally measured by enumerating numbers of  
antigen-specific ASC following in vitro polyclonal stimulation of B cells by agents 
such as Staphylococcus aureus Cowan strain (SAC) and/or CpG-ODN (Crotty and 
Ahmed 2004). In this study, numbers of IgG ASC in adenotonsillar MNC following 
stimulation by both CpG-ODN and TIGR4wt CCS were enumerated (n=6) (figure-
5.4.7e+f). Both stimulations elicited significant numbers of IgG ASC in 
unfractionated MNC, whereas the numbers of ASCs to both RrgA and RrgB were 
markedly reduced in CD45RO
+
 cell-depleted MNC than in unfractionated whole 
MNC (Figure-5.4.7e+f). This suggests that the ASC detected in adenotonsillar MNC 
following pneumococcal CCS stimulation were predominantly antigen-specific 
memory B cells.    
 
 (e)                                                         (f) 
 
 
 
 
 
Figure-5.4.7e+f: Numbers of IgG ASC in undepleted and memory (CD45RO
+
 depleted) 
adenotonsillar MNC following stimulation by CpG-ODN and TIGR4wt CCS; (e) ASCs 
to RrgA, (f) ASCs to RrgB. Results expressed as the mean±SEM (error bar) of numbers of 
antigen-specific ASC/10
6
 MNC (n=6). Both CpG-ODN and TIGR4wt CCS significantly 
induced pilus-1 (RrgA and RrgB) specific IgG ASC in unfractionated adenotonsillar MNC; 
significance (*p<0.05) was compared to unstimulated (medium control) in paired t test. 
Frequencies of ASC to both RrgA and RrgB after stimulation with CpG-ODN and TIGR4wt 
CCS were significantly reduced in CD45RO
+
 cell-depleted MNC; significance (*p<0.05) 
was compared to CD45RO
+
 depleted
 
MNC in paired t test.  
Undepleted CD45RO
-
0
5
10
15
20
25
Medium CpG CCS
*
*
A
S
C
 t
o
 R
rg
A
 /
 1
0
6
 M
N
C *
*
Undepleted CD45RO
-
0
5
10
15
20
25
Medium CpG CCS
*
*
A
S
C
 t
o
 R
rg
B
 /
 1
0
6
 M
N
C
*
*
151 
 
5.4.8 Association of in vitro tonsillar MNC antibody production and 
pneumococcal colonisation  
To examine whether there is any relationship between pneumococcal carriage and 
the in vitro B cell antibody response following stimulation, antibody production by 
adenotonsillar MNC from colonised and non-colonised patients were compared. 
Production of anti-RrgA in adenotonsillar MNC culture supernatants following in 
vitro stimulation with pneumococcal TIGR4wt CCS were found to be higher in 
patients currently colonised with pneumococcus than in those non-colonised (Figure 
5.4.8a, p<0.01). Similarly, anti-RrgB production in culture-positive patients was also 
shown to be higher than in culture-negative patients (Figure 5.4.8b, p<0.01). 
        (a)                                                                  (b) 
 
 
 
 
 
Figure-5.4.8a+b:  Relationship between pneumococcal colonisation status and antibody 
response to pilus-1 antigens following CCS stimulation. (a) Anti-RrgA IgG (b) Anti-RrgB 
IgG. Data showing means± SEM (error bars) of IgG titre in colonised (n=28) and non-
colonised (n=30) children. Significance level (**p<0.01) was compared with culture 
negative subjects in unpaired student’s t test. 
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Numbers of antibody secreting cells in adenotonsillar MNC following pneumococcal 
CCS stimulation were also compared in colonised and non-colonised patients. 
Numbers of IgG ASC to both RrgA and RrgB following stimulation by TIGR4wt 
CCS were also shown to be higher in colonised than in non-colonised patients 
(Figure 5.4.8c+d, *p<0.05).  
 (c)                                                                  (d) 
 
 
 
 
Figure-5.4.8c+d: relationship between pneumococcal colonisation status and memory B 
cell response to pilus antigens; (c) ASC to RrgA (d) ASC to RrgB. Data showing antibody 
secreting cell/million ± SEM (error bars) in colonised (n=28) and non-colonised (n=30) 
children.  Significance level (*p<0.05) compared with culture negative subjects unpaired 
student’s t test. 
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5.5 Discussion 
Pneumococcus commonly colonises the mucosal surfaces of human nasopharynx. 
Although carriage can be regarded as a pre-requisite for pneumococcal disease 
process, it also induces natural immunity to the organism. Younger children are 
particularly susceptible to pneumococcal colonisation and infection. As the age 
progresses, both carriage and infection rates gradually decline, possibly due to the 
development of natural immunity and maturation of the immune system (Bogaert et 
al. 2004b).   
Natural immunity to pneumococcus develops during the episodes of colonisation 
and/or infection. Carriage induces protective immune response to pneumococcal 
capsular polysaccharides and protein antigens in both local mucosal and systemic 
compartments (Ferreira et al. 2013). The nasal associated lymphoid tissues (NALT) 
plays a crucial role in development of local mucosal immunity to pneumococcus. 
Human NALT is important induction and effector site for natural immune response 
to pneumococcal protein antigens (Zhang et al. 2006b). They harbour significant 
numbers of antibody-secreting cells against those proteins (Zhang et al. 2002). The B 
cell response following in vitro pneumococcal stimulation was shown to be higher in 
tonsillar MNC from colonised patients. This may suggest that recent 
colonisation/carriage boosted memory B cell numbers. 
The ability of pneumococcal protein antigens to induce local mucosal immunity may 
have important implication in future vaccination strategy against pneumococcus. 
Currently available vaccines are formulated as intramuscular injections to induce a 
predominantly systemic immunity for protection against invasive infection. 
Activation of mucosal immune system with these vaccines is minimal. A vaccine 
preparation applied intranasally may induce local mucosal immunity that could 
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protect against invasive diseases as well as carriage (Brandtzaeg 2007). A number of 
pneumococcal proteins were shown to induce protective response against both 
invasive infection and colonisation with intranasal application in murine models 
(Briles et al. 2000). 
Expression of pilus-1 in pneumococcus is associated with enhanced colonisation and 
invasiveness of the bacteria; which is associated with an intensified inflammatory 
response in the host (Barocchi et al. 2006). This gave an early indication that the 
pilus-1 components might possess immunogenic properties, which could be 
exploited for vaccination. Indeed recombinant pilus-1 proteins, RrgA, RrgB and 
RrgC were shown to induce protective antibody response against invasive 
pneumococcal infection in experimental mice model (Gianfaldoni et al. 2007). So 
far, data regarding their immunogenicity in humans is limited. It remains unclear 
whether these proteins prime mucosal B cell memory in humans. 
In this study we have shown significant antigen-specific anti-RrgA and -RrgB 
antibody production in adenotonsillar cells following stimulation by pneumococcal 
CCS that contain secreted native RrgA and RrgB proteins. Using an ELISpot assay, 
we also detected significant numbers of IgG ASC upon stimulation by pneumococcal 
CCS and CpG-ODN. The frequency of IgG ASC was predominant in adenotonsillar 
MNC and depletion of memory T cells by CD45RO microbeads significantly 
reduced the numbers of IgG ASC elicited by either pneumococcal CCS or CpG-
ODN. It suggests that memory B cells are abundant in the NALT tissue, which are 
likely to be primed in vivo by previous colonisations. It is known that protein 
antigen-specific antibody production is T cell-dependent and memory T cells are 
crucial in memory B cell response (Crotty and Ahmed 2004).   
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In vitro production of antibodies to both RrgA and RrgB proteins was shown upon 
stimulation with pneumococcal CCS (Figure-5.4.3a+b). Stimulation of 
adenotonsillar MNC with TIGR4wt CCS (containing both RrgA and RrgB proteins) 
induced a significant (~6.8 fold-increase) anti-RrgA antibody response. Stimulation 
with the RrgB
-/- 
mutant CCS also induced a similar (~6.2 fold-increase) response; 
whereas, CCS lacking RrgA (RrgA
-/-
) did not induce any (Figure-5.4.3a). Significant 
induction of anti-RrgB antibody response following TIGR4wt stimulation was also 
observed, although the magnitude was somewhat lower (~2.9 fold increase). 
Stimulation with the RrgA
-/- 
mutant CCS induced an anti-RrgB response comparable 
(~2.8 fold-increase) to that induced by the wild type, whereas the RrgB
-/-
 mutant 
CCS failed to induce any response (Figure-5.4.3b). Production of these antigen-
specific antibodies were mostly contributed by the memory (CD45RO
+
) B cell, as 
their depletion markedly reduced both anti-RrgA and -RrgB levels (Figure-
5.4.3c+d).  
Considering that RrgA acts as a pneumococcal adhesin, it may be a good mucosal 
immunogen and induce local immune response in the nasopharynx. A relatively 
stronger response to RrgA compared to the response to RrgB following the CCS 
stimulation may suggest a stronger immunogenicity of RrgA antigen at the mucosal 
level. It is possible that RrgA interacts with the mucosal immune system through its 
adherence property and induce more significant immunity especially in young 
children. In the previous chapter, it was shown that serum anti-RrgA antibodies 
appeared to develop earlier in childhood than anti-RrgB antibodies.  
The failure of RrgA
-/-
 and RrgB
-/-
 mutant CCS to induce  anti-RrgA and -RrgB 
production respectively suggests that in vitro stimulations by CCS induce antigen-
specific antibody production, not by a non-specific polyclonal stimulation. This was 
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supported by the finding that total immunoglobulin productions in TIGR4wt CCS-
stimulated cell culture supernatants were not increased; whereas stimulation with a 
polyclonal B cell activator (CpG-ODN) resulted in a significant production of total 
IgM, IgG and IgA (Figure-5.4.4).  
Stimulation of the adenotonsillar MNC with concentrated culture medium (THBY) 
alone, which was used to prepare pneumococcal CCS did not induce any antibody 
response. It excluded any non-specific contribution from the components of 
pneumococcal culture medium in the production of RrgA- and RrgB specific 
antibodies with CCS stimulations (Figure-5.4.5a+b). This finding was in accordance 
with the previous reports that stimulation of adenotonsillar MNC with THYB 
medium does not enhance in vitro antibody response to tetanus toxoid; which is 
known to be a potent immunogen (Zhang et al. 2006b). 
Stimulation with either recombinant RrgA (rRrgA) or RrgB (rRrgB) alone did not 
induce an antibody response. However, their ability to induce specific antibody 
production was shown to be restored to some extent, when they were co-incubated 
with CCS derived from their corresponding mutant strains (Figure-5.4.6a+b). This 
phenomenon was also observed with other antigenic proteins of pneumococcus 
(Zhang et al. 2006b). It is possible that pneumococcal CCS contains something 
which has adjuvant effect for regaining of immunogenicity in recombinant proteins. 
It might well be the putative contribution by the mixture of antigenic proteins, 
inducing a stronger response to all of the components than what could have been 
generated by a single antigen per se.   
This study demonstrates a significant B cell response to pneumococcal pilus-1 
proteins in human NALT, upon stimulation by pneumococcal CCS. For enumerating 
antigen-specific memory B cell response we performed an ELISpot analysis, 
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following the methods developed by Shane Crotty and colleagues with some 
adaptation (Crotty et al. 2004). Adenotonsillar MNC was stimulated either with a 
polyclonal B cell activator CpG-ODN or pneumococcal TIGR4wt CCS (containing 
pilus-1 antigens RrgA and RrgB, confirmed by Western immunoblotting). 
Stimulation with both CpG and TIGR4wt CCS elicited significant numbers of RrgA- 
and RrgB-specific antibody secreting cells in adenotonsillar MNC. These antigen-
specific antibody secreting cells mostly represent the memory B cells in the 
adenotonsillar MNC, as evidenced by the significant reduction of their number when 
the memory T (CD45RO
+
) cells were depleted (Figure-5.4.7e+f). 
Antigen-specific memory B cells, primed during an earlier exposure are readily 
activated in subsequent antigenic challenges (Crotty and Ahmed 2004). Accordingly, 
we believe that the source of the IgG ASCs to RrgA and RrgB is from the IgG
 
memory B cell repertoire in the human NALT (Figure 5.4.7e+f). This pool of 
antigen-specific IgG cells is likely to be primed by previous episodes of carriage 
and/or infection by pilus-1 expressing pneumococcal strains. The abundance of these 
IgG
 
memory cells in the NALT suggests the role of NALT in the induction of 
antibody responses to pneumococcal proteins antigens. The predominance of IgG 
immunocytes is one of the distinguishing characteristics of NALT from other 
mucosal inductive sites such as Payer’s patches in GI tract where IgA immunocytes 
are predominant.  IgG antibodies may contribute significantly to the local mucosal 
immune response against respiratory pathogens (Boyaka et al. 2000).  
In vitro stimulation of adenotonsillar cells with pneumococcal culture supernatants 
induced a higher anti-RrgA and anti-RrgB antibody response in culture-positive than 
culture-negative patients. This result is consistent with the previous findings of 
higher in vitro antibody production to some other protein antigens (CbpA and 
158 
 
pneumolysin) in culture-positive children (Zhang et al. 2006b), indicating an 
enhanced memory response upon antigen re-exposure (Figure-5.4.8a+b). This 
suggests that recent pneumococcal colonisation or carriage in vivo may boost the 
antigen-specific memory B cell pool. This is supported by the enhancement in the 
number of antigen-specific ASCs in adenotonsillar cells of colonised patients 
(Figure-5.4.8c+d). In the previous chapter, we showed higher serum antibody levels 
to pilus proteins in non-colonised than colonised patients. Both systemic and local 
mucosal responses may contribute to the regulation of acquisition and elimination of 
pneumococcal carriage in the nasopharynx, and may exert their effects 
independently. High antecedent levels of antibodies in serum may help prevent 
colonisation, and enhanced memory-type local immune responses in NALT 
following re-exposure may help terminate it (Zhang et al. 2006b). 
Since pneumococcus frequently colonises nasopharyngeal mucosa, NALT is likely 
to be the major induction and effector site for B cell response to pneumococcal 
proteins. Our results suggest that previous episodes of colonisation and/or infection 
by pilus-1 expressing strains of pneumococcus prime the local mucosal immune 
system in NALT and resulted in the generation of a memory B cell repertoire.  
This study have presented evidences that both of these RrgA and RrgB are 
immunogenic and, and are capable of priming for memory B cell response in human 
NALT. Among these two pilus-1 antigens, the mucosal adhesin RrgA appeared to 
induce a relatively stronger immune response than the core structural protein RrgB. 
These findings provide supporting evidence that, pilus proteins especially RrgA 
could be exploited as component of mucosal pneumococcal vaccines.  
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6.1 Introduction 
For many years antibody production was considered to be the most important host 
protective immune responses to pneumococcal infection. However, recent studies 
suggest cellular immunity may also be important. Mice, genetically rendered 
unresponsive to polysaccharide antigens (CBA/N) or deficient of mature B cells 
(µMT), showed no remarkable decline in clearance of experimental pneumococcal 
colonisation (McCool and Weiser 2004). A new dimension of acquired immunity to 
pneumococcus is revealed, showing the limitations of antibodies to eliminate 
pneumococcal infection.  
In a murine model, it was revealed that both innate and CD4
+
 T cell mediated 
immunity were more important than antibody mediated immunity against 
pneumococcus (van Rossum et al. 2005). In vivo migration of CD4
+
 T cells towards 
the site of infection was documented in a study, which also revealed that MHC-II 
deficient mice (low CD4
+
 cell) were more vulnerable to pneumococcal colonisation 
and invasion (Kadioglu et al. 2004). Importance of CD4
+
 T cell mediated immunity 
to pneumococcal infection was demonstrated when experimental mice lacking 
antibody responses inhibited nasopharyngeal colonisation, but mice lacking T 
lymphocytes failed to do so (Malley et al. 2005). This cellular protective response 
was found to be mediated by CD4
+
 cells, not by the CD8
+
 subset (Malley et al. 
2005). A number of pneumococcal proteins, including pneumolysin, PspA, CbpA, 
PsaA can trigger this CD4
+
 T cell mediated protective response (Basset et al. 2007a, 
Mureithi et al. 2009, Zhang et al. 2007).  
More recently, CD4
+
 T cells producing IL-17 (Th17 cells) have been suggested to be 
an important immune effector in pneumococcal defence.  Nasopharyngeal clearance 
of pneumococcus in a high dose challenge model of mice was found to be 
161 
 
significantly reduced when treated with anti-IL-17A antibody (Malley et al. 2006). 
Pneumococcal cell wall polysaccharides up-regulated IL-17A production by cultured 
splenocytes of mice, previously vaccinated with these antigens (Malley et al. 2006). 
IL-17A recruits phagocytic cells in primary and secondary bacterial colonisation in 
the respiratory tract (Zhang et al. 2009). As shown in a mouse infection model, 
influx of neutrophils as part of an acute inflammatory response might not be 
sufficient to clear the bacterial load in case of primary pneumococcal colonisation. A 
TLR-2 dependent recruitment of other phagocytes (monocyte or macrophages) 
mediated by IL-17A was required to accomplish the task. However, on subsequent 
exposures, Th17 memory cell response was found to be associated with a quicker 
and vigorous influx of neutrophils resulting in an earlier clearance of carriage (Zhang 
et al. 2009).  
IL-17A mediated recruitment of neutrophil may play an important role in the 
elimination of pneumococcal carriage from nasopharynx (Lu et al. 2008). Clearance 
of pneumococcal carriage in mice vaccinated with a whole cell vaccine was 
associated with a heightened IL-17A response. Significant induction of IL-17A 
secretion was also observed in human adenotonsillar MNC culture following 
pneumococcal stimulation. Moreover, bacterial phagocytosis by human 
polymorphonuclear cells was enhanced when pre-incubated with IL-17A (Lu et al. 
2008). Patients suffering from a genetic disorder (autosomal dominant hyper IgE 
syndrome or HIES), with impaired IL-17 response are more susceptible to mucosal 
infections by several extracellular bacteria including Streptococcus pneumoniae 
(Milner et al. 2008). These suggest a crucial role by Th17 cells in natural immunity 
to pneumococci. 
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Th17 cells secrete a number of cytokines including IL-17A, IL-17F, IL-21 and IL-
22. IL-22 has been described as an important mediator of host mucosal immunity to 
invading pathogens. It plays a crucial role on maintaining the integrity of epithelial 
barriers at different mucosal sites (Aujla and Kolls 2009). Mice treated with anti-IL-
22 antibodies showed decreased survival during bacterial infection of respiratory 
tract (Aujla et al. 2008). Although it is a member of Th17 cytokine family, it can act 
independently and may not co-express with IL-17A (Lundgren et al. 2012). 
Pneumococcal whole cell antigen (WCA) and pneumolysoid (PdT) have been shown 
to induce both IL-17A and IL-22, which seems to be originated from the 
effector/memory (CD45RO
+
) T cells in a MHC-II dependent mechanism (Lundgren 
et al. 2012). Besides pneumococcal WCA and PdT, several other pneumococcal 
proteins; such as, PcsB (protein required for cell separation in group B streptococci), 
StkP (serine/threonine protein kinase) and PsaA (pneumococcal surface adhesin A) 
have also been shown to stimulate Th17 immunity in humans (Schmid et al. 2011).  
Pneumococcal pilus-1 proteins play an important role in virulence by facilitating 
adherence to host respiratory epithelium (Barocchi et al. 2006). It has been reported 
that presence of pilus locus is associated with pneumococcal invasiveness (Aguiar et 
al. 2008). Expression of pneumococcal pilus-1 (RrgA and RrgB) proteins by 
pneumococcus was shown to be associated with a heightened host inflammatory 
response (Barocchi et al. 2006). We have observed higher serum antibody levels to 
RrgA and RrgB in pneumococcal culture-negative children than in those who were 
culture-positives, indicating that these antibodies may contribute to protection 
against carriage.  
Pneumococcus frequently colonises human nasopharynx, but evasion of local 
mucosal immune system is relatively rare. An episode of colonisation, either 
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transient or persistent, is likely to prime local mucosal immune system (NALT) in 
the nasopharynx. Adenotonsillar tissues, as important components of human NALT, 
may play an important role in protection against pneumococcal carriage. Human 
adenotonsillar MNCs contain a large numbers of naturally developed T and B cells 
to pneumococcal protein antigens (Zhang et al. 2007, Zhang et al. 2006b). In this 
study, we have investigated CD4
+ 
T cell proliferative responses and Th17 related 
cytokine production in both adenotonsillar mononuclear cells (MNC) and peripheral 
blood mononuclear cells (PBMC) after stimulation with recombinant RrgA and 
RrgB proteins and pneumococcal CCS (containing or lacking these proteins). 
6.2  Aims of Study 
To investigate the CD4
+
 T cell and Th17 Cell responses to pneumococcal RrgA and 
RrgB antigens in human adenotonsillar MNC and PBMC.  
6.3  Experimental Design  
1. Adenotonsillar MNC and PBMC were stimulated by purified recombinant RrgA 
and RrgB antigens followed by analysis of T cell proliferation. These cells were 
also stimulated by pneumococcal culture supernatants derived from TIGR4 wild 
type pneumococcus (containing RrgA and RrgB) or the isogenic mutants lacking 
RrgA or RrgB followed by analysis of T cell proliferation.   
2. Th17 cell response following stimulation with pneumococcal CCS derived from 
TIGR4wt and its isogenic RrgB
-/-
 and RrgA
-/-
 mutant strains was evaluated by 
measurement of IL-17A, IL-17F and IL-22 by ELISA. 
6.3.1  Patients and samples 
Surgically removed adenotonsillar tissues were obtained from both children and 
adults (1–30 years). A nasopharyngeal swab from each patient was obtained on the 
same day of operation. Patients who were known to be immunocompromised or had 
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received antibiotics or steroids three weeks before surgery were excluded. The study 
was approved by the local ethics committee (Liverpool Paediatric Research Ethics 
Committee). An informed written consent was obtained from each patient/guardian 
as appropriate. 
 6.3.2 Recombinant RrgA and RrgB Antigens  
Purified His-tagged recombinant RrgA and RrgB proteins from Streptococcus 
pneumoniae serotype 4 TIGR4 strain (obtained from Novartis Vaccines, Sienna, 
Italy) (Gianfaldoni et al. 2007) were used for stimulation of adenotonsillar MNC and 
PBMC.   
6.3.3  Pneumococcal Culture Supernatant  
Pneumococcal CCS were produced from a pilus expressing Streptococcus 
pneumoniae serotype 4 (TIGR4) wild type (Tettelin et al. 2001) and its isogenic 
RrgA
-
/
- 
and RrgB
-
/
- 
mutants (Hilleringmann et al. 2009) following methods discussed 
in chapter-2. Both adenotonsillar MNC and PBMC were stimulated with these CCS 
to estimate the CD4
+
 T cell proliferative response and Th17 cytokine responses. Use 
of pneumococcal CCS to stimulate cell proliferation and cytokine induction has a 
major limitation. Although, the presence or absence of pilus-1 (RrgA and RrgB) 
proteins was documented by Western Blot analysis, these CCS contain other 
components, some of which might also be immunogenic. The effects of those 
components on the cell proliferation index and cytokine production remain 
undetermined. Therefore, the interpretation of the data obtained with pneumococcal 
CCS stimulations has to take this limitation into considerations and the inferences 
drawn from this would be less conclusive when compared to the T cell proliferation 
and cytokine responses after stimulations with purified recombinant proteins. 
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6.3.4  Cell culture and stimulation by recombinant pilus-1 antigens and 
pneumococcal CCS 
Adenotonsillar MNC (4x10
6
/ml) and PBMC (2x10
6
/ml) were cultured at in RPMI-
1640 culture medium with or without recombinant (RrgA and RrgB) proteins 
(0.5µg/ml) and pneumococcal (TIGR4wt, RrgB
-/-
 and RrgA
-/-
) CCS (1µg/ml). For 
analysing CD4
+
 T cell proliferative responses, cells were incubated (at 37°C, in 5% 
CO2) for 5 days before FACS analysis. To measure the Th17 cytokine production 
with in vitro CCS stimulation, cell culture supernatants were collected after 72 hours 
and stored at –70°C before analysed by ELISA. 
6.3.5 Analysis of CD4
+ 
T cell proliferation  
T cell proliferation was analysed by CFSE staining followed by flow cytometry. 
Memory and naive T cell responses were analysed following naïve (CD45RA
+
) T 
cell depletion and memory (CD45RO
+
) T cell depletion respectively from tonsillar 
MNC using magnetic (MACS) cell sorting described in details in chapter-2. Briefly, 
adenotonsillar MNC and PBMC were labelled with CFSE (at 37°C, for 8 min) and 
the reaction was quenched with ice cold media. After washing, cells were 
resuspended in RPMI 1640 media and stimulated with recombinant pilus-1 antigens 
or pneumococcal CCS, and incubated (at 37°C, in 5% CO2) for 5 days. Then the 
cells were harvested, washed and resuspended in 0.02% BSA in PBS for surface 
staining with phycoerythrin (PE) conjugated anti-CD4 antibody. CD4
+
 T cell 
proliferation index was analysed by flow cytometry (BD FACS Calibre; Becton 
Dickinson). The data was analysed using WinMDI software version2.9. The gating 
strategy for CD4
+
 T cell proliferation index is presented in figure 6.3.5. 
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Figure-6.3.5: The gating strategy for CD4
+
 T cell proliferation index. Lymphocyte and 
CD4
+
 T cell gating were used for this analysis. Lymphocytes were gated on the basis of their 
forward scatter (FSC) and side scatter (SSC) properties (size and granularity). Lymphocytes 
were gated on region 1 (R1) (Figure-6.3.5). Within R1, CD4
+
 T cells were gated on region 2 
(R2) (Figure 6.3.5) based on CD4-PE staining plotted against the forward scatter. Finally, 
R2-gated CD4
+ 
T cells plotted as CD4-PE staining on y axis against CFSE-labelling on x 
axis. The CD4
+ 
T cell proliferative index was calculated as the percentage of proliferating 
CD4
+
 T cell of total CD4
+
 T cells. Figure shows an example of CD4
+
 T cell proliferative 
index in (a) unstimulated medium control (b) anti-CD3 antibody stimulated positive control 
(c) stimulated with recombinant RrgA and (d) and RrgB antigens. 
6.3.6 Phenotyping of CD4
+
 T helper (Th1/Th2/Th17) cells  
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Phenotyping of different CD4
+
 T helper cell subsets induced by recombinant pilus-1 
antigens (rRrgA and rRrgB) and pneumococcal TIGR4wt CCS in PBMC and 
adenotonsillar MNC were performed with Human Th1/Th2/Th17 Phenotyping kit 
(BD Bioscience, UK), by a method described in chapter-2. Briefly, cell suspensions 
were incubated at 37°C for 24 hours in 5% CO2. A protein transport inhibitor 
‘monensin’ (BD GolgiStop ) was then added and incubated for another 6 hours. 
The cells were harvested, washed and fixed with 4% paraformaldehyde (BD 
Cytofix™). The cells were permeabilised with (Perm/Wash™) before the addition of 
20µl fluorochrome-labeled antibody cocktail (CD4 PerCP-cy5.5, IL-17A PE, IFN-γ 
FITC and IL-4 APC) for surface staining of CD4
+ 
T cells and for detection of 
intracellular cytokine production,  followed by flowcytometry (BD Biosciences) 
using CFlow sampler software.  
 
Figure-6.3.6a+b: The gating strategy for CD4
+
 T cells. (a) Lymphocytes were gated on 
the basis of their forward scatter (FSC) and side scatter (SSC) properties on plot 1 (P1); (b) 
CD4
+
 T cells were gated on region 1 (R1) based on the properties of CD4 PerCP-Cy5.5 
staining plotted against the forward scatter.  
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Figure-6.3.6c-f: Intracellular cytokine staining for IFN-γ, IL-4 and IL-17. R1-gated CD4+ 
T cells plotted as CD4-PerCP-Cy5.5 staining on the ‘X’ axis and IFN-γ FITC, IL-4 APC, IL-
17A PE staining on the ‘Y’ axis. The Th1/Th2/Th17 phenotyping of the CD4+ T cells were 
calculated as the percentage of IFN-γ, IL-4 and IL-17A expressing cells (in the upper right 
quadrants) in the CD4 gated (R1 in figure-6.3.6b) population of T cells. Figure shows 
example of a representative adenotonsillar sample in (c) unstimulated medium control, and 
stimulated with (d) PMA and ionomycin (e) recombinant RrgA (f) RrgB antigens. 
169 
 
6.3.7 Measurement of Th17 (IL-17A, IL-17F and IL-22) cytokines in the 
adenotonsillar MNC and PBMC culture supernatants by ELISA   
In vitro production of Th17 cytokines (IL-17A, IL-17F and IL-22) in adenotonsillar 
MNC and PBMC culture supernatants were measured by Human IL-17A, IL-17F 
and IL-22 Ready-Set-Go® ELISA sets (eBioscience, UK), following manufacturer’s 
instructions. The detailed procedures are described in chapter 2. Briefly, ELISA 
plates were coated with the capture antibody for overnight incubation. After 
blocking, standards (total of 8, starting from 500 pg/ml by 2-fold serial dilutions) and 
diluted samples (1:20) were added and incubated for 2h at RT. After washing, 
detection antibody was added and incubated for 1h at RT. Avidin-HRP was then 
added and incubated for 30min at RT, followed by the addition of TMB substrate 
solution for 15min at RT in dark. The reaction was stopped with 1M H2SO4 before 
the absorbance was measured using a microtiter plate reader (Opsys MR, Thermo 
labsystems, UK) at 450nm. The cytokine concentration (pg/ml) was calculated 
against the standard curve, with the help of microplate analysis software DeltasoftPC 
(Biometallics, Inc., USA). 
6.3.8 Statistical analysis 
At first the data were tested for normality with D’Agostino and Pearson omnibus 
normality test. Further analyses of the data that did not pass the normality test were 
done by nonparametric (Wilcoxon matched-pairs signed rank) test; and the data that 
pass the normality test were analysed by parametric (paired t) test, when the 
responses between different stimulations were compared. A p value of <0.05 was 
considered statistically significant. Statistical analysis was performed using 
GraphPad Prism (version 5). 
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6.4 Results 
6.4.1 Optimum dose of recombinant pilus-1 antigens and TIGR4wt CCS for 
CD4
+
 T cell stimulation 
Doses of pneumococcal recombinant pilus-1 antigens (rRrgA and rRrgB) and 
TIGR4wt CCS were optimised for analysis of CD4
+
 T cell proliferative response in 
adenotonsillar MNC (n=6). Four doses (0.1, 0.5, 1.0 and 2.0 µg/ml) of recombinant 
antigens and three doses (0.1, 0.5 and 1.0 µg/ml) of TIGR4wt CCS were used. The 
optimum response for rRrgA was at 0.5 µg/ml stimulation, and for rRrgB which was 
(0.1µg/ml). The strongest response with TIGR4wt CCS showed observed at a dose 
of 1.0 µg/ml (Figure-6.4.1).  
 
 
 
 
 
 
 
 
Figure-6.4.1: Dose-response curve for CD4
+
 T cell stimulation with pneumococcal 
TIGR4wt CCS and recombinant RrgA and RrgB antigens in NALT (n=6). Optimum 
concentration for rRrgA (filled circle) was 0.5 µg/ml and for rRrgB (open circle)
 
was 0.1 
µg/ml. Pneumococcal TIGR4wt CCS (filled square) showed strongest response at 1.0 µg/ml 
dose. The medium control is designated as 0 µg/ml stimulation. 
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6.4.2 Induction of CD4
+ 
T cell proliferation with pneumococcal recombinant 
pilus-1 antigens  
To investigate whether pneumococcal pilus-1 antigens induce CD4
+ 
T cell 
proliferation in human adenotonsillar tissue, CFSE-labelled tonsillar cells were 
stimulated with recombinant RrgA (rRrgA) and RrgB (rRrgB) antigens and analysed 
by FACS.  Possibly due to some pre-activated lymphocytes in human NALT, a high 
background proliferation was observed in some unstimulated MNC. For this reason, 
we depleted pre-activated (CD69
+
) T cells from the adenotonsillar MNC followed by 
cell stimulation. This cell population retained CD45RO
+
 (memory) T cells 
representing a memory type of response in the adenotonsillar MNC. A significant 
CD4
+
 T cell proliferative response was observed in the CD69
+
 depleted 
adenotonsillar cells, following stimulation with both rRrgA and rRrgB (figure-
6.4.2a: n=11, p=0.0020 and 0.0262 respectively, in Wilcoxon matched-pairs signed 
rank test).  
                         (a) 
 
                              
 
 
Figure-6.4.2a: CD4
+
 T cell proliferative response in the CD69
+
 depleted adenotonsillar 
MNC after stimulation with recombinant pilus-1 (rRrgA and rRrgB) antigens (n=11). 
Data represent the median with interquartile range for percentage of CD4
+
 T cell 
proliferation. Anti-CD3 stimulations used as positive control. Significant induction 
(*p<0.05, **p<0.01 and ***p<0.001) with different stimulations was compared with 
medium controls (yellow bars).  
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To investigate the naive CD4
+
 T cell response adenotonsillar MNC, samples were 
analysed after magnetic depletion of memory (CD45RO
+
) T cell population. 
Stimulation of these memory (CD45RO
+
) T cell-depleted MNC with recombinant 
rRrgA and rRrgB also induced a T cell proliferative response (figure-6.4.2b: n=21, 
p=0.0023 and 0.0066 respectively, in Wilcoxon matched-pairs signed rank test).   
                   (b) 
                                                                        
 
 
 
 
 
 
 
Figure-6.4.2b: Proliferative response in the naïve (CD45RO
+ 
depleted) CD4
+
 T cell 
populations in adenotonsillar MNC after stimulation with recombinant pilus-1 (rRrgA 
and rRrgB) antigens (n=21). Data represent the median with interquartile range for 
percentage of CD4
+
 T cell proliferation. Significant induction (**p<0.01) with different 
stimulations was compared with medium controls (yellow bars).  
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6.4.3 CD4
+ 
T cell proliferation with pneumococcal CCS stimulation 
Stimulation with pneumococcal CCS derived from TIGR4wt and its isogenic (RrgB
-
/- 
and RrgA
-/-
) mutants induced a significant CD4
+
 T cell proliferation in the 
undepleted adenotonsillar MNC (figure-6.4.3: n=24, p<0.0001, 0.0002 and 0.0039 in 
Wilcoxon matched-pairs signed rank test). The CD4
+
 T cell proliferative response 
elicited by CCS derived from the RrgB
-/- 
and RrgA
-/-
 mutants appeared to be lower 
than that by TIGR4wt CCS stimulation (figure-6.4.3: n=24, p=0.0009 and <0.0001 
respectively, in Wilcoxon matched-pairs signed rank test). 
 
 
 
 
 
 
 
 
Figure-6.4.3: CD4
+
 T cell proliferative response in the adenotonsillar MNC after 
stimulation with pneumococcal (TIGR4wt, RrgB
-/- 
and RrgA
-/-
) CCS (n=24). Data 
represent the median with interquartile range for percentage of CD4
+
 T cell proliferation. 
Significant induction (**p<0.01 and ***p<0.001) with different stimulations was compared 
with medium controls (yellow bars). Significantly higher proliferation (***p<0.001) was 
also observed in samples stimulated with TIGR4wt CCS compared to the stimulations with 
mutant (RrgB
-/- 
and RrgA
-/-
) CCS. 
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6.4.4 Recombinant pilus-1 antigens do not induce CD4
+ 
T cell proliferation in 
human PBMC 
To investigate whether pneumococcal recombinant pilus-1 antigens could induce 
proliferative response in CD4
+ 
T cell in human peripheral blood, we analysed some 
PBMC samples (n=12) after rRrgA and rRrgB stimulation. No significant induction 
of CD4
+ 
T cell proliferation was found following either rRrgA or rRrgB stimulation 
(figure-6.4.3: n=12, p=0.0977 and 0.3394 respectively in Wilcoxon matched-pairs 
signed rank test).  
 
 
 
 
 
 
 
 
 
 
 
Figure-6.4.4: CD4
+
 T cell proliferative response in the peripheral blood mononuclear 
cells (PBMC) after stimulation with recombinant pilus-1 (rRrgA and rRrgB) antigens 
(n=12). Data represent the median with interquartile range for percentage of CD4
+
 T cell 
proliferation. Induction of proliferative response with different stimulations was compared 
with medium control (yellow bars). No significant induction (p>0.05) was observed with 
either rRrgA or rRrgB stimulations.  
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6.4.5 Phenotyping (Th1/Th2/Th17) of adenotonsillar CD4
+
 T cells stimulated by 
pneumococcal pilus-1 antigens and CCS 
To investigate which phenotypes of CD4
+ 
T cells were induced in adenotonsillar 
MNC by pneumococcal pilus-1 antigens, intracellular cytokine staining of IFN-γ, IL-
4 and IL-17A was performed following rRrgA and rRrgB stimulation. There was no 
marked induction of individual cytokine expressing (IFN-γ+, IL-4+ and IL-17A+) 
CD4
+
 T cells after stimulation with the recombinant antigens compared to the 
medium control (figure-6.4.5a: n=9, p=0.177, 0.1336 and 0.0978 for rRrgA and 
p=0.1052, 0.1995 and 0.1078 for rRrgB respectively in paired t test).  
               (a) 
 
 
 
 
 
 
 
 
 
 
 
Figure-6.4.5 a: Phenotyping (Th1/Th2/Th17) of CD4
+
 T cells based on the expression of 
their signature cytokines (IFN-γ, IL-4 and IL-17A) after stimulation with recombinant 
rRrgA and rRrgB antigens in human adenotonsillar MNC. Data represent the 
mean±SEM (error bars) of percentage of CD4
+
 T cells (n=9) expressing theses cytokines. No 
significant induction (p>0.05) was observed for either rRrgA or rRrgB stimulations when 
compared to medium control (yellow bars).  
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However, stimulation with pneumococcal TIGR4wt CCS markedly induced IFN-γ+, 
IL-4
+
 and IL-17A
+
 cells compared to unstimulated control (figure-6.4.5b: n=9, 
p=0.0129, 0.0152 and 0.0199 respectively in paired t test). For this reason, the 
subsequent experiments for cytokine induction were carried out with TIGR4wt and 
its isogenic RrgB
-/-
 and RrgA
-/-
 mutant strains. 
 
                 (b)  
 
 
 
 
 
 
 
 
 
 
 
Figure-6.4.5b: Phenotyping (Th1/Th2/Th17) of CD4
+
 T cells based on the expression of 
their signature cytokines (IFN-γ, IL-4 and IL-17A) after TIGR4wt CCS stimulation in 
human adenotonsillar MNC. Data represent the mean±SEM (error bars) of percentage of 
CD4
+
 T cells expressing theses cytokines. Significant induction (*p<0.05) was observed 
with CCS stimulation compared to the medium control (yellow bars). 
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6.4.6 Time-course of Th17 cytokines production in adenotonsillar MNC culture 
Induction of in vitro production of Th17 cytokines (IL-17A, IL-17F and IL-22) in 
human adenotonsillar MNC culture after stimulation with pneumococcal TIGR4wt 
CCS was analysed in culture supernatants collected at different time points(6, 24, 48, 
72 and 96 hours interval) to standardise the optimum duration of stimulation before 
collection of culture supernatants. For all of the three Th17 cytokines (IL-17A, IL-
17F and IL-22) the maximum concentration of cytokine was measured after 72 hours 
stimulation (figure-6.4.8). For all of the subsequent experiments, supernatants from 
adenotonsillar MNC and PBMC culture were collected after 72 hours of stimulation. 
 
 
 
 
 
 
 
 
Figure-6.4.6: Time course of in vitro Th17 cytokines (IL-17A, IL-17F and IL-22) 
production in TIGR4wt CCS stimulated adenotonsillar MNC culture supernatants. 
Data represent the mean±SEM (error bars) of cytokine levels (pg/ml) measured by ELISA. 
All three cytokines showed maximum concentration after 72 hours of incubation  
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6.4.7 Induction of Th17 cytokines in adenotonsillar MNC with pneumococcal 
TIGR4wt CCS stimulation is stronger than stimulation with CCS derived from 
RrgB
-/-
 and RrgA
-/-
 mutants  
Induction of Th17 cytokines (IL-17A, IL-17F and IL-22) was analysed in 
adenotonsillar MNC culture supernatants, 72 hours after stimulation with 
pneumococcal TIGR4wt and its isogenic (RrgB
-/-
 and RrgA
-/-
) mutants CCS.  
Production of IL-17A was shown to be higher with TIGR4wt CCS stimulation than 
that induced by CCS derived from its isogenic RrgB
-/-
 or RrgA
-/-
 mutant strains 
(figure-6.4.7a: n=22, p=0.0007 and <0.0001 respectively, in Wilcoxon matched-pairs 
signed rank test).  
Similarly, stronger IL-17F production was observed after stimulation with TIGR4wt 
CCS compared to stimulations with either RrgB
-/-
 or RrgA
-/-
 mutant strains (figure-
6.4.7b: n=22, p=0.0008 and 0.0074 respectively, in Wilcoxon matched-pairs signed 
rank test).  
TIGR4wt CCS also induced a higher IL-22 production in adenotonsillar MNC 
culture supernatants than RrgB
-/-
 or RrgA
-/-
 mutant strains (figure-6.4.7c: n=22, 
p=0.0123 and 0.0054 respectively, in Wilcoxon matched-pairs signed rank test).  
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(a)                                                     (b) 
 
 
 
 
 
 
 
 
                                 
 
 
 
 
                                    (c) 
 
 
 
 
 
 
 
 
 
 
Figure-6.4.7 a-c: Induction of Th17 cytokines in adenotonsillar MNC culture supernatants; 
(a) production of IL-17A, (b) production of IL-17F and (c) production of IL-22 72 hours 
after stimulation with TIGR4wt, RrgB
-/-
 and RrgA
-/-
 CCS. Data represent the median with 
interquartile range of cytokine levels (pg/ml) measured by ELISA. Significant induction of 
cytokine production (*p<0.05, **p<0.01, ***p<0.001) with different stimulations was 
compared with medium control (open bars). Also the cytokine production after stimulation 
with CCS derived from TIGR4wt was compared with that of RrgB
-/-
 and RrgA
-/-
 mutants and 
the significant differences (*p<0.05, **p<0.01, ***p<0.001) are shown in the graphs.      
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6.4.8 Induction of Th17 cytokines in PBMC with pneumococcal TIGR4wt CCS 
stimulation is stronger than stimulation with CCS derived from RrgB
-/-
 and RrgA
-/-
 
mutants  
Induction of Th17 cytokines (IL-17A, IL-17F and IL-22) was analysed in the culture 
supernatants of PBMC, stimulated for 72 hours with pneumococcal TIGR4wt and its 
isogenic (RrgB
-/-
 and RrgA
-/-
) mutants CCS.  
Production of IL-17A was shown to be higher with TIGR4wt CCS stimulation than 
that induced by CCS derived from its isogenic RrgB
-/-
 or RrgA
-/-
 mutant strains 
(figure-6.4.8a: n=21, p=0.0178 and 0.0054 respectively, in Wilcoxon matched-pairs 
signed rank test).  
Similarly, stronger IL-17F production was observed after stimulation with TIGR4wt 
CCS compared to stimulations with either RrgB
-/-
 or RrgA
-/-
 mutant strains (figure-
6.4.8b: n=21, p=0.0130 and 0.0145 respectively, in Wilcoxon matched-pairs signed 
rank test).  
TIGR4wt CCS also induced a higher IL-22 production in culture supernatants of 
PBMC than RrgB
-/-
 or RrgA
-/-
 mutant strains (figure-6.4.8c: n=22, p=0.0136 and 
0.0181 respectively, in Wilcoxon matched-pairs signed rank test).  
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Figure-6.4.8 a-c: Induction of Th17 cytokines in PBMC culture supernatants; (a) production 
of IL-17A, (b) IL-17F and (c) IL-22 72 hours after stimulation with TIGR4wt, RrgB
-/-
 and 
RrgA
-/-
 CCS. Data represent the median with interquartile range of cytokine levels (pg/ml) 
measured by ELISA. Significant induction of cytokine production (**p<0.01 and 
***p<0.001) with different stimulations was compared with medium control (open bars). 
Also the cytokine production after stimulation with CCS derived from TIGR4wt was 
compared with that of RrgB
-/-
 and RrgA
-/-
 mutants and the significant differences (*p<0.05 
and **p<0.01) are shown in the graphs.     
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6.5 Discussion 
The present study has revealed that pneumococcal pilus-1 proteins, RrgA and RrgB 
are able to induce CD4
+
 T cell proliferative response in human adenotonsillar 
MNCs. We have previously shown pneumococcal CCS containing RrgA and RrgB 
induces in vitro antibody production in human NALT. The ability to induce a CD4
+
 
T cell response may augment the B cell antibody production in NALT. Our results 
also suggest that native form of these pilus-1 antigens may induce Th17 related 
cytokine response in human adenotonsillar MNCs. 
Previous studies showed several pneumococcal protein antigens including 
pneumolysin, PspA, CbpA, PsaA are capable of inducing CD4
+
 T cellular immune 
response in human (Basset et al. 2007a, Mureithi et al. 2009, Zhang et al. 2007). 
Among them, pneumolysin have been shown to induce both primary and memory 
CD4
+
 T proliferative response in human NALT and PBMC, which may modulate 
nasopharyngeal colonisation of pneumococcus (Zhang et al. 2007). This study 
revealed that both RrgA and RrgB antigens were also able to stimulate a CD4
+ 
T cell 
proliferative response in adenotonsillar MNC. A small CD4
+
 T cell response was 
observed in CD45RO
+
 cell depleted adenotonsillar MNC following stimulation with 
both rRrgA and rRrgB (figure-6.4.2b). No significant response was observed 
following stimulation of PBMC (figure-6.4.4). However, we have observed a 
stronger proliferative response of CD4
+
 T cells in adenotonsillar MNC following 
stimulation with pneumococcal CCS. The finding that CCS derived from isogenic of 
RrgB
-/- 
and RrgA
-/-
 mutant strains induced a smaller response than with the wild type 
(TIGR4wt) suggests that these two antigens in native form may induce significant 
activation of CD4
+
 T cells that help antibody production by B cells  
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In human nasopharynx, pneumococcal colonisation may prime for antigen-specific 
CD4
+
 T cell memory to pneumococcal proteins leading to the development of a 
protective T cell immunity against carriage (Zhang et al. 2007). Colonisation by a 
pilus-1 expressing strain of pneumococci is likely to prime for RrgA- and RrgB-
specific memory CD4
+
 T cells in human adenotonsillar tissues, which would be 
activated by subsequent antigenic stimulation. This could help to explain the CD4
+ 
T 
cell response in tonsillar MNC observed following stimulation with recombinant 
rRrgA and rRrgB antigens, which is likely to represent a memory response.  
Recently, immune response mediated by IL-17A secreted by Th17 cells has been 
implicated as the key protective mechanism against pneumococcal infections 
(Malley et al. 2006). IL-17A mediated recruitment of phagocytic cells plays an 
important role in the clearance of both primary and secondary bacterial colonisation 
in the nasopharynx (Zhang et al. 2009). A number of pneumococcal proteins have 
been identified, which are capable of inducing Th17 mediated protective responses 
(Moffitt et al. 2012). Apart from IL-17A, Th17 cells secrete a number of other 
cytokines, like IL-17F and IL-22, which also play an important role in the mucosal 
immune response against extracellular bacteria like pneumococcus (Aujla and Kolls 
2009).  
This study has revealed that TIGR4wt CCS (containing RrgA and RrgB) induced 
significant production of Th17-related cytokines including IL-17A, IL-17F and IL-
22. The finding that CCS derived from RrgA
-/-
 and RrgB
-/-
 mutants induced less 
production of these cytokines suggests that these pilus proteins may contribute to the 
induction of Th17 related cytokines in both adenotonsillar MNC and PBMC. A 
similar pattern of response was observed for both IL-17F and IL-22. The protective 
role of IL-22 at the different mucosal sites including respiratory tract is well 
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documented (Aujla and Kolls 2009). Significant production of IL-22 following 
stimulation with pneumococcal CCS supports previous report that pneumococcal 
protein antigens are capable of inducing this cytokine (Lundgren et al. 2012).  
Significant production of IL-17F in adenotonsillar cells following stimulation by 
pneumococcal CCS was also observed. IL-17F is a structural homologue of IL-17A, 
which has also been reported to contribute on the protective responses against 
invading microbial pathogens. Like IL-17A, it recruits neutrophils and induce 
secretion of anti-microbial peptides (Kawaguchi et al. 2004). However, it may have 
lesser contribution than IL-17A into the pathogenesis of autoimmune diseases 
(Ishigame et al. 2009). This may be explained by their differential receptor (IL-17RA 
or IL-17RC) distribution pattern, and the diversity of gene expression programs of 
the immune effector cells (Dubin and Kolls 2009).  
Relatively higher production of IL-17F and IL-22 than IL-17A was observed in both 
NALT and peripheral blood following stimulations with pneumococcal CCS. So far, 
no information is available regarding their relative importance in the protection 
against pneumococcal infection. Induction of IL-22 has been reported to be 
independent of the IL-17A induction (Lundgren et al. 2012). It has been reported that 
APCs, like dendritic cells and macrophages also secretes IL-22 (Dubin and Kolls 
2008). It is possible that the higher level of IL-22 in both NALT and PBMC might 
result from a contribution by other cell types than CD4
+ 
T cells. Both IL-17A and IL-
17F have been shown to contribute onto the mucosal immune response 
against extracellular bacteria. However, IL-17A has been reported to be more 
critically involved in the development of autoimmune reactions (Dubin and Kolls 
2009).  
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While several reports of IL-17A mediated protection against pneumococcal infection 
are available (Malley et al. 2006, Lu et al. 2008, Moffitt et al. 2012); there is limited 
data regarding the specific protective role played by IL-17F. Both IL-17A and IL-
17F have shown to induce IL-6, CCL3 and G-CSF by peritoneal macrophages. In 
addition, IL-17A was shown to induce several proinflammatory cytokines such as 
IL-1β, IL-12p70, and GM-CSF. In CD4+ T cells, IL-17A have been shown to induce 
CCL2, CCL3, GM-CSF, IL-1β, and IL-9, which were not induced by IL-17F (Dubin 
and Kolls 2009). This suggests that production of different Th17 related cytokines 
(IL-17A or IL-17F) may be linked to their post-secretion cytokine activation profile.  
The magnitude of Th17 cytokine response in NALT was higher than that observed in 
PBMC. Th17 related cytokine response following pneumococcal stimulation has 
been shown to be originating from the effector/memory T cell population (Lundgren 
et al. 2012). The adenotonsillar cells possess higher number of memory cell than the 
peripheral blood, and therefore generate a strong Th17 (IL-17A, IL-17F, IL-22) 
cytokine response.    
In conclusion, our results suggest that pneumococcal pilus proteins RrgA and RrgB 
proteins are capable of activating CD4
+
 T cells including Th17 cells in human 
nasopharynx-associated lymphoid tissue (NALT). In vitro production of Th-17 
cytokines in cell culture supernatants after stimulation with pneumococcal CCS 
containing both of these proteins (TIGR4wt) was significantly higher than that with 
isogenic (RrgA
-/-
 and RrgB
-/-
) mutants, suggesting a contribution from these proteins. 
The ability of these pilus-1 proteins to induce a CD4
+
 T cell response including Th17 
response may contribute to the natural immunity developed with age in humans. 
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Chapter 7 
General Discussion and Conclusion 
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7.1 Discussion 
Streptococcus pneumoniae is an important human pathogen that accounts for 
significant morbidity and mortality around the world. The disease burden is 
particularly high in the developing countries (O'Brien et al. 2009). The vulnerability 
is highest in children younger than five years and in the elderly over sixty five 
(Örtqvist et al. 2005). Natural immunity to pneumococcus was believed to be 
mediated by the antibody responses to the capsular polysaccharides; which were 
targeted for development of vaccine against pneumococcus (Weinberger et al. 2008).  
So far, the available vaccines are prepared from capsular polysaccharides. The 
efficacy of these vaccines is limited to the serotypes included in the formulation. 
These polysaccharide vaccines induce a T cell independent antibody response and 
therefore, not effective in young children less than 2 years (Bogaert et al. 2004b). 
Although conjugate polysaccharide vaccines are effective in these children, the 
serotype coverage is limited (Singleton et al. 2007). Also these conjugate vaccines 
are too expensive to be affordable for routine use in the developing countries, where 
they are needed most. For these reasons, development of suitable protein vaccines 
remains a priority in pneumococcal vaccine research (Tai 2006). A number of 
proteins expressed by pneumococci have been identified as potential vaccine 
candidate, and studies in animal models and humans have revealed their protective 
efficacy (Gámez and Hammerschmidt 2012; Bologa et al. 2012; Kamtchoua et al. 
2013). 
Studies in experimental mice have shown that pneumococcal pilus-1 proteins, RrgA 
and RrgB are good immunogens (Gianfaldoni et al. 2007; Nelson et al. 2007; 
Harfouche et al. 2012). This PhD study investigated the immunogenicity of these 
two antigens in humans. Significant levels of serum anti-RrgA and RrgB antibodies 
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were detected in both children and adults (figure-4.4.3a), which presumably derived 
from previous colonization by S. pneumoniae. Furthermore, serum anti-RrgA 
antibody titres was found to be higher in children who were culture-negative than in 
those who were culture-positive for S. pneumoniae in their nasopharynx (figure-
4.4.7.1). Similarly, anti-RrgB antibody titres were also higher in culture-negative 
than in culture-positive children older than 6 years (figure-4.4.7.2). These results 
suggest a possible protective immune response by pneumococcal pilus-1 proteins 
against pneumococcal carriage or new colonization in humans.  
S. pneumoniae is a frequent colonizer of the mucosa in the nasopharynx of young 
children, as shown in this study that over 50% of children aged under 3 years were 
carrying S. pneumoniae (table-3.4.1). Colonization of the nasopharynx by this 
bacterium is considered to be an essential first step for pneumococcal infection. The 
high carriage rate in young children may explain why they are prone to some 
common infections such as pneumonia. As is the case for many mucosal pathogens, 
colonization may not only precede pneumococcal infections but also serves as a 
prerequisite for the spread of the organism within the community (Bogaert et al. 
2004a). Reduction of carriage through vaccination may therefore be an effective way 
of preventing pneumococcal disease.  
Serum anti-RrgA IgG antibody levels were found to rise earlier in young children 
than anti-RrgB antibody, which suggests that RrgA protein may be a strong 
immunogen in early childhood (figure-4.4.3a-c). It is possible that RrgA interacts 
more closely with the mucosal immune system while facilitating the adhesion of S. 
pneumoniae to nasopharyngeal mucosa. A stronger in vitro production of anti-RrgA 
compared to anti-RrgB antibodies in adenotonsillar MNC following pneumococcal 
stimulation (figure-5.4.3a+b) further supports the notion that RrgA protein may be a 
strong immunogen in children.  
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The presence or absence of anti-RrgA and -RrgB antibodies shown by ELISA was 
further supported and confirmed by Western blotting, and there was a good 
correlation in the antibody levels detected by the two methods (figure-4.4.5a-c). 
Based on both methods, about 50-60% of the serum samples in this study were 
positive for anti-RrgA and -RrgB antibodies (figure-4.4.5.3). This suggests that 
pilus-expressing pneumococcal strains may frequently colonize children during 
childhood. Among the strains isolated from this study, all of the pilus-I expressing 
isolates were from young children <6 years. The overall percentage of pilus-1 
expressing pneumococcal carriage isolates in this study was 11% (figure-3.4.2), 
which was lower than that reported in previous studies (25% to 50%) (Aguiar et al. 
2008; Moschioni et al. 2010a; Basset et al. 2007b). This lower percentage of pilus-
expressing strains may be associated with the recent introduction of pneumococcal 
conjugate vaccines in the UK, as reported previously in the US (Regev-Yochay et al. 
2010). The conjugate vaccine serotypes were reported more likely to carry rrgC gene 
than the non-vaccine serotypes (Basset et al. 2007b). It was reported that the 
prevalence of pilus-1 positive strains dropped from 25% to 15% after 3 years of 
introduction of conjugate vaccination, although it was shown to rise again after 7 
years which was attributed to replacement by non-vaccine serotypes (Regev-Yochay 
et al. 2010). It was shown previously that pneumococcal colonization could be a 
dynamic process, with most young children (<2 years) colonized serially with single 
or multiple serotypes of S. pneumoniae (Syrjänen et al. 2001). So it is possible that 
many children in this study had been exposed to pilus-expressing strains previously. 
We observed that both serum anti-RrgA and anti-RrgB antibody levels increased 
with age in children until they reach adolescence (figure-4.4.3b+c). This trend was 
seen in antibodies to a number of pneumococcal protein antigens including 
pneumolysin and choline-binding proteins (Laine et al. 2004). Using a general linear 
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model of analysis of variance, we showed that anti-RrgA antibody titres appeared to 
have an age-independent association with pneumococcal carriage, in that the 
difference in antibody titres between carriage negative and culture positive children 
existed in all age groups, although for anti-RrgB antibody this difference was only 
shown in older children. 
As shown previously from studies of immune response to other pneumococcal 
proteins including CbpA and pneumolysin (Zhang et al. 2006b), IgG1 was the 
predominant immunoglobulin subclass of anti-RrgA and -RrgB antibodies (figure-
4.4.4a+b). This is typical of antibody responses to protein antigens, with a 
predominance of IgG1 followed by IgG3 and minimal levels of IgG2 and IgG4.  
Both IgG1 and IgG3 are known to be capable of complement activation and 
opsonisation of S. pneumoniae, potentially leading to its clearance from 
nasopharynx.  
Salivary IgG antibodies to both RrgA and RrgB antigens were also detected, and 
again, there was a difference in these salivary IgG antibody levels between 
pneumococcal culture-negative and culture-positive patients, with higher titres in the 
former (figure 4.4.8.1). The higher salivary IgG titres in non-colonised patients 
support our hypothesis that it may contribute to protection against pneumococcal 
colonization at the mucosal level. A good correlation between the serum and salivary 
IgG antibodies for both anti-RrgA and anti-RrgB (figure 4.4.8a+b) suggests that the 
salivary IgG antibodies were mostly derived from serum leakage (Zhang et al. 2000), 
although local mucosal immune tissue NALT could also contribute to this local pool 
of antibodies(Zhang et al. 2006b, Ivarsson et al. 2004).  
On the other hand, salivary secretory IgA antibodies to both RrgA and RrgB were 
shown to be relatively higher in culture-positive than culture-negative children 
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(figure 4.4.8.2). This increase of IgA in colonised patients could be explained by the 
fact that they were secreted locally induced by the current colonisation. These locally 
produced secretory IgA antibodies may contribute to protection against epithelial 
penetration by S. pneumoniae to cause invasive disease.   
Considering that RrgA acts as a pneumococcal adhesin, it may be a good mucosal 
immunogen and induce local immune response in the nasopharynx. In this study, we 
show that stimulation with a wild type (TIGR4) pneumococcal culture supernatant 
(containing both RrgA and RrgB proteins) induced a significant anti-RrgA antibody 
response (~6.8 fold-increase) in adenotonsillar cells (figure 5.4.3a). An anti-RrgB 
antibody response was also induced following stimulation, although at a lower (~2.9 
fold) magnitude (figure 5.4.3b). Stimulation with CCS derived from isogenic mutant 
(RrgB
-/- 
and RrgA
-/-
) strains failed to induce antibody responses against respective 
(lacking) antigens; but retained the ability to induce antibody production against the 
other proteins (RrgA and RrgB respectively). Production of these antigen-specific 
antibodies were mostly contributed by the memory (CD45RO
+
) B cell, as their 
depletion markedly reduced both anti-RrgA and -RrgB levels (Figure-5.4.3c+d).  
This in vitro stimulation of adenotonsillar cells was shown to induce a higher anti-
RrgA and anti-RrgB antibody response in culture-positive than culture-negative 
patients (figure 5.4.8a+b). This result is consistent with our previous findings of 
higher in vitro antibody production to some other protein antigens (CbpA and 
pneumolysin) in culture-positive children (Zhang et al. 2006b). It is possible that a 
recent or current colonization in the host boosted the antigen-specific memory B cell 
pool in the NALT, and upon antigen stimulation in vitro, an enhanced memory 
response was elicited. Both systemic and local mucosal responses may contribute to 
the regulation of acquisition and elimination of pneumococcal carriage in the 
nasopharynx, and may exert their effects independently. High antecedent levels of 
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antibodies in serum may help prevent colonization, and enhanced memory-type local 
immune responses in NALT following re-exposure may help terminate it (Zhang et 
al. 2006b).  
It has been shown that CD4
+
 T cells mediated immunity is important for clearance of 
pneumococcus from the nasopharynx, which is the natural colonisation site 
(Kadioglu et al. 2004, Malley et al. 2005). Several pneumococcal proteins have been 
shown to induce CD4
+
 T cellular immune response in humans (Basset et al. 2007a, 
Mureithi et al. 2009, Zhang et al. 2007). Pneumolysin was able to induce both 
primary and memory CD4
+
 T proliferative response in human NALT and PBMC 
(Zhang et al. 2007). Here, we observed that both RrgA and RrgB antigens were also 
able to stimulate a CD4
+
 T cell proliferative response in adenotonsillar MNC (figure-
6.4.2a); but no significant response was observed following stimulation of PBMC 
(figure-6.4.4). We also observed a stronger proliferative response of CD4
+
 T cells in 
adenotonsillar MNC following stimulation with pneumococcal TIGR4wt CCS 
compared to that of CCS derived from its isogenic RrgB
-/- 
and RrgA
-/-
 mutant strains 
(figure-6.4.3). It suggests that the native form of both RrgA and RrgB may aid in the 
antibody production by activating CD4
+ 
helper T cells. 
Th17 cells contribute to the innate and adaptive cellular immunity against 
pneumococci by recruiting phagocytes (Malley et al. 2006; Zhang et al. 2009; Lu et 
al. 2008). Th17 cells secrete a number of cytokines, including IL-17A, IL-17F and 
IL-22. These cytokines have been shown to play a crucial role in the mucosal 
immune response against extracellular bacteria like pneumococcus (Aujla and Kolls 
2009). Several pneumococcal proteins have been shown to generate Th17 mediated 
protective responses (Moffitt et al. 2012).  
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In this study, significant production of Th17-related cytokines (IL-17A, IL-17F and 
IL-22) was observed following stimulation with pneumococcal CCS (figure-6.4.7a-c 
and figure-6.4.8a-c). Notably, stimulation with TIGR4wt CCS (containing RrgA and 
RrgB) induces significantly higher production of Th17 cytokines compared to that of 
CCS derived from RrgA
-/-
 and RrgB
-/-
 mutants. This suggests that these pilus-1 
proteins may contribute to the induction of Th17 related cytokines in both 
adenotonsillar MNC and PBMC.  
Production of IL-17F and IL-22 following stimulations with pneumococcal CCS was 
relatively higher than IL-17A production in both NALT and peripheral blood 
(figure-6.4.7a-c and figure-6.4.8a-c). There are several reports of IL-17A mediated 
protection against pneumococcal infection (Malley et al. 2006, Lu et al. 2008, 
Moffitt et al. 2012). But limited information is available regarding the relative 
importance of different Th17 related cytokines (like IL-17A, IL-17F and Il-22) in the 
protection against pneumococcal infection. Induction of IL-22 production following 
stimulation with pneumococcal antigens has been shown (Lundgren et al. 2012). The 
contribution of IL-17F in the mucosal immune response against other extracellular 
bacteria has also been reported (Dubin and Kolls 2009).  
This study has revealed that both of these pilus-1 proteins, RrgA and RrgB are 
immunogenic and, and are capable of priming for memory B and T cell response in 
human NALT. Immunogenicity of the adhesin RrgA has been found to be 
developing earlier in the childhood. Moreover, antibodies to one of the clades of 
RrgA have been reported to be cross- protective against both clades (Moschioni et al. 
2010). On the other hand, lack of cross-protection by antibodies to different clades of 
RrgB might be overcome by using a fusion of three clades (RrgB321) (Harfouche et 
al. 2012). However, considering the low prevalence of pilus-1 among the colonising 
pneumococcal isolates, the inclusion of these RrgA or RrgB proteins as a vaccine 
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component needs to be critically evaluated. Particularly, with the availability of 
PCV13 which seems to cover all of the serotypes associated with pilus-1 and pilus-2 
(Kulohoma et al. 2013), a vaccine formulation with their component proteins is 
unlikely to offer any extra advantage. Moreover, due to strong competition in the 
development of pneumococcal protein vaccines, pilus-1 components would likely to 
become underdog compared to some more conserved and better immunogenic 
proteins, such as pneumolysin, PspA, CbpA and PhtD (Bologa et al. 2012; Darrieux 
et al. 2013; Kamtchoua et al. 2013; Seiberling et al. 2012). However, in the context 
of rapidly changing perspectives in this field the information regarding the 
immunogenicity of RrgA and RrgB should always be valuable.   
7.2 Conclusion 
In the present study we detected significant level of serum antibodies to pilus RrgA 
and RrgB proteins in children and adults. An important finding of this work was 
higher antibody levels in carriage-negative than in carriage-positive children. These 
results suggest pneumococcal pilus antigens, especially RrgA are capable of 
inducing significant antibody response in children that may contribute to protection 
against pneumococcal carriage. The study also revealed that pneumococcal pilus-1 
proteins, RrgA and RrgB are able to induce CD4+ T cell proliferative response in 
human adenotonsillar MNCs, which may augment the antibody production in 
NALT. Our results also suggest that native form of these pilus-1 antigens may 
induce Th17 related cytokine response in human adenotonsillar MNCs. In 
conclusion, these findings add significant information to our understanding on the 
natural immunity to pilus-1 proteins.  
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Appendix –I 
Preparation of different media and buffers 
 
Skim milk, Tryptone, Glucose, Glycerol Transport Medium (STGG) 
Skim-milk tryptone glucose glycerol (STGG) transport medium was prepared using the 
following procedure.  
1. In a sterile 100 ml glass bottle, 40 ml 10% milk was prepared by adding 4 gram 
skimmed milk powder (Oxoid, UK) into 40 ml distilled water. 
2. The bottle was autoclaved in 121°C for 5 minutes with the cap loosened one turn. 
3. After autoclaving, the cap was tightened and taken into a bio-safety cabinet. 
4. In another sterile 500 ml glass bottle, 6 ml Tryptone soya broth (Oxoid, UK), 2.2 ml 
45% D-Glucose solution (Sigma Aldrich, UK), 20 ml Glycerol (Sigma Aldrich, UK) 
were taken. 
5. 131.8 ml distilled water was added into the bottle to make the final volume 160 ml.  
6. The bottle was shaken gently to dissolve all ingredients.  
7. Then bottle was autoclaved in 121°C for 10 minutes with the cap loosened one turn. 
8. After that, the cap was tightened and taken into a bio-safety cabinet. 
9. Then the previously prepared sterile 10% skimmed milk (40 ml) was added into the 500 
ml bottle to make 200 ml 2% skimmed milk medium. 
10. The milk was mixed thoroughly with the other contents by gentle shaking. 
11. Aliquot of 1.0 ml media was prepared into 1.5 ml screw-capped vials. 
12. The tubes were then kept in a refrigerator (2-8°C) until used for nasal swab inoculation. 
13. Quality control test for sterility of the STGG medium was performed periodically by 
plating a full loop of a homogenized vial from each lot onto a blood agar plate, then 
incubating the plate at 37°C overnight.  
14. The lot was discarded if growth of any organism was suspected.   
Todd-Hewitt-Yeast Broth (THYB)  
Todd-Hewitt Broth with 0.5% yeast extract was prepared using the following procedure. 
1. 36.4 gram of Todd-Hewitt Broth (Oxoid, Basingstoke, UK) and 5 gram of yeast extract 
were taken into a sterile 1 litre glass bottle. 
2. 1000 ml of distilled water was added to the bottle and mixed thoroughly, until all 
components were dissolved completely. 
3. The bottle was autoclaved at 115°C for 10 minutes with the cap loosened one turn. 
4. After autoclaving, the bottle cap was closed tightly and then kept in the cold room until 
used for growing bacteria. 
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Laemmli Reducing Buffer  
10.0 ml Laemmli reducing Buffer for western Blot sample dilution was prepared using 
following recipe- 
0.5 M Tris pH 6.8   1.25 ml 
10% (w/v) SDS   2.0 ml 
0.5% Bromphenol Blue      0.20 ml 
Glycerol    2.50 ml 
Deionized H2O   3.55 ml 
β-mercaptoethanol   0.50 ml (50 µl for each 0.95 ml) 
10x Tris Buffered Saline (TBS) p
H
 7.4  
1. 1 Litre 10x TBS was prepared in a sterile 1 litre glass bottle, using following recipe- 
Tris    30 gm 
NaCl    80 gm 
KCl        2 gm 
Deionized H2O   900 ml 
2. Then pH was adjusted to 7.4 by adding concentrated HCl drop by drop, with gentle 
shaking of the bottle and simultaneous measurement with a p
H
 meter. When the p
H
 is 
adjusted then the bottle was topped-up to 1 litre by adding deionized water. 
Western Blot Washing Buffer (TBS-T)  
1 litre of Western Blot washing buffer (1xTBS with 0.05% Tween20) was prepared in a 
sterile glass bottle, using following recipe- 
10x TBS     100 ml 
Deionized H2O   900 ml 
Tween-20    0.5 ml 
Western Blot Blocking Buffer (5% skimmed milk in TBS-T)  
1. 500  ml of Western Blot blocking buffer (5% skimmed milk in TBS-T) was prepared in a 
sterile glass bottle, with a magnetic stirrer bead inside, using following recipe- 
Skimmed milk    25 gram 
10x TBS     50 ml 
Deionized H2O   450 ml 
Tween-20    0.25 ml  
2. The bottle was kept on a magnetic stirrer for allowing the proper dissolving of the milk. 
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10x Phosphate Buffered Saline (PBS) p
H
 7.4  
1. 1 litre of 10x PBS was prepared in a sterile 1 litre glass bottle, using following recipe- 
Na2HPO4    14.4 gm 
KH2PO4    2.4 gm 
NaCl    80 gm 
KCl        2 gm 
Deionized H2O   900 ml 
2. Then pH was adjusted to 7.4 by adding concentrated HCl drop by drop, with gentle 
shaking of the bottle and simultaneous measurement with a p
H
 meter. When the p
H
 is 
adjusted then the bottle was topped-up to 1 litre by adding deionized water. 
ELISA/ELISpot Washing Buffer (PBS-T)  
1 litre of ELISA/ELISpot washing buffer (1xPBS with 0.05% Tween20) was prepared in 
a sterile glass bottle, using following recipe- 
10x PBS     100 ml 
Deionized H2O   900 ml 
Tween-20    0.5 ml 
P-Nitrophenyl Phosphate (PNPP) Substrate for ELISA 
1. 1 litre of p-nitrophenyl phosphate (PNPP) substrate (1M diethanolamine) buffer (pH 9.8) 
was prepared in a sterile glass bottle, using following recipe- 
Diethanolamine    97 ml 
Deionized H2O   800 ml 
MgCl2    100mg  
2. Then the bottle was placed on a magnetic stirrer with a magnetic flea inside. Whilst 
stirring the p
H
 was measured and adjusted to 9.8 by adding 10M hydrochloric acid. 
3. Once the pH is correctly adjusted, the buffer was transferred to a measuring cylinder and 
distilled water was added to give a final volume of 1000 ml. 
4. Thereafter, the buffer was transferred back to the bottle and stored at 4˚C. 
5. Finally, the substrate was prepared by dissolving p-nitrophenyl phosphate disodium salt 
(5mg) tablet into 5 ml of substrate buffer to give a PNPP concentration of 1 mg/ml. 
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Acetate buffer for AEC Substrate  
1. 1 litre of 50 mM acetate buffer (pH 5.0) was prepared in a sterile glass bottle, using 
following recipe- 
2. 0.2M Acetic acid solution was prepared by adding 1.16 ml glacial acetic acid into 100 
ml deionized H2O.  
3. 0.2M Sodium acetate solution was prepared by adding 6.8 gm sodium acetate into 250 
ml deionized H2O. 
4. Then, the acetate buffer was prepared by adding 74 ml of 0.2M acetic acid solution, 176 
ml of 0.2M sodium acetate solution and 700 ml of deionized H2O. 
5. Thereafter, the bottle was placed on a magnetic stirrer with a magnetic flea inside. 
Whilst stirring the p
H
 was measured and adjusted to 5.0 by adding glacial acetic acid. 
6. Once the pH is correctly adjusted, the buffer was transferred to a measuring cylinder and 
distilled water was added to give a final volume of 1000 ml. 
7. Finally, the buffer was transferred back to the bottle and stored at 4˚C. 
 
3-Amino-9-ethylcarbazole (AEC) Substrate for ELISpot 
1. AEC Substrate was prepared using following recipe- 
2. 2.5 gm of 3-Amino-9-ethylcarbazole was added into 250 ml of dimethyl formamide 
(DMF) solution and kept in dark at 4°C (refrigerator). 
3. Finally, the working substrate solution for the ELISpot assay was prepared by adding 
0.5 ml of AEC substrate into 9.5 ml of acetate buffer; and 25 µl of H2O2 immediately 
before dispensing into the plate.  
 
 
 
 
 
 
 
 
 
224 
 
Appendix –II 
List of antibodies/chemicals/reagents/consumables  
A. Antibodies/kits Manufacturer Catalogue no Lot/batch no 
Anti-human IgA-Alkaline phosphatase                                                                          
(α chain specific, produced in goat) 
Sigma Aldrich,
UK 
A9669 048K4869 
Anti-human IgG (Fab)2                                    
(produced in goat) 
Sigma Aldrich,  
UK 
I3266 109K4786 
Anti-human IgG1 (hinge)-AP          
(clone: 4E3, produced in mouse)  
Southern Biotech, 
USA 
9052-04 J3809-S520B 
Anti-human IgG2 (FC)-AP             
(clone: 317-4, produced in mouse)                             
Southern Biotech, 
USA
9060-04 J3709-ZC09C 
Anti-human IgG3 -AP                    
(clone: HP6050, produced in mouse) 
Southern Biotech, 
USA 
9210-04 D610-PM40B 
Anti-human IgG4-AP                     
(clone: HP6025, produced in mouse) 
Southern Biotech, 
USA 
9200-04 C8010-QK20C 
Anti-human IgG-Alkaline phosphatase                                    
(clone: GG-5, produced in mouse) 
Sigma Aldrich,
UK 
A2064 011M4757 
Anti-human IgM-Alkaline phosphatase                                                                        
(clone: MB-11, produced in mouse) 
Sigma Aldrich,  
UK 
A2189 107K4861 
Anti-human secretory component (IgA)                                    
(clone: GA-1, produced in mouse) 
Sigma Aldrich,
UK 
I6635 101M4772 
Anti-mouse IgG-Alkaline phosphatase                                    
(produced in goat) 
Sigma Aldrich,
UK 
A3562 079K6034 
Anti-rabbit IgG FITC conjugate 
(produced in goat) 
Sigma Aldrich,  
UK 
F0382 060M6052 
Anti-rabbit IgG-HRP                  
(produced in donkey)                                             
Santa Cruz 
Biotech, Germany 
SC2077 K0810 
CD45RO microbeads                      
(mouse anti-human IgG2a) 
Myltenyi Biotech, 
Germany 
130-046-001 5130527257 
CD69 microbead kit II  
Anti-human CD69-Biotin               
(isotype: mouse IgG1) 
Anti-Biotin microbeads 
Myltenyi Biotech, 
Germany 
130-092-355 5110704223 
Goat anti-human IgA (Fab)2 Biotin   Invitrogen, USA AHI 1109 816042A 
Goat anti-human IgG (H+L) Biotin  Invitrogen, USA 81-7140 730149A 
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Goat anti-human IgM (Fab)2 Biotin   Invitrogen, USA AHI 1609 445320A 
Human CD-4 PE                           
(clone: RPAT4) 
BD Biosciences, 
UK 
555347 2219543 
Human CD-4 PE-Cy7                          
(clone: SK3) 
BD Biosciences, 
UK 
557852 2237922 
Human IFN-γ AlexaFluor488 
(clone:B27) 
BD Biosciences, 
UK 
557718 42448 
Human IL-17A PE                        
(clone: N49-653) 
BD Biosciences, 
UK 
560486 41725 
Human IL-17F AlexaFluor488 
(clone:O33-782) 
BD Biosciences, 
UK 
561331 2251561 
Human IL-17F AlexaFluor647 
(clone:O33-782) 
BD Biosciences, 
UK 
561333 21883 
Human IL-22 AlexaFluor660 
(clone:22URTI) 
eBioscience, UK 50-7229-42 E12178-1630 
Human IL-4 APC                          
(clone: 8D4-8) 
BD Biosciences, 
UK 
560671 26947 
Human Th1/Th2/Th17 phenotyping Kit  
CD4 PerCP-Cy5.5 (clone: SK3) 
IFN-γ FITC (clone:B27) 
IL-17A PE (clone: N49-653) 
IL-4 APC (clone: MP4-25D2) 
BD Biosciences, 
UK 
51-9006615 2178901 
Human total IgA standard                                      
(purified IgA from human colostrum) 
Sigma Aldrich,  
UK 
I2636 021M4831 
Human total IgG standard                                       
(purified IgG from normal sera) 
Sigma Aldrich,  
UK 
I2511 100M4830 
Human total IgM standard                                       
(purified IgM from normal sera) 
Sigma Aldrich,  
UK 
I8260 050M4751 
Polyclonal rabbit anti-human IgA                                     Dako, Denmark A0262 00054730 
Polyclonal rabbit anti-human IgM                                     Dako, Denmark A0425 00055979 
Ready set go ELISA kit                   
Human IL-17A (homodimer)     
eBioscience,      
UK 
88-7176-88 E09433-1635 
Ready set go ELISA kit                   
Human IL-17F (homodimer)            
eBioscience,      
UK 
88-7478-88 E11356-1633 
Ready set go ELISA kit                   
Human IL-22 (homodimer)    
eBioscience,      
UK 
88-7522-88 E11112-1634 
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B. Chemicals/reagents Manufacturer Catalogue no. 
3-Amino-9-ethylcarbazole (AEC) Sigma Aldrich, UK A5754 
Agar Sigma Aldrich, UK A1296 
Agarose Sigma Aldrich, UK A9539 
Amphotericin B                                                                                       Sigma Aldrich, UK A2942 
Biomix red (PCR reaction mixture) Bioline Ltd, UK BIO-25005 
Blood agar base  Oxoid Ltd, UK CM0055B 
Bovine serum albumin (BSA)                                                           Sigma Aldrich, UK A8327 
Bradford protein dye reagent                                                               Sigma Aldrich, UK B6916 
Brefeldin A eBioscience, UK 00-4506-51 
Celltrace CFSE cell proliferation kit Molecular Probe, USA C34554 
CpG oligonucleotide (Human TLR9 ligand)  InvivoGen, USA tlrl-2006 
Cytofix fixation buffer BD Biosciences, UK 51-9006613 
Deionised water (ddH2O), DNase/RNase free InvitroGen, USA 10977-035 
Diethanolamine Sigma Aldrich, UK D8885 
Dimethyl sulfoxide (DMSO)                                                                                               Sigma Aldrich, UK D2650 
Dulbecco’s phosphate buffered saline       
(10L power)         
Sigma Aldrich, UK D5652 
Ficoll-paque premium                                                                              GE Healthcare Life 
Sciences, UK 
17-5442-03 
Foetal bovine serum (FBS)                                            Sigma Aldrich, UK F7524 
Gentamycin                                                                          Sigma Aldrich, UK G1272 
Glucose                                                                              Sigma Aldrich, UK G8769 
Glycerol                                                                           Sigma Aldrich, UK G5516 
Golgistop protein transport inhibitor 
(Monensin) 
BD Biosciences, UK 51-2092KZ 
Hank’s balanced salt solution (HBSS) Sigma Aldrich, UK H9269 
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Heparin sodium (mucous injection BP)                             LEO Pharma, UK DE0248 
Horse blood (defibrinated) Oxoid Ltd, UK SR0050C 
Horseradish peroxidase Avidin D                                                    Vector Lab. Inc.,  USA A-2004 
Hydrogen peroxide (H2O2) Sigma Aldrich, UK H1009 
IC fixation buffer eBioscience, UK 00-8222-49 
Immun-Star WesternC Chemiluminescent  kit Bio-Rad, UK 170-5070 
L-glutamine                                                                                     Sigma Aldrich, UK G7513 
NN Dimethylformamide (DMF) Sigma Aldrich, UK D4551 
Normal donkey serum                                                        Sigma Aldrich, UK D9663 
Optochin disk                                                                   Oxoid Ltd, UK DD0001B 
Penicillin/streptomycin                                                               Sigma Aldrich, UK P0781 
Perm/wash buffer BD Biosciences, UK 51-2091KE 
Permeabilization buffer (10x) eBioscience, UK 00-8333 
p-Nitrophenyl phosphate disodium salt tablet Sigma Aldrich, UK N9389 
Quick-load DNA ladder (1kb) New England Biolabs, USA N3232L 
RPMI 1640 media                                                            Sigma Aldrich, UK R5886 
Skim milk powder                                                           Oxoid Ltd, UK LP0031B 
Sodium acetate trihydrate Sigma Aldrich, UK S8625 
Streptactin-HRP                                                                               Bio-Rad, UK 61-0381 
Thermopol reaction buffer (10x) New England Biolabs, USA B9004S 
Tris Borate EDTA (TBE) buffer (10x) National Diagnostics, USA EC-860 
Tris/Glycine (10x) National Diagnostics, USA EC-880 
Tris/Glycine/SDS (10x) National Diagnostics, USA EC-870 
Tryptone soya broth                                                     Oxoid Ltd, UK BO0369E 
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Tween-20                                                                                      Sigma Aldrich, UK P1379 
Ultrasafe blue  Syngene, UK USB0112 
Yeast extract Sigma Aldrich, UK Y1625 
 
C. Consumables Manufacturer Catalogue No. 
BD Falcon cell strainer (70µm, nylon) BD Biosciences, UK 352350 
Columbia blood agar plate Oxoid Ltd, UK  OXPB 0199A 
Dryswab™ in peel pouch                                                                  Medical Wire & Equipment, 
UK 
MW113 
ELISA plates (96 well,  flat, high protein 
binding EIA/RIA plate) 
Corning, USA via Appleton 
Woods, UK 
CC679 
ELISpot plates (Multiscreen 
HTS
 filter, 0.45µm 
hydrophobic, high protein binding membrane) 
Millipore, USA MSIPN4550 
MACS cell separation LD columns                                                 Myltenyi Biotech Ltd, 
Germany 
130-042-901 
Mini Protean precast TGX gel (12%) Bio-Rad, UK 456-1044 
Oracol saliva collection system                                                  Malvern Medical Dev. Ltd, 
UK 
510 
Transblot turbo mini transfer pack Bio-Rad, UK 170-4156 
Vivaspin 15R hydrosart                                                   
(MWCO: 5000) 
Sartorius Stedim, Germany VS15RH11 
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List of publications 
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